Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
12/2009 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
12/31/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090325859 - Citric acid polymers: The present invention provides polymers (e.g., elastomeric citric acid polymers) and methods of making and using these polymers (e.g., as a biologically active molecule delivery platform). In certain embodiments, the polymer has adsorbed biologically active molecules. In particular embodiments, the polymer comprises pores that are between about 7 and 15... Agent: Casimir Jones, S.c.

20090325856 - Composition designed for the treatment of multiple sclerosis: e

20090325858 - Reduction of zinc-induced neurotoxic injury by blockade of nitric oxide synthesis: The present invention provides methods of inhibiting release of zinc from neurons and of preventing zinc-mediated brain injury. Also provided are methods of improving cerebral blood flow while preventing zinc-mediated brain injury. Inhibitors of or activators of nitric oxide synthases modulate nitric oxide synthesis to reduce nitric oxide-induced release of... Agent: Don D. Cha

20090325857 - Use of opioid receptor antagonists: The present invention relates to a new use of opioid receptor antagonists. More particularly, the present invention relates to the use of opioid receptor antagonists in hair care, particularly for the prevention of the graying of hair and/or for restoration and/or maintenance of the natural hair color.... Agent: Nixon & Vanderhye, PC

20090325860 - Compositions for intranasal delivery of human insulin and uses thereof: What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.... Agent: Eckman Law Group

20090325861 - Dry wound dressing and drug delivery system: Dry dressings incorporate drug-delivery systems for anti-infective agents, growth factors, fibronectin or other substances to enhance tissue healing. A pharmaceutical composition includes hyaluronate polyvinylpyrrolidone (PVP), maltodextrin, and hydroxyethylcellulose and glycerin in the form of a membranous, wafer-like material after being freeze-dried.... Agent: Barnes & Thornburg LLP

20090325862 - Histone deacetylase inhibitors for the treatment of neurodegeneration: The instant invention is directed to methods for treating neurodegenerative diseases comprises administering an effective amount of a selective histone deacetylase 8 inhibitor to a patient in need thereof.... Agent: Merck And Co., Inc

20090325863 - Somatostatin analogs and igf-i inhibition for breast cancer prevention: The present invention relates generally to the use and application of compounds or agents, including somatostatin analogs, with effect on, affinity for, or specificity to SSTR3 and/or SSTR5 somatostatin receptors, particularly in the breast, for the treatment of breast hyperplasia, pre-neoplastic lesions and breast carcinoma and/or prevention or reduction of... Agent: Klauber & Jackson

20090325882 - Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion: Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example... Agent: Knobbe Martens Olson & Bear LLP

20090325877 - Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer: A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.... Agent: Wyeth Patent Law Group

20090325879 - Controlled release copolymer formulation with improved release kinetics: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a... Agent: Schwegman, Lundberg & Woessner, P.A.

20090325870 - Foamy viral envelope genes: The present invention concerns the technical field of nucleic acids and expression-optimized nucleic acids. The present invention concerns especially nucleic acids comprising a mutated foamy viral envelope gene encoding a foamy viral envelope polypeptide, which comprises a leader peptide (LP), a surface unit (SU) and a transmembrane domain (TM). The... Agent: Vedder Price, PC

20090325873 - Human glp-1 mimetibodies, compositions, methods and uses: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of... Agent: Philip S. Johnson Johnson & Johnson

20090325874 - Inhibition of inositol 1,4,5-triphosphate receptor calcium channel/cytochrome c interactions and uses thereof: The present invention demonstrates selective pharmacological targeting and inhibition of apoptotic calcium release in lymphocytes from inositol 1,4,5-trisphosphate receptor calcium channels may enhance the immunologic response to tumor cells which have acquired adaptive changes in death receptor signaling to promote survival. The present invention provides methods of protecting lymphocytes from... Agent: Benjamin Aaron Adler Adler & Associates

20090325865 - Liquid formulations of pegylated growth hormone: Pharmaceutical compositions comprising pegylated growth hormone at pH 7 or below are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090325868 - Materials and methods for foxp3 tumor suppression: Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such... Agent: Marshall, Gerstein & Borun LLP

20090325881 - Modified factor viii: Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially... Agent: Greenlee Winner And Sullivan P C

20090325875 - Muteins of human tear lipocalin: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention... Agent: Foley And Lardner LLP Suite 500

20090325866 - Non-activated wnt inhibition polypeptides and method for preparing the same: The present invention relates to non-activated Wnt inhibition polypeptides (WIPs) containing: (a) a protein transduction domain (PTD) which enables said WIPs to permeate a cell membrane without the aid of a cell membrane receptor; and (b) a Wnt antagonist domain which is inactive by itself, but is activated in mammalian... Agent: Moore & Van Allen PLLC

20090325864 - Novel protein and process for preparing the same: e

20090325878 - Organ preconditioning, arrest, protection, preservation and recovery: The present invention relates to a method for reducing electrical disturbance of a cell's resting membrane potential comprising administering an effective amount of a composition comprising an effective amount of a local anaesthetic and of one or more of a potassium channel opener, an adenosine receptor agonist, an anti-adrenergic, a... Agent: Venable LLP

20090325867 - Receptor-specific tumour necrosis factor-related apoptosis-inducing ligand (trail) variants: The invention relates to a tumour necrosis factor- (TNF-) related apoptosis-inducing ligand (TRAIL) which is capable of selectively signalling through death receptor 4 (DR4), comprising Y at position 189. Preferably the TRAIL further comprises 19 IL and/or 199V; preferably also 201R, 213W and 215D, and/or preferably further comprises 193S. The... Agent: David S. Resnick

20090325871 - Role of the mk2 pathway in wound repair: The invention provides a method for screening for a compound that modulates the expression and/or activity of MK2 and the use of the compound for treating a vertebrate that has been wounded.... Agent: Keown & Zucchero, LLP

20090325869 - Synthetic regulators of ferritin protein nanocage pores and methods of use thereof: The present invention provides synthetic regulators of ferritin pores, and compositions comprising the regulators. The regulators function to reduce ferritin demineralization rates. The regulators are useful for treating inflammatory conditions. The present invention also provides methods of treating inflammatory conditions. The present invention further provides synthetic regulators of bacterial mini-ferritins;... Agent: Bozicevic, Field & Francis LLP

20090325880 - Tnf receptor-like molecules and uses thereof: Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.... Agent: Amgen Inc.

20090325872 - Use of alpha-lactalbumin for regulations of glycemia: Use of alpha-lactalbumin in a dietary, health-food or pharmaceutical type of composition to promote the cellular absorption of glucose, to improve the regulation of glycemia, to prevent the appearance of insulin resistance and/or type II diabetes.... Agent: Alston & Bird LLP

20090325876 - Use of lipid conjugates in the treatment of diseases associated with vasculature: wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and... Agent: Pearl Cohen Zedek Latzer, LLP

20090325883 - Peptides which interact with anti-apoptotic members of the bcl-2 protein family, and uses: The invention relates to a method of screening and identifying modulators of the protein interaction between those new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type... Agent: The Firm Of Hueschen And Sage

20090325884 - Method for detecting autoantibodies formed in rheumatoid arthritis: Autoantibodies reacting against citrullinated peptides derived from C-telopeptides of type I and type II collagens are found in patients with rheumatoid arthritis. They detect sequences —YYXA from α1 or —FYXA from α2 chain of type I collagen or —YMXA from α1 chain of type II collagen, where X is citrulline.... Agent: Birch Stewart Kolasch & Birch

20090325885 - Composition for acceleration of type i collagen production: It is an object of the present invention to provide a composition for promoting the production of type I collagen by human skin fibroblasts, and the present invention relates to a composition for promoting type I collagen production containing silybin and a peptide that promotes collagen production (peptide having an... Agent: Knobbe Martens Olson & Bear LLP

20090325886 - Wt1 modified peptide: The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090325887 - Peptides and regulation of calcium channels: Calcium channels can be regulated by natural gamma proteins. Herein we disclose embodiments of compositions and methods, particularly involving short peptides which are capable of regulating calcium channel function. Certain short peptides which can inhibit calcium current have structural features from the first transmembrane domain of gamma6 such as a... Agent: Greenlee Winner And Sullivan P C

20090325889 - Hepatitis c serine protease inhibitors and uses therefor: The present invention provides novel compounds which mimic peptides with a C-terminal penultimate proline, such compounds being useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C. The compounds find utility as antiviral agents directed at hepatitis... Agent: Schwegman, Lundberg & Woessner, P.A.

20090325888 - Peptides having a health benefit and compositions comprising them: The present invention provides the tripeptide MAP and/or the tripeptide ITP and/or salts thereof for use as a health benefit agent, especially in functional food products. The tripeptides have particular application in the areas of the prevention of obesity or body weight control and cardiovascular health maintenance, especially the inhibition... Agent: Unilever Patent Group

20090325890 - Use of galactose c-glycoside derivatives as protective agent and/or gama delta t lymphocyte activator: e

20090325891 - Cartilage regeneration-promoting agent: An object of the present invention is to provide an excellent cartilage regeneration-promoting agent that can promote regeneration of cartilage efficiently and is highly safe, and a medicine and a food that utilizes the cartilage regeneration-promoting agent. Thus, the present invention relates to a cartilage regeneration-promoting agent that includes at... Agent: Arthur G. Schaier Carmody & Torrance LLP

20090325892 - Synergistic pesticidal mixtures: Synergistic pesticidal mixtures are provided.... Agent: Dow Agrosciences LLC

20090325893 - Doxorubicin adjuvants to reduce toxicity and methods for using the same: Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with... Agent: Bozicevic, Field & Francis LLP

20090325894 - Tetracyclic anthraquinones possessing anti-cancer properties: The present invention provides aminoside tetracyclic anthraquinones represented by formula (I) or formula (II), wherein the peptides are introduced to connect tetracyclic anthraquinones and fatty acid saturated or unsaturated in order to make the anticancer agents to be absorbed and released selectively; meanwhile some water-solubility groups are also introduced into... Agent: Matthias Scholl

20090325895 - Methods of treating an inflammatory-related disease: The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition... Agent: Fennemore Craig

20090326040 - Antisense modulation of apolipoprotein b expression: Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.... Agent: Jones Day For Genzyme Corporation

20090326045 - Compositions and methods for topical delivery of oligonucleotides: The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions include liposomes or penetration enhancers for the delivery of such moieties to dermal and/or epidermal tissue in an animal for investigative, therapeutic or prophylactic purposes.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090326042 - Compounds and methods for modulating expression of crp: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090326041 - Compounds and methods for modulating expression of sglt2: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Mcdermott Will & Emery

20090326043 - Method and compound for antiviral (hiv) therapy: Disclosed is an anti-viral therapeutic that inactivates the Human Immunodeficiency Virus (HIV) RNA by siDNA. The siDNA antiviral therapeutic is effective in the treatment and inactivation of cell free virus particles before infection and/or in the treatment and prevention of HIV infections inside the cell. The invention exploits the HIV... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090326046 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090326044 - Rnai-mediated inhibition of ocular targets: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K—2Cl cotransporter. Ocular hypertension is treated by... Agent: Alcon

20090326047 - Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin: The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein... Agent: Morgan, Lewis & Bockius LLP (sf)

20090326049 - Blocking oligos for inhibition of microrna and sirna activity and uses thereof: The present invention relates to methods of identifying sites in the 3′- and/or 5′-UTR of mRNA involved in the binding of miRNA and/or siRNA to their target sites and nucleic acids designed to prevent the binding of endogenous or exogenous miRNA and/or siRNA to their target mRNA and uses thereof.... Agent: Clark & Elbing LLP

20090326054 - Compositions and methods for inhibiting translation of a mect1-maml2 chimeric gene: Composition for the inhibition of the translation of a Mect1-MAML2 chimeric gene consisting essentially of: (a) a fragment of the nucleic acid encoding the chimeric gene, and (b) a nucleic acid complementary to the fragment, and a method of inhibiting the translation of a Mect1-MAML2 chimeric gene comprising contacting a... Agent: Leydig, Voit & Mayer, Ltd.

20090326050 - Di(uridine 5'-)tetraphosphate and salts thereof: The present invention are directed to P1,P4-di(uridine 5′-)tetraphosphate, tetra-alkali metal salts such as tetrasodium, tetralithium, tetrapotassium, and mixed tetra-alkali metal cations thereof. The tetra alkali metal salts of P1,P4-di(uridine 5′-)tetraphosphate are water-soluble, nontoxic, and easy to handle during manufacture. These tetra-monovalent alkali metal salts are more resistant to hydrolysis than... Agent: Howrey LLP-ca

20090326053 - Diagnostic uses of follistatin-like 1: The present invention generally relates to methods, systems and computer readable media for the diagnosis and/or prognosis of a cardiac stress and/or skeletal muscle stress in a subject. In particular, in one embodiment, the methods, systems and computer readable media detect a level of Fstl expression, such as Fstl1 polypeptide... Agent: Ronald I. Eisenstein

20090326048 - Method for enhancing pancreatic beta cell proliferation, increasing serum insulin concentration, decreasing blood glucose concentration and treating and/or preventing diabetes: By enhancing the function of ERK proteins in the liver, proliferation of pancreatic β cells is promoted, blood insulin concentration increased, blood glucose level decreased, and diabetes is prevented and/or treated. The methods for enhancing the function of ERK proteins in the liver are not particularly limited, and include various... Agent: Barnes & Thornburg LLP

20090326051 - Modulation of gene expression through endogenous small rna targeting of gene promoters: Gene expression can be selectively regulated by endogenous miRNAs that target promoters of genes. Altering of the activity of these promoter-targeting miRNAs with single-stranded complementary oligonucleotides that bind the miRNA causes modulation of expression of the target gene. Endogenous miRNAs that modulate expression of target genes can be identified by... Agent: Fulbright & Jaworski L.L.P.

20090326052 - Promoters exhibiting endothelial cell specificity and methods of using same: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090325896 - Partial and full agonists of a1 adenosine receptors: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20090325897 - Designer therapy of pancreatic tumors: Chemotherapeutic and Radiation sensitizing agents which target tumor cells, specifically, based on the elevation of enzyme pathways, provide highly selective drug therapy. These agents are combined with modulating doses of cytidine deaminase inhibitors to increase selectivity. Furthermore, high doses of these cytidine deaminase inhibitors have the potential of counteracting the... Agent: Darby & Darby P.C.

20090325899 - Medical composition for protuberance of epithelium: A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s−1; (2) from 45 to 300 mPa·s at... Agent: Sughrue-265550

20090325898 - Skin material for external use and antiprutiric agent for external use and wrinkle-instrument using the same: A skin composition for external use containing an acidic composition (A) which contains an alginate(s), at least one of weak acid selected from among phosphoric acid-type weak acids and ethylenediaminetetraacetic acid-type weak acids, and water; and a solidifying/gelling agent (B) containing a calcium salt(s) which is to be supplied to... Agent: Watchstone P+d, PLLC

20090325900 - Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof: The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof... Agent: Sughrue Mion, PLLC

20090325902 - Heterocyclic urea derivatives and methods of use thereof: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20090325901 - Improvements in pharmaceutical compositions: The present invention relates to compounds of formula I or II: —wherein R is an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group, that may be substituted or unsubstituted, and that optionally includes at least one heteroatom in its carbon skeleton; R1 is hydrogen, or an alkyl, substituted alkyl,... Agent: Venable LLP

20090325903 - Boronate ester compounds and pharmaceutical compositions thereof: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20090325904 - Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same: The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same.... Agent: Birch Stewart Kolasch & Birch

20090325905 - Method for treating diseases associated with alterations in cellular integrity using rho kinase inhibitor compounds: This invention is directed to methods of preventing or treating diseases or conditions associated with alterations in cellular integrity including alterations in endothelial permeability, excessive cell proliferation or tissue remodeling. Particularly, this invention is directed to methods of treating diabetic nephropathy, malaria, or cancer. The method comprises identifying a subject... Agent: Howery LLP

20090325906 - Methods and compositions for therapeutic treatment: Methods and compositions are described for the modulation of hyperglycemia and/or one or more symptoms of hyperglycemia. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the methods... Agent: Wilson, Sonsini, Goodrich & Rosati

20090325907 - Amino phosphate derivative and s1p receptor modulator having same as an active ingredient: t

20090325908 - 9-substituted minocycline compounds: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090325909 - Suppression of hiv replication and prevention and treatment of hiv: The invention provides a new and effective treatment for human immunodeficiency diseases, particularly for HIV-infected individuals. The treatment utilizes tetracycline analogs, particularly minocycline, in amounts that are effective to prevent HIV replication both the central nervous system and in peripheral blood.... Agent: Edwards Angell Palmer & Dodge LLP

20090325910 - Compositions and methods for tranquilizing heart muscle: A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient. A method for treating or preventing heart failure in a subject diagnosed as having heart failure... Agent: Harness, Dickey & Pierce, P.L.C

20090325911 - Use of androgens for the treatment of parkinson's disease: The invention generally provides therapeutic and prophylactic methods relating to the use of androgens for the treatment of Parkinson's disease or other neurodegenerative diseases. In addition, the invention provides related methods of screening for compounds for the treatment of Parkinson's disease.... Agent: Edwards Angell Palmer & Dodge LLP

20090325916 - 5-aryl indan-1-one and analogs useful as progesterone receptor modulators: Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.... Agent: Howson & Howson LLP / Wyeth

20090325914 - Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy: Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.... Agent: Buchanan, Ingersoll & Rooney PC

20090325915 - Crystalline levosalbutamol sulphate and polymorphic forms thereof: p

20090325912 - Quinolinone derivatives and their pharmaceutical compositions: in salt or solvate form, wherein W, Rx, Ry, R1, R2, R3, R4, R5, R6 and R7 and A have the meanings as indicated in the specification, are useful for treating diseases mediated by the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also... Agent: Novartis Corporate Intellectual Property

20090325913 - Treatment of pain using satraplatin: The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the treatment of pain associated with metastatic hormone refractory prostate cancer.... Agent: Leon R. Yankwich

20090325917 - Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate: A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.... Agent: Conley Rose, P.C.

20090325918 - Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action: Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to... Agent: Gildo E. Fato, Esq. C/o Laurence M. Dunlap

20090325919 - Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation: The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa... Agent: Notaro & Michalos P.C.

20090325920 - Methods for the treatment of a traumatic central nervous system injury: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of... Agent: Foley And Lardner LLP Suite 500

20090325921 - Method of improving the overall health of a patient with use of a transdermal dhea cream and/or dhea sulfate cream: A method is described herein for improving the overall health of a patient by providing a topical DHEA cream and applying the topical DHEA cream to at least one part of a body. In another embodiment, the topical DHEA cream is mixed with a moisturizing lotion and the resulting DHEA/lotion... Agent: Michael A. O'neil. P.C.

20090325922 - Turfgrass fungicide formulation with pigment: Oil-in-water fungicidal formulations are prepared having pigment dispersed therein, the pigment being stable within the oil-in-water emulsion as a result of the addition of suitable silicone surfactants and suitable emulsifiers. The formulations can be prepared either as a 2-pack formulation or as a single formulation. In the case of the... Agent: Sean W. Goodwin

20090325924 - Gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090325925 - Thiophenes and uses thereof: m

20090325923 - New method for the treatment of inflammatory diseases: The present invention relates to the use of an inhibitor of the formation of nicotinamide adenyl dinucleotide for the preparation of a medicament used in the treatment of inflammatory diseases such as rheumatoid arthritis and endotoxemia.... Agent: Pepper Hamilton LLP

20090325928 - 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors: and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions... Agent: Osi Pharmaceuticals, Inc.

20090325927 - Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor: Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.... Agent: Philip S. Johnson Johnson & Johnson

20090325926 - Pyrrolo[3,2-d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus: The present invention relates to substituted pyrrolo[3,2-d]pyrimidines of formula (I), wherein R1 and R2 are defined as in claim 1, including the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090325929 - Quaternary ammonium salt compounds of spirocyclopiperazines, preparation methods and uses thereof: Compounds represented by general formula (I), their stereoisomers, tautomers, derivatives, prodrugs or pharmaceutically acceptable salts, and their preparation methods or uses for the manufacture of a medicament of analgesics. In which R1 is selected from H, substituted or unsubstituted phenyl, or substituted or unsubstituted heteroaryl; A is bond, or saturated... Agent: Fay Sharpe LLP

20090325930 - Selective estrogen receptor modulator: formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a... Agent: Birch Stewart Kolasch & Birch

20090325931 - Use of cdk inhibitors for the treatment of granulocyte mediated disorders: Described herein is the use of CDK inhibitors such as roscovitine for inducing apoptosis of granulocytes, for example neutrophils. Their use for treating inflammatory diseases is also provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090325932 - 4-piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11 βHSD1) and are accordingly useful in the... Agent: High Point Pharmaceuticals, Inc.

20090325933 - Pyrimidinone derivatives and their use as a drug: The present application relates to new pyrimidinone derivatives. These products have a good affinity for certain sub-types of cannabinoid receptors, especially the CB2 receptors. They are particularly attractive for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions... Agent: Hunton & Williams LLP Intellectual Property Department

20090325934 - Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds: This invention is directed to methods of preventing or treating neurological or neuropathic diseases or conditions associated with excessive inflammation, neurodegeneration, neuro-remodeling, and axonal/neurite retraction. Particularly, this invention relates to methods treating neurological or neuropathic diseases such as cerebral ischemia, stroke, neuropathic pain, spinal cord injury, Alzheimer's disease, and multiple... Agent: Howery LLP

20090325935 - Gyrase inhibitors and uses thereof: The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals.... Agent: Vertex Pharmaceuticals Inc.

20090325936 - Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases: The present invention relates to compounds represented by Formula (I) and Formula (II): (I) (II) or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.... Agent: Merck And Co., Inc

20090325938 - Controlled-release cns modulating compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20090325937 - Pyridazine compounds as glycogen synthase kinase 3 inhibitors: s

20090325939 - 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent: Millen, White, Zelano & Branigan, P.C.

20090325940 - Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof: e

20090325941 - Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes: The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith.... Agent: High Point Pharmaceuticals, Inc.

20090325942 - Phenothiazin derivates, method for the production thereof and use thereof as pharmaceuticals: e

20090325943 - Veterinary pharmaceutical compositions for the treatment of pain and inflammation: This invention relates to veterinary pharmaceutical compositions based on a combination of tramadol and meloxicam or carprofen for the treatment of pain and inflammation in animals.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090325944 - Methods and compositions for modulating glycosylation: The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20090325945 - Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds: The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: wherein: J is independently —O— or —NRN1−; RN1, if present, is independently —H... Agent: Michael Best & Friedrich LLP

20090325946 - Novel phenolic and catecholic amines and prodrugs thereof: The present invention relates to novel phenolic and catecholic amines of Formula I, to processes for their preparation, pharmaceutical compositions containing them, to their use in therapy and to their use in radiolabeled form as PET- or SPECT ligands.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090325949 - 5 ht receptor mediated neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the... Agent: Dla Piper LLP (us)

20090325950 - Benzoxazine derivatives and uses thereof: e

20090325948 - Inhibitors of undecaprenyl pyrophosphate synthase: The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection.... Agent: Novartis Corporate Intellectual Property

20090325947 - Nitrate esters of piperidines: The application relates to novel nitrate ester derivatives of substituted piperidines of the general formula (I), wherein R1, R2, R3, X, Y and Z0, and m, n, p and q have the meanings explained in more detail in the description, a process for their preparation and the use of these... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090325951 - Thienyl-and furanyl-isoquinolinones and methods for using them: The present invention relates to substituted thienyl- and furanyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thienyl and furanyl-isoquinolinones and to their use in treating various diseases and disorders.... Agent: Wyeth Patent Law Group

20090325953 - P38 kinase inhibiting agents: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis,... Agent: Merck And Co., Inc

20090325952 - Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors: e

20090325954 - 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders: The invention concerns pyrimidine derivatives of Formula (I), wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative effect in... Agent: Astrazeneca R&d Boston

20090325955 - Gyrase inhibitors and uses thereof: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with... Agent: Vertex Pharmaceuticals Inc.

20090325956 - Aromatic amine derivative and use thereof: wherein ring A is an optionally substituted aromatic ring, ring B is an optionally substituted ring, ring C is an optionally substituted aromatic ring, R is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and X is a spacer having 1 to 5 atoms... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090325957 - Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders: e

20090325960 - Method for treating inflammatory diseases using rho kinase inhibitor compounds: This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, edema and inflammation. Particularly, this invention is directed to methods of treating inflammatory diseases or conditions such as rheumatoid arthritis and inflammatory bowel disease. The method comprises identifying a subject in... Agent: Howery LLP

20090325959 - Method for treating ophthalmic diseases using rho kinase inhibitor compounds: This invention is directed to methods of preventing or treating ocular diseases with inflammation, excessive cell proliferation, remodeling, neurite retraction, corneal neurodegeneration, excessive vaso-permeability and edema. Particularly, this invention relates to methods treating ocular diseases such as allergic conjunctivitis, corneal hyposensitivity, neurotrophic keratopathy, dry eye disease, proliferative vitreal retinopathy, macular... Agent: Howery LLP

20090325958 - Method for treating pulmonary diseases using rho kinase inhibitor compounds: This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness... Agent: Howery LLP

20090325961 - Indane modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof: or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are... Agent: Louis J. Wille Bristol-myers Squibb Company

20090325962 - Tyrosine derivative: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.... Agent: Genentech, Inc.

20090325963 - Iontophoretic delivery of curcumin and curcumin analogs for the treatment of alzheimer's disease: A method of delivering a curcuminoid to a patient, which includes iontophoretically delivering a charged curcuminoid across the skin of an Alzheimer's Disease patient.... Agent: Philip S. Johnson Johnson & Johnson

20090325964 - Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression: m

20090325965 - Biocidal compositions: Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability.... Agent: The Dow Chemical Company

20090325967 - Adenosine derivatives as a2a receptor agonists: A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A... Agent: Novartis Corporate Intellectual Property

20090325966 - S-triazine compounds, pharmaceutical compositions and method of using the same: c

20090325968 - Compositions useful as inhibitors of protein kinases: or a pharmaceutically acceptable salt or mixtures thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK mammalian protein kinase, and more particularly inhibitors of GSK-3 mammalian protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds... Agent: Vertex Pharmaceuticals Inc.

20090325970 - Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity:

20090325969 - Methotrexate adjuvants to reduce toxicity and methods for using the same: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine... Agent: Bozicevic, Field & Francis LLP

20090325971 - Pentacyclic alkaloid compounds and methods of use thereof: The present invention relates to Pentacyclic Alkaloid Compounds, compositions comprising an effective amount of a Pentacyclic Alkaloid Compound and methods for treating or preventing cancer, a bacterial infection, a fungal infection, or a yeast infection, comprising administering to a subject in need thereof an effective amount of a Pentacyclic Alkaloid... Agent: Wilmerhale/columbia University

20090325973 - Formulations containing pyridazine compounds: are independently hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkoxy, alkenyloxy, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkoxy, aryl, aryloxy, arylalkoxy, aroyl, heteroaryl, heterocyclic, acyl, acyloxy, amino, imino, azido, thiol, thioalkyl, thioalkoxy, thioaryl, nitro, cyano, halo, sulfate, sulfenyl, sulfinyl, sulfonyl, sulfonate, sulfoxide, silyl, silyloxy, silylalkyl, silylthio, ═O, ═S, phosphonate, ureido, carboxyl, carbonyl, carbamoyl,... Agent: Millen, White, Zelano & Branigan, P.C.

20090325974 - 1,5-diphenylpyrazoles ii as hsp90 inhibitors: Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R1-R6 have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20090325972 - Novel cinnamaldehyde derivatives having improved solubility in water, a method for preparing the same and a pharmaceutical composition comprising the same: Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of... Agent: Arent Fox LLP

20090325975 - Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain: The present invention refers to the use of compounds active on the sigma receptor for the production of a medicament for the treatment of diabetes-associated pain.... Agent: Cooper & Dunham LLP

20090325976 - Prostacyclin derivatives: This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases... Agent: Foley & Lardner LLP

20090325977 - Cancer combination therapy comprising azd2171 and imatinib: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor... Agent: Morgan Lewis & Bockius LLP

20090325979 - Novel imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof: Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel.... Agent: Frommer Lawrence & Haug LLP

20090325978 - Stable lyophilized preparation: The present invention provides a lyophilized preparation that has excellent stability over time and excellent solubility when reconstituted, and that contains (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide. The present invention discloses a lyophilized preparation containing 1) (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or a pharmaceutically acceptable salt thereof, 2) a pH regulator for adjusting a pH of the preparation to... Agent: Birch Stewart Kolasch & Birch

20090325980 - Piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid mtp inhibiting compounds: The present invention is concerned with novel piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine... Agent: Philip S. Johnson Johnson & Johnson

20090325981 - Compounds and compositions as lxr modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).... Agent: Genomics Institute Of The Novartis Research Foundation

20090325982 - Phosphodiesterase 4 inhibitors: e

20090325983 - New purine derivatives:

20090325984 - Use of 1,7-dimethylxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder: The present invention relates to the use of paraxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder.... Agent: Birch Stewart Kolasch & Birch

20090325985 - Diketopiperidine derivatives as hiv attachment inhibitors: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090325986 - Deazapurine analogs of 1'-aza-l-nucleosides: The invention relates to compounds of the formula (I), which are L-enantiomeric forms of nucleoside analogues, and to pharmaceutical compositions containing the compounds, methods of treating certain diseases, including cancer, bacterial infection, parasitic infection, and T-cell mediated diseases, using the compounds, processes for preparing the compounds, and intermediates useful in... Agent: Amster, Rothstein & Ebenstein LLP

20090325987 - Quinazolinedione derivatives as trpa1 modulators: The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates... Agent: Glenmark Pharmaceuticals S.a. C/o Darby & Darby P.C.

20090325988 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof: wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090325989 - Indazolyl derivatives useful as potassium channel modulating agents: Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular respiratory diseases, epilepsy, convulsions, seizures, absence seizures, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow... Agent: Birch Stewart Kolasch & Birch

20090325990 - Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators: Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction,... Agent: Merck And Co., Inc

20090325992 - Compound having cyclic group bound thereto through spiro binding and use thereof: a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy,... Agent: Sughrue-265550

20090325993 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R1, R2, R3, R4, R5, R6, R7, R9, R10, X, n, p and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090325991 - Spirolactam bicyclic cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, B, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine.... Agent: Merck And Co., Inc

20090325994 - Methods of treating diarrhea caused by small intestinal bacterial overgrowth: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom... Agent: Davis Wright Tremaine LLP/los Angeles

20090325995 - Preparation of pharmaceutical formulations: A process for the production of a composition comprising a water-insoluble opioid which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble opioid, ii) a water soluble carrier, and iii) a solvent for each of the opioid and the carrier, and b) spray-drying the mixture to remove... Agent: Unilever Patent Group

20090325996 - Camptothecin derivatives and their use: New camptothecin derivatives with the following structure of the formula (I), their use and the pharmaceutical compositions containing the same. The compounds of the present invention have good anti-tumor activities and good solubility in water, and can be used in development of medicines.... Agent: Baker & Hostetler LLP

20090325997 - Pharmaceutical compositions for the treatment of capillary arteriopathy: The present invention relates to the use of ergot derivatives or ergolines, and in particular of lisuride and terguride for the prophylaxis and treatment of constrictive capillary arteriopathy. Constrictive capillary arteriopathy refers to the diseases pulmonary arterial hypertension, endogenously induced or exogenously induced glomeruloscleroses as well as secondary Raynaud's syndrome.... Agent: Rankin, Hill & Clark LLP

20090325998 - Soil treating agent or seed treating agent comprising quinoline compounds or salts thereof as active ingredient,or method for preventing plant diseases by using the same: (wherein R1, R2: C1-C6 alkyl (may be substituted), aryl (may be substituted), heteroaryl (may be substituted), aralkyl (may be substituted) and the like; R3, R4: H, C1-C6 alkyl (may be substituted), halogen, C1-C6 alkoxy and the like; X: halogen, C1-C6 alkyl (may be substituted), C2-C6 alkenyl (may be substituted), C2-C6... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090325999 - Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions: This invention relates to personalized pharmaceutical kits, packaging, compositions, and methods for treatment of a mammal, comprising at least one antihistamine for treating an allergic disease or condition in a mammal, in combination with at least one wakefulness promoting agent for preventing sedative effects during day time use, while promoting... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090326000 - Resveratrol formulations and methods of use: A method is provided for preventing or treating obesity and for reducing the percentage body fat content of an individual. The method involves administration, preferably topical administration, of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, and analogs thereof, and combinations of any... Agent: Italia Ip

20090326002 - Thieno [2,3-b] pyridine compounds with mglur activity: Provided herein are Thieno[2,3-b]pyridine compounds with mGluR activity. Also provided herein are processes and intermediates for the preparation of the Thieno[2,3-b]pyridine compounds, pharmaceutical compositions containing these compounds, and the use of these compounds in treatment, therapy, and/or prevention of conditions which require modulation of mGluR1 and mGluR5 receptors.... Agent: Fish & Richardson P.C.

20090326001 - Thienopyridine derivatives as modulators of metabotropic glutamate receptors: The present invention relates to new mGluR1 and niGluR5 receptor subtype preferring ligands of formula (I): wherein X represents a group selected from (CH2)n, CH═CH, NH, N(CH3), NHCH2, N(CH3)CH2, O, OCH2, CH2COO, NHCH2COO; n is an integer of 0 to 2; Y represents a subtituent selected from H, CH3, F,... Agent: Fish & Richardson P.C.

20090326003 - Pyrazolo (3, 4-b) pyridine derivatives as pde4 inhibitors: e

20090326004 - Muscarinic receptor antagonists: The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed... Agent: Ranbaxy Inc.

20090326005 - Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof: Disclosed are new quinine sulfate/bisulfate solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.... Agent: Cantor Colburn, LLP

20090326006 - Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors: The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20090326007 - Compounds and methods for modulating sir2 protein activity: The present invention embraces compounds that modulate the activity of sirtuin deacetylase protein family members and use thereof for modulating Sir2 activity as well as for preventing or treating diseases or disorders associated with Sir2.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090326008 - Nf-kappa b inhibitor: or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090326009 - Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity: An object of the present invention is to study synthesis of a novel 1,2-dihydroquinoline derivative and to find a pharmacological action of the derivative. A compound represented by the general formula (1) or a salt thereof is effective in the treatment of a glucocorticoid receptor-related disease. In the formula, the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090326010 - Piperidinyl derivative as a modulator of chemokine receptor activity:

20090326011 - Azab i cyclo [3 . 1 . 0] hexane derivatives as dopamin d3 receptor modulators:

20090326012 - Malononitrile compounds: Compounds of formula I wherein X is O or S(═O)n; n is 0, 1 or 2; R1 is optionally substituted alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, cycloalkenyl, halocycloalkenyl, phenyl, hetaryl, phenylalkyl, hetaryl alkyl, optionally fused to phenyl, hetaryl or heterocyclyl; A is —NRb2, —C(=G)GRb, —C(=G)NRb2, —C(═NORb)Rb, C(=G)[N═SRb2], —C(=G)NRb—NR2,... Agent: Brinks, Hofer, Gilson & Lione

20090326013 - Isomers of inositol niacinate and uses thereof: An ester formed from an inositol or an inositol derivative and niacin, wherein the inositol or the inositol derivatives comprises a stereoisomer selected from allo-inositol, cis-inositol, epi-inositol, muco-inositol, neo-inositol, scyllo-inositol, D-chiro-inositol and L-chiro-inositol, or pharmaceutically acceptable salts thereof. Examples of esters include inositol hexaniacinates such as allo-inositol hexaniacinate and cis-inositol... Agent: Venable LLP

20090326014 - Use of 5-ht7 receptor agonists for the treatment of pain: The present invention refers to the use of 5-HT7 receptor agonists for the treatment of pain and the symptoms of pain, especially certain subtypes of pain like neuropathic pain and inflammatory pain and symptoms involving allodynia and hyperalgesia, the prevention or the prophylaxis of pain and the symptoms of pain,... Agent: Cooper & Dunham LLP

20090326015 - Compounds with embedded benzopyran motif for core structures and preparation method thereof: The present invention relates to a compound having benzopyran core, a preparation method of the derivatives by liquid phase synthesis and solid phase synthesis through diversity-oriented synthesis, and an anticancer agent comprising the compound that exhibit excellent cytotoxicity against cancer cells.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090326016 - Fungicidal n-cycloalkyl-carboxamide derivatives: The present invention relates to N-cycloalkyl-thiocarboxamide or N-cycloalkyl-N-substituted carboximidamide derivatives of formula (I) wherein A and B represent a 5-membered heterocyclyl groups, T represents an oxygen, sulphur or amino derivatives, Z1 represents a cycloalkyl group and Z2 and Z3 represent various substituents, their process of preparation, their use as fungicide... Agent: Ostrolenk Faber Gerb & Soffen

20090326017 - Pain-relieving compositions and uses therefor: This invention discloses compositions and methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention discloses the use of sub-normovasodilatory doses of nitric oxide donors in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain, especially neuropathic pain. According to... Agent: Knobbe Martens Olson & Bear LLP

20090326018 - 2-phenyl indene derivatives useful as estrogen receptor ligands: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides also provides the use of such compounds in the... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090326019 - 3,4-bicyclic pyrrolidine antivirals: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a... Agent: Elmore Patent Law Group, PC

20090326020 - Compounds for treatment of cancer: where Q is S, N, or O; X is optional, and can be O═, S═, ═N—NH2, ═N—OH, or —OH; Y is optional and can be —N(H)—, O, or C1 to C20 hydrocarbon; and R1 and R2 are each independently substituted or unsubstituted single-, fused- or multiple-ring aryl or (hetero)cyclic ring... Agent: Nixon Peabody LLP - Patent Group

20090326021 - Thiazolo naphthyl acids: e

20090326022 - Biocidal composition for leather tanning: The invention relates to a concentrated solution of TCMTB for the preparation of an emulsion of TCMTB. The concentrated solution comprises (i) 2-(thiocyanomethylthio)-benzothiazole, (ii) an ester of a C6-C20 fatty acid derived from vegetable oil or a blend of such esters of C6-C20 fatty acids, (iii) a surfactant or blend... Agent: Rankin, Hill & Clark LLP

20090326023 - Indane derivatives as modulators of ion channels: The present invention relates to indane derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090326025 - New pharmaceutical composition: The invention provides a new pharmaceutical compositions for treating cardiovascular disease, which contains the active component 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid, 1-[(isopropoxy)carbonyloxy]methyl ester dispersing in pharmaceutically acceptable carriers. The composition can be prepared to solid dosage forms e.g. powders, granules, dripping pills, micro-pellets, tablets, capsules, lozenges etc. by mouth or other way e.g.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090326024 - Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same: The present invention provides pharmaceutically acceptable salts of imidazole-5-carboxylic acid derivatives, methods for preparing same and pharmaceutical compositions comprising same. The salts obtained by the present invention can be easily dissolved in common solvents, such as water and methanol. The bioavailability thereof is good in animal body. Thereby it is... Agent: Dorsey & Whitney LLP Intellectual Property Department

20090326026 - Tricyclic compounds useful as angiotensin ii agonists: There is provided compounds of formula (I), wherein X1, X2, X3, Y4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090326027 - N-phenyl-2-0x0-1,4-diazaspiro [4.5] dec-3-en-1-yl acetamide derivatives and their use as glycine transporter inhibitors: e

20090326028 - Process for the preparation of temozolomide and analogs: where in R is as defined above in the presence of at least one metal halide, an acid and a source of nitrous acid, followed by conversion of acidic solution containing temozolomide. The conversion can be carried out by a liquid-liquid extraction technique in a water immiscible solvent. The temozolomide... Agent: Conley Rose, P.C.

20090326029 - Non-cyclic substituted benzimidazole thiophene benzyl ether compounds: The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090326030 - Use of levo-ornidazole in the preparation of anti-anaerobic bacteria infection drugs: The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090326031 - Antiviral use of cationic surfactant: Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the protection against the growth of the microorganisms. The cationic surfactants of... Agent: Renner Otto Boisselle & Sklar, LLP

20090326032 - Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers: t

20090326033 - Carvedilol: This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.... Agent: Kenyon & Kenyon LLP

20090326035 - Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals: Disclosed are compositions and methods for preventing or reducing postoperative ileus and gastric stasis. Such compositions include a combination of a carrier component and a bioactive component which acts to prevent or reduce post-operative ileus. Such methods include administering atherapeutically effective amount of the composition directly to the serosal surfaces... Agent: Philip S. Johnson Johnson & Johnson

20090326034 - Ketorolac tromethamine compositions for treating or preventing ocular pain: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than... Agent: Allergan, Inc.

20090326036 - [2-(6-fluoro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders: [2-(6-fluoro-1H-indol-3-ylsulfanyl)benzyl]methyl amine and pharmaceutically acceptable salts thereof, provided it is not the free base in a non-crystalline form are provided for the treatment of affective disorders.... Agent: Darby & Darby P.C.

20090326037 - Medicinal agent for treating viral infections: The invention relates to medicine, in particular to searching and developing novel medicinal agents for treating and preventing viral infections, mainly influenza viruses. The aim of said invention is to develop more efficient and low toxic medicinal agents by combining arbidol and the analogs thereof with a preparation exhibiting another... Agent: Fitch Even Tabin & Flannery

20090326038 - Method for treating a immunology-related disease: , wherein R1 and R2 are each hydrogen; R3 is hydrogen; R4 is C1-C2 alkyl; n is 2; X is ═N-D, wherein D is hydrogen, C1-C4 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2 or phenylene; Z is ethylene or trimethylene; R5 is unsubstituted C3-C10 cycloalkyl, unsubstituted C3-C10 aryl, or... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090326039 - Inhibitors for the soluble epoxide hydrolase: Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.... Agent: Townsend And Townsend And Crew, LLP

20090326055 - Chroman-derived compounds for the treatment of cancer: The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.... Agent: Quarles & Brady LLP

20090326056 - Novel actives against prostate carcinoma: The present invention relates to the use of a composition comprising lycopene and genistein in the prevention and coadjuvant treatment of prostate carcinoma. The present invention is also directed to the use of a composition comprising lycopene and epigallocatechin gallate in the prevention and coadjuvant treatment of prostate carcinoma. More... Agent: Nixon & Vanderhye, PC

20090326057 - Therapeutic uses of urolithins: The subject invention is drawn to ellagitannin metabolites (e.g., urolithin) that find use in treating or preventing a neoplastic disease in a subject.... Agent: Bozicevic, Field & Francis LLP

20090326058 - Casr antagonist: e

20090326059 - Benzyloxy anilide derivatives useful as potassium channel modulators:

20090326061 - Apoptotic and anti-tumor activities of metallo-salens: The present invention describes the synthesis and biochemical activities of metallo-salen compounds and their derivatives. The Mn(III)-salen and Fe(III)-salen derivatives of the present invention are potential anti-tumor agents, that affect cell viability, induce strong apoptotic activity, cause nuclear condensation, fragmentation, and ultimately death in breast cancer cells MCF-7.... Agent: Chalker Flores, LLP

20090326060 - Method of reversing, preventing, delaying or stabilizing soft tissue calcification: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090326062 - Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form: The present invention relates to a new method for obtaining Entacapone substantially free of Z-isomer from 3,4-dihydroxy-5-Nitrobenzaldehyde and N,N-Dimethylcyanoacetamide, or directly from a mixture of (E)- and (Z)-isomers of Entacapone, by formation of organic or inorganic salts, specially piperidine and sodium ones. A new crystalline form G of Entacapone can... Agent: Barnes & Thornburg LLP

20090326063 - Synthetic triterpenoids and methods of use in the treatment of disease: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.... Agent: Fulbright & Jaworski L.L.P.

20090326065 - Aqueous pesticidal composition: wherein R represents a hydrogen atom, a methyl group, a methoxy group or a methoxymethyl group, and X and Y independently represent a chlorine atom, a methyl group or a hydrogen atom; an alkylbenzene sulfonate, a polyoxyethylene styrenated phenyl ether having an HLB of 11 to 13, a hydrophilic solvent,... Agent: Sughrue Mion, PLLC

20090326064 - Pesticidal composition: wherein R1 represents a hydrogen atom or a methyl group, R2 represents a methyl group or a group represented by the formula —CH═CR21R22 (wherein R21 and R22 independently represent a hydrogen atom, a methyl group or a chlorine atom), and R3 represents a hydrogen atom, a methyl group or a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090326066 - Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of nep inhibitors: wherein R1, R1′ and R2 are defined as above, with hydrogen in the presence of a transition metal catalyst and a chiral ligand, wherein the transition metal is selected from group 7, 8 or 9 of the periodic table. Furthermore, the invention relates to products obtainable by said process and... Agent: Novartis Corporate Intellectual Property

20090326067 - Levodopa prodrug mesylate, compositions thereof, and uses thereof: (2R)-2-Phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090326068 - Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production: The present invention relates to methods of treating a cancerous tumor using selective inhibitors of ATP production. The present invention also relates to pharmaceutical preparations comprising such inhibitors and methods for administering them intraarterially directly to a tumor, as well as methods for identifying compositions that selectively inhibitor ATP production... Agent: Foley Hoag, LLP (w/jhv)

20090326069 - Azelaic acid ester compositions and methods for diagnosing and treating tissue conditions using azelaic acid ester compositions and proteinaceous biomarkers: Therapeutic and cosmetic treatments are performed through the application of azelaic acid ester compositions to patients suffering from or exhibiting tissue inflammation. The diagnosis, characterization and treatment of a patient suffering from or exhibiting tissue inflammation may be enhanced by using selected proteinaceous biomarkers obtained from analysis of said markers... Agent: Law Offices Of Christopher L. Makay

20090326070 - Vinyl substituted fatty acids: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.... Agent: Buchanan, Ingersoll & Rooney PC

20090326071 - Method of feeding milk replacer with carnitine: A method of the present invention includes feeding a calf a milk replacer at an enhanced rate with carnitine. The method of the present invention enhances weight gain, starter intake and reduces weaning time.... Agent: Westman Champlin & Kelly, P.A.

20090326072 - Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-l,3- cyclohexanedione in the treatment of parkinson's disease: The present invention relates to, inter alia, the use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-1,3-Cyclohexanedione (compound 2) in the treatment of a neurodegenerative disease, such as Parkinson's disease. The invention also relates to the use of the compound depicted as compound 2 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament... Agent: Morgan, Lewis & Bockius LLP (sf)

20090326073 - Protection of normal cells: The invention provides compositions comprising sulindac, R-epimer sulindac, S-epimer sulindac, derivatives, metabolites, and structural analogs thereof which protect normal cells against damage caused by solar rays, oxidative damage, environmental factors, diseases and organisms.... Agent: Darby & Darby P.C.

20090326074 - Alkoxy compounds for disease treatment: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD)... Agent: Wilson Sonsini Goodrich & Rosati

20090326075 - Enantiomers of o-desmethyl venlafaxine: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central... Agent: Wyeth Patent Law Group

20090326076 - Foamable alcohol compositions, systems and methods of use: i

20090326077 - Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same: The present invention pertains to polyisobutylene urethane, urea and urethane/urea copolymers, to methods of making such copolymers and to medical devices that contain such polymers. According to certain aspects of the invention, polyisobutylene urethane, urea and urethane/urea copolymers are provided, which comprise a polyisobutylene segment, an additional polymeric segment that... Agent: Mayer & Williams PC

20090326078 - Process for preparing a solid dosage form: This invention provides a process for preparing a solid dosage form, comprising:—preparing an aqueous slurry, solution or suspension of (a) a powder material, and (b) a mixture of one or more polyols and one or more maltodextrins, and—spray drying the resultant aqueous slurry, solution or suspension, thereby obtaining particles which... Agent: Clark & Elbing LLP

20090326079 - Methyl cyclohexane carboxylates and their use in perfume compositions: i

  
12/24/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090318330 - Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take: The invention relates to a combination of a solution of a gelatin derivative and at least one amino acid, if desired in the form of a pharmaceutically acceptable salt or carboxylic acid derivative, for inhibiting renal uptake of substances, that are potentially damaging for the kidneys, in a living being.... Agent: Patterson & Sheridan, L.L.P.

20090318332 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent: Philip S. Johnson Johnson & Johnson

20090318331 - Oral insulin therapies and protocol: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired... Agent: Pearl Cohen Zedek Latzer, LLP

20090318334 - Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease: The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells... Agent: Fulbright & Jaworski, LLP

20090318333 - Modified metallothioneins and methods for screening and treatment of diseases associated with oxidative stress: The present invention is based on the therapeutic potential of a reduced form of thionein. Accordingly, the invention features modified metallothionein or thionein proteins, for example, where at least one sulfur atom is substituted with selenium (e.g., a cysteine substituted with selenocysteine), and fragments thereof. The invention also features methods... Agent: Clark & Elbing LLP

20090318335 - Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders: Peptides having a structure characterized by the presence of two loops constrained in cyclic structure by the presence of covalent bonds between amino acid side chains, the amino acid sequences of the first and the second loop being substantially homologues to that of loop 1 (residues 29-38) and of loop... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090318336 - Deuterated cyclosporine analogs and methods of making the same: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution... Agent: Fish & Richardson P.C.

20090318353 - Acylated exendin-4 compounds: This invention provides new therapeutic peptides, i.e. new protracted Exendin-4 compounds, pharmaceutical compositions and the use of such.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090318339 - Biodegradable polymers having a pre-determined chirality: Optically active polymers that are composed of monomer residues derived from chiral pre-polymerized monomers, which maintain the chirality of the pre-polymerized monomers upon polymerization are disclosed. These polymers can be composed of monomer residues that are derived from readily available chiral monomers and can be designed to have pre-determined characteristics... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090318346 - Bivalent erbb ligand binding molecules and methods for their preparation and use: A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding... Agent: K&l Gates LLP

20090318337 - Compositions and methods for activating innate and allergic immunity: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic... Agent: Seed Intellectual Property Law Group PLLC

20090318344 - Compositions and methods for modulating hemostasis using variant forms of activated factor v: Methods for the treatment of coagulation disorders using Factor V/Va variants are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20090318355 - Compositions and methods for promoting tissue repair and wound healing: A method is described for using the Ea4-peptide of pro-IGF-I or human Eb-peptide of pro-IGF-I for enhancing the proliferation of fibroblasts and closure of wound. The peptide species can be homologous of trout Ea4-peptide, human Eb-peptide of pro-IGF-I or a fusion protein comprising the Ea4- or Eb-peptide of pro-IGF-I. It... Agent: Mccarter & English, LLP Hartford Cityplace I

20090318358 - Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains: The present invention relates to compositions and methods of use comprising peptidyl-prolyl isomerase (PPI) polypeptides of group C and G streptococci and polynucleotides encoding same. The invention also relates to immunogenic compositions comprising the PPI polypeptides and polynucleotides, as well as antibodies and antibody fragments that bind the PPI polypeptides.... Agent: Wyeth Patent Law Group

20090318359 - Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains: The present invention relates to polynucleotides encoding Streptococcus group C and G polypeptides and their use in immunogenic compositions. The invention also relates to immunogenic compositions comprising polypeptides encoded by those polynucleotides. In addition, the invention relates to methods of inducing an immune response in mammals against beta hemolytic Streptococcus... Agent: Wyeth Patent Law Group

20090318342 - Compounds: A mutant TIMP-3 (Tissue Inhibitor of MetalloProteinase-3) polypeptide wherein an additional residue or residues, for example an alanine residue, precedes the N-terminal residue of the TIMP-3 polypeptide; or wherein the residue corresponding to Threonine2 of TIMP-3 is mutated to Glycine. Such a mutant is considered to retain activity as an... Agent: Nikolai & Mersereau, P.A.

20090318340 - Il-17 homologous polypeptides and therapeutic uses thereof: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides... Agent: Goodwin Procter LLP

20090318352 - Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth... Agent: Marshall, Gerstein & Borun LLP

20090318345 - Means and methods for modulating stem cell mobilization: Mobilization of stem cells in individuals is currently used in methods for their collection and in methods for therapeutically intervening in disease processes in the human body. The present invention provides means and methods for increasing numbers of mobilized stem cells and provides uses therefore.... Agent: Traskbritt, P.C.

20090318351 - Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist: Compositions, kits and methods are provided for preventing or treating tissue injury caused by stresses or shocks related to oxygen deficiency, such as ischemia, anoxia, hypoxia, reperfusion and other environmental stresses. In particular, protein kinase C (PKC) isozyme-specific agonists and antagonists are provided for treating cardiac tissue damage due to... Agent: Morrison & Foerster LLP

20090318356 - Methods and compositions for control of fetal growth via modulation of relaxin: The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to... Agent: Morrison & Foerster LLP

20090318338 - Methods for modulating bone formation and mineralization by modulating krc activity: This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization. TGF-β signaling in osteoblasts promotes the formation of a multimeric complex between KRC, Runx2, Smad3, and the E3 ubiquitin ligase, WWP1 which inhibits Runx2... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090318341 - Methods of using osk1 peptide analogs: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells... Agent: Amgen Inc.

20090318357 - Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use: The present invention is based, at least in part, on the finding that certain molecules are preferentially associated with effector T cells or regulatory T cells. Accordingly, immune responses by one or the other subset of cells can be preferentially modulated. The invention pertains, e.g., to methods of modulating (e.g.,... Agent: Fish & Richardson P.C.

20090318347 - Novel compounds and their effects on feeding behaviour: The invention provides a compound of formula (I): X-PYY*(3-36) (I) wherein X is selected from H, PYY1-2 (ie Tyr Pro) and D-Allo-Ue; PYY*(3-36) representing PYY (3-36) in which one or more residues is replaced by an acylated lysine group, the acyl group being selected from: CO—C1-20 alkyl, CO—C2-20 alkenyl, CO—C5-10... Agent: Nixon & Vanderhye, PC

20090318350 - Pan-her antagonists and methods of use: The present invention features human epidermal receptor (HER) antagonists. These antagonists are polypeptide variants of ligands of HER. The HER ligand polypeptide variants of the invention possess Pan-HER antagonistic properties and can inhibit at least one HER-mediated biological activity of one or more HER subtypes, such as inhibition of the... Agent: Elmore Patent Law Group, PC

20090318343 - Protein formulations for use at elevated temperatures: Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.... Agent: Philip S. Johnson Johnson & Johnson

20090318348 - Proteins, nucleic acids encoding the same, and associated methods of use: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research... Agent: Mccarter & English, LLP Hartford Cityplace I

20090318349 - Transglutaminase variants with improved specificity: Variants of transglutaminase from Streptoverticillium ladakanum, which variants have improved selectivity for Gln-141 of human growth hormone are provided.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090318354 - Use of at least one isoform of progesterone receptor membrane component 1 (pgrmc1): The invention relates to the use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1) as diagnostic marker and/or therapeutic target for diseases associated with neogenin and/or DCC and/or for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090318360 - Use of the neurotoxic component of a botulinum toxin for treating arthritis: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20090318361 - Anti-hemorrhage medication pack: An anti-hemorrhage medication pack for administering an anti-hemorrhage drug, in particular for the treatment of hemorrhage caused by trauma in emergency situations comprises an active ingredient selected from the group comprising the 1-24 amino acid sequence of the adrenocorticotropic hormone (ACTH 1-24) and all its fragments and analogues, and analogues... Agent: Tutunjian + Bitetto, P.C.

20090318362 - Oligomeric compounds for the modulation of survivin expression: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin,... Agent: Dechert LLP

20090318364 - Method and peptide for regulating cellular activity: Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.... Agent: Klarquist Sparkman, LLP

20090318363 - Peptide aptamer for neutralizing the binding of platelet antigene specific antibodies and diagnostic and therapeutic applications containing the same: The present invention relates to a peptide aptamer which mimics particularly the human platelet antigene HPA-Ia epitope present on the platelet GPIIb/IIIa molecules and which is capable of neutralizing the binding of HPA-I a specific antibodies (anti-HPA-1 a). This peptide aptamer is advantageously used in a method for detecting and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090318365 - Metastin derivatives and use thereof: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivatives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.... Agent: Edwards Angell Palmer & Dodge LLP

20090318366 - Cholesterol lowering protein hydrolysates: The present invention relates to the production of novel peptides which have a length of between 4 and 8 amino acids and comprises the amino acid sequence -Xaa-Xbb-Xcc-Xdd- or -Xbb-Xcc-Xdd-Xaa-, whereby Xaa and Xcc can be His (H), Arg (R) or Lys (K), and Xbb and Xdd can be Pro... Agent: Nixon & Vanderhye, PC

20090318368 - Angiotensin-converting enzyme inhibitory peptides: e

20090318367 - Use of sh2 stat3/stat1 peptidomimetics as anticancer drugs: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention display selective inhibition of specific STAT isoform homo-dimerization. The peptidomimetic probes of STAT1 function, described herein,... Agent: Smith Hopen, Pa

20090318369 - Biomarkers for alzheimer's disease and methods using the same: The present invention provides various biomarkers of Alzheimer's Disease (AD). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of AD, methods of determining predisposition to AD, methods of monitoring progression/regression of AD, methods of assessing efficacy of compositions for treating AD, methods of... Agent: Brinks, Hofer, Gilson & Lione

20090318370 - Novel glycoconjugated chlorin derivatives and method of producing the same: Disclosed is a novel glycoconjugated chlorin derivative which is useful as a substance for photodynamic therapy, is stable, and can act a photosensitizer having high phototoxicity even when used in a small quantity. Also disclosed is a method of producing the derivative. Specifically disclosed are a S-glycosylated chlorin derivative represented... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090318371 - Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (microsponged benzoyl peroxide): The present invention relates to a topical preparation for treating acne in the form of a gel and cream comprising Retinoid (Tazarotene or Adapalene) Antibiotic (Clindamycin Phosphate) and/or Keratolytic (Benzoyl Peroxide in microsponges) as active ingredients and a carrier formulated with all or some of the following components: Polyoxyl 35... Agent: Banner & Witcoff, Ltd.

20090318372 - Method for producing 2-o-glyceryl-alpha-d-glucopyranoside: The present invention relates to a method for producing 2-O-glyceryl-α-D-glucopyranoside (αGG; FIG. 1) from a glucosyl donor and a glucosyl acceptor comprising the steps:—providing a sucrose phosphorylase (EC 2.4.1.7), incubating said sucrose phosphorylase with a mixture comprising a glucosyl donor and glycerol as glucosyl acceptor and isolating and/or purifying 2-O-glyceryl-α-D-glucopyranoside.... Agent: Chalker Flores, LLP

20090318373 - Receptor-type kinase modulators and methods of use: The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090318374 - Methods of diagnosing and treating migraine: The present invention provides methods of diagnosing migraine attacks and determining predisposition of an individual to the development of migraine based on sodium level in the cerebrospinal fluid (CSF) and/or brain extracellular fluid. The invention also provides methods of treating migraine, wherein the individual is selected for treatment based in... Agent: Morrison & Foerster LLP

20090318375 - Crystalline azithromycin l-malate monohydrate and pharmaceutical composition containing same: This invention provides a crystalline azithromycin L-malate monohydrate for treating various microbial infections, which has high thermostability, solubility and non-hygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.... Agent: Sughrue Mion, PLLC

20090318376 - High throughput screening method of binding inhibitor between caspase3 and xiap and binding inhibitor screened thereby: The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors... Agent: Moore & Van Allen PLLC

20090318377 - Medicagenic acid saponin and uses thereof: A cholesterol-lowering preparation comprising medicagenic acid saponin is disclosed. The amount of medicagenic acid saponin in the preparation is greater than 50% by weight to produce the cholesterol-lowering effect in an animal. A method of purifying a preparation of at least 30% medicagenic acid saponin is also disclosed. The preparation... Agent: Schwegman, Lundberg & Woessner, P.A.

20090318378 - Antibiotic combinations for providing total solution to the treatment of infections: The invention relates to a new pharmaceutical composition, a method of treatment of infection and also a process to prepare the composition. The infectious complications are important causes of morbidity and mortality. Hospital acquired pneumonia (HAP) remains the most severe nosocomial infection in intensive care units. Beta-lactams alone are always... Agent: Amin Talati, LLC

20090318379 - Statins for the treatment of viral influenza infections: The present invention relates to methods for the treatment of viral influenza using statins, or pharmaceutically effective salts, pro-drugs or metabolites thereof. In particular it is disclosed that statin hydroxyl acid salts including, but not limited to, mevastatin, lovastatin, pravastatin and simvastatin, are effective in conferring resistance to infection with... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090318533 - Annexin a9 (anxa9) biomarker and therapeutic target in epithelial cancer: Amplification of the ANXA9 gene in human chromosomal region 1q21 in epithelial cancers indicates a likelihood of both in vivo drug resistance and metastasis, and serves as a biomarker indicating these aspects of the disease. ANXA9 can also serve as a therapeutic target. Interfering RNAs (iRNAs) (such as siRNA and... Agent: Lawrence Berkeley National Laboratory

20090318535 - Beta -trcp1, beta -trcp2 and rsk1 or rsk2 inhibitors and methods for sensitizing target cells to apoptosis: The invention relates to modulating BimEL levels (Bcl-2-Interacting Mediator of cell death, Extra Long isoform) to sensitize cancer cells to cell death or apoptosis. In certain embodiments, the invention relates to increasing BimEL levels. In certain embodiments, the invention relates to inhibitors of at least one of β-TrCP1/2 or RSK1/2... Agent: Darby & Darby P.C.

20090318532 - Compounds and methods for modulating expression of ptp1b: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Mcdermott Will & Emery

20090318534 - Methods and compositions for the treatment of skin diseases and disorders: The disclosure demonstrates the role of cathelicidin, serine protease and/or vitamin D3 in rosacea pathology.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090318536 - Methods for treating hypercholesterolemia: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an... Agent: Drinker Biddle & Reath (dc)

20090318538 - Polymeric oligonucleotide prodrugs: Polymer conjugates containing nucleotides and/or oligonucleotides are disclosed.... Agent: Lucas & Mercanti, LLP

20090318537 - Silencing of tgf beta type ii receptor expression by sirna: The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory... Agent: Licata & Tyrrell P.C.

20090318531 - Small interfering rna specific for hcv and therapeutic agent for hepatitis c comprising the same: The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV... Agent: Sughrue Mion, PLLC

20090318540 - Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells: The invention relates to regulatory polynucleotides derived (i) from rat and human AFP promoter sequences and (ii) from rat and human HIP/PAPI promoter sequences, which regulatory polynucleotides are useful for expressing nucleic acids of interest specifically in mammalian cancer cells, including mammalian cancer liver cells.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090318539 - Process for preparing a particle comprising a biological molecule and a carrier polymer: A process for preparing a particle comprising a biological molecule typically a DNA plasmid, and a carrier polymer, typically poly-lactic acid (PLA), in which an organic solvent solution of the biological molecule and the carrier polymer in an organic solvent medium, nearly saturated with the biological molecule, is prepared, then... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090318380 - 2',4'-substituted nucleosides as antiviral agents: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2′,4′-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.... Agent: Merchant & Gould PC

20090318381 - Halogenated alkyl di-and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.... Agent: Owen J Bates

20090318383 - Compositions and methods for modulation of vascular structure and/or function: The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as... Agent: Jones Day

20090318382 - Use of bacterial polysaccharides for biofilm inhibition: A method comprises preventing or inhibiting bacterial adhesion and/or bacterial biofilm development by treating a substrate with a composition of a soluble group II capsular polysaccharide obtained from a bacterial strain.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090318384 - Composition intended for the treatment of amyotrophic lateral sclerosis: The invention relates to the use of a composition for controlling the evolution of amyotrophic lateral sclerosis, characterised in that it comprises at least: a conjugate of poly-lysine and at least one anti-oxidant, and a conjugate of poly-lysine and at least one fatty acid. The invention also relates to a... Agent: Young & Thompson

20090318385 - Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient: e

20090318386 - Active compound combinations having insecticidal and acaricidal properties: The invention relates to novel active compound combinations of certain cyclic ketoenols and certain active compounds that together have unexpectedly good insecticidal and acaricidal properties.... Agent: Bayer Cropscience Lp

20090318387 - Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as hsp90-inhibitors: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.... Agent: Biogen Idec / Finnegan Henderson, LLP

20090318388 - Method of activation of oxazaphosphorines: The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest... Agent: Myers Bigel Sibley & Sajovec

20090318389 - Agonists of the sphingosine-1 phosphate receptor: The invention provides compounds formulae I-III, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090318390 - Combinations comprising epothilones and pharmaceutical uses thereof: wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl and Z is O or a bond, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable... Agent: Novartis Corporate Intellectual Property

20090318329 - Methods for assessing suitability of cancer patients for treatment with histone deacetylase inhibitors: This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs).... Agent: Clark & Elbing LLP

20090318391 - Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent: The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of... Agent: David S. Resnick

20090318392 - Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk: The invention concerns a method for diagnosing a child's susceptibility for developing type 1 diabetes by using a serum metabolite as biomarker. The invention concerns also a method for prevention of the onset of type 1 diabetes in a child.... Agent: Young & Thompson

20090318393 - Film-forming liquid formulations for controlled release of pesticides: A controlled pesticide delivery system includes a film-forming alkanol solution of at least one amphiphilic polymer and at least one pesticide composition for the treatment of at least one pest in gardens, landscapes, forests, and wooden structures, targeting at least one pest selected from fire ants, tent caterpillars, gypsy moths,... Agent: Leigh P. Gregory

20090318394 - Long chain polyunsaturated fatty acids and methods of making and using the same: Disclosed are compositions containing DHA and DPAn-6 and methods of administering and using the same to treat or prevent at least one symptom of inflammation or neurodegeneration or disease states associated with inflammation or neurodegeneration. Also discloses are compositions containing specific dosages and/or ratios of long chain polyunsaturated fatty acids... Agent: Sheridan Ross PC

20090318395 - 3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases: The present invention relates to the use of 3β-hydroxychlormadinone acetate (17α-acetoxychloropregna-4,6-dien-3β-ol-20-one) and/or 3α-hydroxychlormadinone acetate (17α-acetoxychloropregna-4,6-dien-3α-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3β-hydroxy-chlormadinone acetate and/or 3α-hydroxychlormadinone acetate.... Agent: Norris, Mclaughlin & Marcus, Pa

20090318397 - Combination of azelastine and steroids: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.... Agent: Conley Rose, P.C.

20090318396 - Corticosteroid linked beta-agonist compounds for use in therapy: New chemical entities which comprise corticosteroids and phosphorylated β-agonists for use in therapy and compositions comprising and processes for preparing the same.... Agent: Gilead Sciences Inc

20090318398 - Androgen pharmaceutical composition and method for treating depression: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent: Mayer Brown LLP

20090318399 - Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder: e

20090318400 - Method for inhibiting tumor growth with dehydrosulphurenic acid extracted from antrodia cinnamomea: The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical... Agent: Wpat, PC Intellectual Property Attorneys

20090318401 - Use of estriol in low doses: The invention relates to the use of low doses of estriol by vaginal route for treatment and/or prevention of urogenital atrophy due to estrogen deficit in women.... Agent: Hoffmann & Baron, LLP

20090318402 - Ruthenium (ii) compounds: A ruthenium (II) compound of formula (I) wherein X is halo or a neutral or negatively charged O, N- or S-donor ligand; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; A is either: (i) (Ru)—NRN1RN2—RN3—(N), where RN1 and RN2 are independently selected from... Agent: Curatolo Sidoti Co., Lpa

20090318403 - Antibiotic composition: The present invention provides antimicrobial compositions comprising an antibiotic and a sensitizer that enhances the effectiveness or activity of the antibiotic, wherein the sensitizer is preferably a primary amine containing a long alkyl chain. Such compositions are particularly useful for the treatment of infections by drug resistant bacteria.... Agent: Morgan Lewis & Bockius LLP

20090318404 - Substituted beta-lactams: e

20090318406 - Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands:

20090318408 - Halo-substituted pyrimidodiazepines: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090318407 - Inhibitors of protein kinases: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a... Agent: Townsend And Townsend And Crew, LLP

20090318409 - Pyrrolidine inhibitors of iap: e

20090318405 - 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors: The present invention provides substituted bicyclic heteroaryl compounds, including, for example, 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20090318410 - Imidazopyridazines as lipid kinase inhibitors: e

20090318411 - Purine pi3k inhibitor compounds and methods of use: Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I... Agent: Genentech, Inc.

20090318412 - Tricyclic heterocyclic compound and use thereof: r

20090318413 - Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma: The present invention thus provides a method of inhibiting bronchial smooth muscle remodeling in asthma, comprising the step of administering to a subject having asthma an agent that inhibits calcium-dependent mitochondrial biogenesis.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090318415 - Dibenzothiazepine derivatives and uses thereof - 424: e

20090318414 - Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome: The invention relates to the use of a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof to treat prodromal syndrome and in the manufacture of a medicament for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome using a functional muscarinic M1/M4 agonist... Agent: Nixon & Vanderhye, PC

20090318416 - Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it: e

20090318418 - Delta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20090318419 - Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20090318420 - Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20090318417 - Gamma-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20090318422 - Ophthalmic percutaneous absorption type preparation: The present invention provides an ophthalmic percutaneous absorption type preparation containing an ophthalmic drug and a vasoconstrictor, which can increase the amount of the ophthalmic drug transferred through the eyelid to a topical area in the eye, particularly the anterior segment of the eye such as conjunctiva, lacrimal fluid, aqueous... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090318421 - Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity: e

20090318423 - Ion channel modulators & uses thereof: Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is... Agent: Sunstein Kann Murphy & Timbers LLP

20090318424 - Novel compounds: Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090318425 - Apoptosis signal-regulating kinase 1 inhibitors: v

20090318426 - Use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders: The invention relates to the use of flumazenil in the manufacture of a medicament for the treatment of depressive disorders, for example disorders including depressive symptoms, without psychotic alteration. The flumazenil can be administered sequentially in small quantities at short intervals until a quantity that is therapeutically effective for the... Agent: Banner & Witcoff, Ltd.

20090318427 - Benzodiazepine derivatives for treating hepatitis c infection: Use of a benzodiazepine of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing a hepatitis C infection, wherein: —R1 represents C1-6 alkyl, aryl or heteroaryl; —R2 represents hydrogen or C1-6 alkyl; —each R3 is the same or different... Agent: Astrazeneca R&d Boston

20090318428 - Heteroaryl derivatives as protein kinase inhibitors: e

20090318429 - Compounds, compositions and methods comprising heteroaromatic derivatives: The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set... Agent: Foley & Lardner LLP

20090318430 - Medical use of cyclin dependent kinases inhibitors: e

20090318431 - Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents: The present invention provides a compound of formula (I) wherein X is a structure of the following formula (i), (ii) (iii), or iv G is O, or S; U is —(CR3R4)n—; W is CH2NHC(=G)R1, CH2NH-het, CH2-G-het, CH2het, C(═O)NHR2; and Y1, Y2 and Y3 are independently CH, or CF. The compounds... Agent: Pfizer Inc Mary J Hosley

20090318432 - Nitrate esters of aminoalcohols: The application relates to novel nitrate ester derivatives of substituted aminoalcohols of the general formula (I), wherein R1, R2, R3, V, X, Y and Z0 have the meanings explained in more detail in the description, to a process for their preparation and to the use of these compounds as therapeutics... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090318433 - Very fast time resolved imaging in multiparameter measurement space: The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H3-receptors of histamine.... Agent: Stites & Harbison PLLC

20090318434 - Composition and process - 356: e

20090318435 - Pyrazolopyridines and analogs thereof: Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, and 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090318436 - Fused heterocyclic derivatives and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20090318437 - Substituted pyrazolo[1,5-a] pyridine compounds and their methods of use: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.... Agent: King & Spalding LLP

20090318439 - 5-furopyridinone substituted indazoles: Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20090318438 - Heterocyclic compounds and their use as anticancer agents: The present invention relates to heterocyclic compounds that have anticancer activity, and pharmaceutical compositions that contain such compounds, methods of treating diseases and conditions in mammals using such compounds and composition and methods for their manufacture.... Agent: Imclon Lerner, David, Littenberg, Krumholz & Mentlik, LLP

20090318440 - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors: Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.... Agent: Pfizer Inc

20090318443 - Kinase inhibitors: The present invention provides kinase inhibitors of Formula I.... Agent: Eli Lilly & Company

20090318441 - Pyrrolopyrimidine compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090318442 - Thiazolyl-and oxazolyl-isoquinolinones and methods for using them: The present invention relates to substituted thiazolyl- and oxazoyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders.... Agent: Wyeth Patent Law Group

20090318445 - Pdf inhibitors: The invention relates to novel compounds that are inhibitors of peptidyl deformylase (PDF). The compounds are useful as antimicrobials and antibiotics. The compounds of the invention display selective inhibition of peptidyl deformylase versus other metalloproteinases such as MMPs. Methods of preparation and uses of the compounds are also disclosed.... Agent: Novartis Corporate Intellectual Property

20090318444 - Tetrahydro- and dihydroquinazolinones: The present invention relates to the use of tetrahydro- and dihydroquinazolinones of formula I as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases, their use for the manufacture of a pharmaceutical composition and new tetrahydro-... Agent: Millen, White, Zelano & Branigan, P.C.

20090318446 - 4-(1h-indol-3-yl)-pyrimidin-2-ylamine derivatives and their use in therapy: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof. The present invention seeks to provide further substituted heteroaryl-substituted pyrimidine derivatives. More specifically, the invention relates to compounds that have broad therapeutic applications in the treatment of a number of different diseases and/or that are capable... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090318450 - Compositions for modulating a kinase cascade and methods of use thereof: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090318448 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090318451 - Morpholine dopamine agonists for the treatment of pain: e

20090318447 - N-[6-(4-morpholinyl)-3-pyridinyl]-2-(tetrahydro-2h-pyran-4-yl)-n-[(1--4-piperidinyl) methyl] acetamide derivatives and related compounds as glyt1 transport inhibitors for the treatment of neurological disorders such as schizophrenia:

20090318449 - Therapeutic lactams:

20090318452 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of... Agent: Ropes & Gray LLP

20090318453 - Postoperative adjuvant chemotherapy for gastric cancer: e

20090318454 - Novel antioxidants and methods of treatment: Formula 1 is an antioxidant compound, wherein R, R1, or D is an antioxidant substituent; R and D are each independently selected from hydrogen or groups containing cysteine, thiols, disulfides, amino acids, amines, amides, or carboxylic acids; when one of R or D is hydrogen, the other includes a thiol,... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090318455 - Compounds and methods for treating inflammatory and fibrotic disorders: Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that... Agent: Marshall, Gerstein & Borun LLP

20090318457 - Methods of using hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide: Disclosed are hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, processes for preparing them and their use as pharmaceutical compositions.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090318456 - Substituted pteridines for the treatment and prevention of viral infections: Tri-substituted pteridines and tetra-substituted pteridines exhibit a significant and selective activity against certain types of viral infections, in particular they selectively inhibit the replication of the hepatitis C virus, and are useful for the prevention and treatment of such infections.... Agent: Maria Herdewijn

20090318460 - Amorphous varenicline tartrate and process for the preparation thereof: The present invention generally relates to an amorphous form of varenicline and its pharmaceutically acceptable salts thereof. More particularly the present invention relates to amorphous forms of varenicline and its L-tartrate salt; a process for their preparation and pharmaceutical compositions comprising the same.... Agent: Glenmark Pharmaceuticals Inc Usa

20090318458 - Novel compounds and use thereof: A semiautomatic vehicle gearbox comprising, for said gearbox, a shift lever (10) directly coupled to the gearbox itself; a shaft of said gearbox; and connection means between said shift lever and said shaft; characterised by comprising a sensor (20) for sensing the operation of said shift lever coupled to said... Agent: Ladas & Parry LLP

20090318459 - Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor: s

20090318461 - Crystalline polymorphism of 5-methyl-2-(piperazin-1-yl) benzenesulfonic acid:

20090318462 - Protein kinase c zeta inhibition to treat vascular permeability: Methods of treating or preventing a disease or disorder in a subject are provided by the present invention which include administering a composition including a therapeutically effective amount of a protein kinase C (PKC) zeta inhibitor. A disease or disorder treated or prevented by administration of a PKC zeta inhibitor... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090318463 - Indolylmaleimide derivatives: Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090318466 - Compounds useful as pesticides: Compounds useful to control pests are provided.... Agent: Dow Agrosciences LLC

20090318465 - Method for identifying compounds that act as insulin-sensitizers: The present invention relates to a method for identifying compounds that act as insulin-sensitizers. The method can include screening of test compounds in two assays of insulin sensitivity. This method can identify lead compounds for the treatment of disorders caused by insulin resistance to glucose uptake. This invention also includes... Agent: Frommer Lawrence & Haug

20090318467 - Novel heteroaryl carboxamide derivatives: e

20090318464 - New pyridine analogues v: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20090318468 - Pyrazole compounds 436: e

20090318470 - 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands:

20090318469 - Use of flibanserin for the treatment of sexual disorders in females: The invention is directed to the use of flibanserin or a pharmacologically acceptable derivative thereof, for the preparation of a medical composition for the treatment of Sexual Disorder in females whereby the medication of a patient is selected to achieve a significant change (with administration of a therapeutically effective amount... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090318471 - New salts and crystalline salt forms of an indolinone derivative: The present invention relates to new salts and crystalline salt forms of an indolinone derivative which have valuable pharmacological properties, to a process for their manufacture, to pharmaceutical formulations containing them and to their use as medicament.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090318472 - Aminopyrazine derivatives and compositions: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090318473 - 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin ii receptor antagonists: The present invention relates to derivatives of 5,6-bisaryl-2-pyridine-carboxamide, their preparation and their application in therapeutics as antagonists of urotensin II receptors.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090318474 - Pyridine and pyrimidine derivatives as mglur 2 antagonists: e

20090318475 - Novel, acyclically substituted furopyrimidine derivatives and use thereof: The present application relates to novel, acyclically substituted furopyrimidine derivatives, methods for their production, their use for the treatment and/or prophylaxis of diseases and their use for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090318476 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck And Co., Inc

20090318477 - Chemical compounds: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090318480 - Method for treating cancer harboring egfr mutations: The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090318479 - Substituted ring fused azines and their use in cancer therapy: The present invention relates to substituted ring fused azines and methods of using said compounds in treating cancers. More specifically, the present invention relates to the preparation of 4-alkyl-2-(heterocyclic)-azines and their use as cancer agents or drugs for cancer therapy. The compounds of the invention display favourable in vivo and... Agent: Occhiuti Rohlicek & Tsao, LLP

20090318478 - Quinazoline derivatives: e

20090318481 - Potentiators of glutamate receptors:

20090318483 - Potentiators of glutamate receptors:

20090318482 - Tablet preparation without causing a tableting trouble: The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.... Agent: Foley And Lardner LLP Suite 500

20090318484 - Inhibitors of jnk: wherein m, n, p, q, Q, r, R1, R2, R3, X, X1, X2, X3, X4, X5, Y1, Y2, Z1 and Z2 areas defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations... Agent: Grant D. Green Roche Palo Alto LLC

20090318485 - Novel inhibitors of rho kinase: The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.... Agent: Global Patent Group - Kal

20090318486 - Tricyclic spiro derivatives as crth2 modulators: The present invention is related to the use of spiro derivatives of Formula (I) for the treatment and/or prevention of allergic diseases, inflammatory dermatoses and other diseases with an inflammatory component. Specifically, the present invention is related to the use of spiro derivatives for the modulation of CRTH2 activity.... Agent: Emd Serono Research Institute

20090318487 - Methods for detection of promoter polymorphism in a ugt gene promoter: The present invention is directed to methods for detecting the presence of genetic polymorphisms that correlate with altered gene expression. More specifically, the present invention is directed to methods for detecting the genetic polymorphisms located in the UGT1A1 promoter. The invention also provides methods for optimizing drug dosages based upon... Agent: Fulbright & Jaworski L.L.P.

20090318489 - Aporphine compounds and pharmaceutical use thereof: The present invention discloses novel aporphine derivatives. Also, the present invention discloses that these novel aporphine derivatives can be used for treating oxidative stress induced diseases such as cardiovascular disease, diabetes, aging, Alzheimer's disease, kidney disease, cancer or brain ischemic disease etc.... Agent: Bacon & Thomas, PLLC

20090318488 - Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same: The present invention discloses novel pharmaceutically acceptable salts of aporphine compounds and carboxyl-group containing agents. Also, the present invention discloses methods for preparing the pharmaceutically acceptable salts. These pharmaceutically acceptable salts are suitable for use in treating and/or preventing hyperglycemic disease and/or several oxidative stress related diseases.... Agent: Bacon & Thomas, PLLC

20090318490 - Compounds and methods for promoting smoking cessation: Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090318491 - Cytisine and acetylcholine analogs and methods of treating mood disorders: The present invention relates to compounds which are derivatives of cytisine or acetylcholine which exhibit activity as agonists, partial agonists or antagonists of nicotinic acetylcholine receptors and may be used in modulating these receptors and in treating mood disorders in patients in need of therapy.... Agent: Coleman Sudol Sapone, P.C.

20090318493 - Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof: Aryl and heteroaryl ketone compounds substituted with pyrrolidines and piperidines, that modulate serotonin norepinephrine and/or dopamine neurotransmission. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090318492 - Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors: Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.... Agent: Mcandrews Held & Malloy, Ltd

20090318494 - Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors: d

20090318495 - Ethenyl carboxamide derivatives useful as microbiocides: Compounds of the formula (I), which are suitable for use as microbiocides, and in which A is A1, or A is A2, or A is A3, or A is A4 and B is a phenyl, naphthyl or quinolinyl group.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090318496 - Preparation containing fibrate agent and process for producing the same: A preparation (pharmaceutical composition) reducing a concentration of a free fatty acid and/or fibrinogen in the blood is prepared. The preparation contains a statin agent comprising at least a statin compound having a benzopyridine skeleton (e.g., pitavastatin) and a fibrate agent (e.g., fenofibrate). The preparation is useful as a preventive... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090318497 - Substituted pyridylmethyl bicycliccarboxyamide compounds: This invention provides a compound of the formula (I): wherein A1 is N and A2 is CR7, or A1 is CR7 and A2 is N; Y1, Y2 and Y3 are each independently CH or N, Y4 and Y5 are each independently CR8 or N, with the proviso that when one... Agent: Pfizer Inc. Patent Department

20090318498 - Piperidyl acrylamide antagonists of ccr2: wherein: R1, R2, R3, R4, R5 and X are as defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is uveitis, including acute, recurring or chronic uveitis. The invention also comprises a method of... Agent: Philip S. Johnson Johnson & Johnson

20090318500 - 4-(2, 6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer: The invention provides the compound of formula (I) 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide in a substantially crystalline form, therapeutic uses thereof and pharmaceutical compositions containing the crystalline compound. The invention also provides novel pharmaceutical formulations containing 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide and novel processes for preparing the compound.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090318499 - Compounds having analgesic and/or immunostimulant activity: The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals.... Agent: Allergan, Inc.

20090318501 - Piperidine derivatives as renin inhibitors: The present invention is directed to aspartic protease inhibitors represented by the following structural formula; or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a subject... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090318502 - Pharmaceutical compositions comprising a hypoglycemic agent and methods of using same: The present invention relates to intranasally deliverable compositions comprising a hypoglycemic agent, for example, repaglinide, and to methods of using such compositions in the treatment of various disorders, including, for example, type-2 diabetes.... Agent: Goodwin Procter LLP Patent Administrator

20090318503 - Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors: Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.... Agent: Crowell & Moring LLP Intellectual Property Group

20090318504 - Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods: This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090318505 - Fungicidal compositions: A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula (I) or a tautomer of such a compound; and component (B) and component (C) are pesticides as described in claim 1.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090318506 - Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine: c

20090318507 - Potassium channel activators for the prevention and treatment of dystonia and dystonia like symptoms: The present invention is directed to the prevention, reversal and medical treatment of dystonia and dyskinesia as well as other diseases related to movement disorders, both in human beings and animals by administering a neuronal potassium channel opener such as flupirtine, retigabine or maxipost.... Agent: Timothy H. Van Dyke

20090318508 - Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore: The invention relates to formulations useful in treating hair disorders, improving the health of hair, increasing hair growth, and in increasing the niacin content of hair follicles. Nicotinic acid alkyl esters having a straight chain alkyl group of from 1 to 22 methylene units, preferably from 6 to 16 methylene... Agent: Fulbright & Jaworski, LLP

20090318509 - Oxime derivatives as inhibitors of macrophage migration inhibitory factor: Provided are compounds of formula (I) and other compounds. Also provided are pharmaceutical compositions comprising these compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal, and methods of treating a mammal having... Agent: Amster, Rothstein & Ebenstein LLP

20090318510 - Topical drug delivery system: The present invention relates to compositions for topical delivery of one or more vasoactive vitamins and their methods of preparation and use. More specifically, the composition includes one or more vasoactive vitamins, one or more alkyl hydroxybenzoate preservatives, an alkanol solvent, an alkoxylated alcohol humectant, and a high molecular weight... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20090318511 - Selective hydroxamate based mmp inhibitors: said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by... Agent: Novartis Institutes For Biomedical Research, Inc.

20090318512 - Methods of maintaining ocular tissue cell membrane integrity using cetylpyridinium chloride: A multi-purpose contact lens care solution having high antimicrobial activity comprising, in an aqueous liquid medium, cetylpyridinium chloride and a non-ionic surfactant. In one embodiment of the invention, the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity... Agent: Abbott Medical Optics, Inc.

20090318513 - Compounds exhibiting thrombopoietin receptor agonism: wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090318514 - Novel pharmaceutical compositions: The invention provides the use of compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, for the manufacture of a medicament for the treatment or prophylaxis of a condition that may... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090318515 - Succinimide derivatives as ocular hypotensive agents: The invention provides a method for treating ocular disorders associated with ocular hypertension by administrating an effective amount of a pharmaceutical composition comprising a succinimide derivative.... Agent: Soroker-agmon Advocate And Patent Attorneys

20090318516 - Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use: Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and hydrates thereof are disclosed, as well as compositions comprising them and methods of their use.... Agent: Lexicon Pharmaceuticals, Inc.

20090318518 - Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists: The invention is directed to indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090318517 - Novel compounds 148: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.... Agent: Pepper Hamilton LLP

20090318519 - Process for release of biologically active species: A process for the release of a biologically active species comprising the steps of: providing a mesoporous oxide-based material having structural order and at least one level of porosity; fixing or immobilizing said biologically active species in said ordered mesoporous oxide; and providing said ordered mesoporous oxide with said fixed... Agent: Clark & Elbing LLP

20090318520 - Use of isoindoles for the treatment of neurobehavioral disorders: The present invention generally relates to the use of drugs for the treatment of neurobehavioral disorders or symptoms of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms... Agent: Birch Stewart Kolasch & Birch

20090318521 - Synthesis of 4-bromomethyl-2'-formylbiphenyl and 4-bromomethyl-2'-hydroxymethylbiphenyl and its use in preparation of giotensin ii antagonists: 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl are useful starting material for the preparation various angiotenzin II antagonists, which are prepared from 4-bromomethyl-2′-cyanobiphenyl or 4′-bromomethylbiphenylcarboxyilic derivatives using selected hydride reagent.... Agent: Arent Fox LLP

20090318522 - Therapy for the treatment of disease: Disclosed herein are pharmaceutical compositions comprising oxybutynin, or a free base thereof or a pharmaceutically acceptable salt thereof, and pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above... Agent: Techlaw LLP

20090318523 - Benzoisoindole derivatives and their use as ep4 receptor agonists: The present invention relates to benzoisoindole phenylacetic acid derivatives, corresponding pharmaceutical compositions, preparation processes and uses in medicine as EP4 receptor angonists.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090318524 - Bicyclic tetrahydropyrrole compounds: The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.... Agent: Cooper & Dunham LLP

20090318525 - Process for preparing a 3-pyrrole substituted 2-indolinone malate salt: The invention relates to the malic acid salt of N-[2-(diethylamino)ethyl]-5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxamide, to the use thereof as an intermediate for preparing the malic acid salt of sunitinib, and to pharmaceutical compositions comprising said malic acid salt of sunitinib.... Agent: Leydig Voit & Mayer, Ltd

20090318527 - Indole compounds and methods of use thereof: Novel indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.... Agent: Lando & Anastasi, LLP

20090318526 - Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia: The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.... Agent: Nixon & Vanderhye, PC

20090318528 - Hydrate crystals: New (2R,4R) monatin monosodium salt hydrate crystals characterized by having specific characteristic X-ray diffraction peaks provide general-purpose, stable, and safe monatin sodium salt crystals incorporating no organic solvent. These crystal may be prepared by a method that requires no organic solvent in the crystallization, separation, and drying steps. These crystal... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090318529 - Salinosporamides and methods for use thereof: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group.... Agent: Dla Piper LLP (us)

20090318530 - Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers: e

20090318541 - Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions: The present invention relates to a novel class of hydroxamic acid derivatives carbamate, urea, amide and sulfonamide substitutions. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell... Agent: Merck And Co., Inc

20090318542 - Ophthamological drugs: The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same... Agent: Michael Best & Friedrich LLP

20090318543 - C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes: Taxanes having an ethyl ester or cyclopropyl ester substituent at C(10), a keto substituent at C(9), a hydroxy substituent at C(7), a thienyl substituent at C(3′) and a cyclobutyloxycarbamate or cyclopentyloxycarbamate substituent at C(3′), pharmaceutical compositions comprising such taxanes, methods of treatment and administration, and methods of preparation of medicaments... Agent: Bryan Cave LLP

20090318544 - Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide: The present invention is directed to a novel crystalline form of (2S)-(−)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of anxiety and related disorders; bipolar depression and mania; depression; epilepsy and related disorders; epileptogenesis; glucose related disorders; lipid related disorders; migraine;... Agent: Philip S. Johnson Johnson & Johnson

20090318545 - Mast cell inhibition in diseases of the retina and vitreous: This application discloses methods for treating or preventing an ophthalmic retinal vascular permeability, angiogenic or fibroproliferative disease, disorder or condition that involve administering to a patient in need thereof a composition that can inhibit mast cell migration into the vitreous or the retina, mast cell proliferation in the vitreous or... Agent: Schwegman, Lundberg & Woessner, P.A.

20090318546 - Chromen-2-one derivatives: i

20090318547 - Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture: Glucopyranosyl-substituted difluorobenzyl-benzene derivatives of general formula (I) as defined according to claim 1, including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090318548 - Para-quinol derivatives and methods of stereo selectively synthesizing and using same: This application relates to para-quinol derivatives, such as analogues of manumycins, aranorosins and gymnastatins. This application also relates to methods of synthesizing and using the para-quinol derivatives. In one embodiment of the invention a compound having the chemical structure (I) is provided wherein X1 and X2 are carbon atoms either... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20090318549 - Combination treatment of glaucoma: The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and administering an eye drop adjunctive composition to the eye of a patient. The sustained release formulation can release latanoprost continuously for at least 90 days from a... Agent: Schwegman, Lundberg & Woessner, P.A.

20090318550 - Emulsions comprising at least one retinoid and benzoyl peroxide: Stable dermatological/cosmetic emulsions useful, e.g., for the treatment of acne vulgaris, contain, formulated into a physiologically acceptable medium, a homogeneous dispersion of at least one dispersed retinoid, dispersed benzoyl peroxide, at least one fatty phase, at least one hydrophilic phase and at least one emulsifier.... Agent: Buchanan, Ingersoll & Rooney PC

20090318551 - Uses of analogs of 3-o-acetyl-11-keto-beta-boswellic acid: These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth... Agent: Rader Fishman & Grauer PLLC

20090318552 - Pharmaceutical composition comprising shikonin derivatives from lithospermum erythrorhizo dor treating or preventing diabetes mellitus and the use thereof: The present invention relates to a composition for preventing and treating diabetes mellitus that includes a shikonin compound as an active ingredient and to a use thereof. More particularly, the present invention relates to a composition for preventing and treating diabetes mellitus that includes isobutyryl shikonin, β,β-dimethylacryl shikonin, isovaleryl shikonin,... Agent: Olson & Cepuritis, Ltd.

20090318553 - Use of docosahexaenoic glycerides for the treatment of tumorous diseases: The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight... Agent: Cozen O''connor

20090318554 - Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils: Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15%... Agent: Ingrassia Fisher & Lorenz, P.C. (floratech)

20090318555 - Treatment of vertigo with acetyl-l-leucine: The use of acetyl-L-leucine and the pharmaceutically acceptable salts of same for the manufacture of a medicament for the treatment of vertigo and other balance disorders. Advantageously, the acetyl-L-leucine is a 100% mixture.... Agent: Birch Stewart Kolasch & Birch

20090318556 - Biomarkers for detecting radiation exposure: methods and uses thereof: Disclosed herein are biomarkers for determining gamma radiation exposure by an animal or human. The biomarkers include 3-hydroxy-2-methylbenzoic acid 3-O-sulfate, N-hexanoylglycine, β-thymidine, taurine, xanthine, xanthosine, 2′-deoxyuridine, 2′-deoxycytidine, 2′-deoxyxanthosine, or any salt, ion, or combination thereof. Also disclosed are methods for determining gamma radiation exposure by an animal or human, which... Agent: Woodcock Washburn LLP

20090318557 - Dermatological compositions: A dermatological composition comprising a salt of a cation and an anion. The cation is derived from a monomeric or polymeric molecule that will generate an amidine moieity, a guanidine moieity or a biguanide moieity. The anion is derived from a monomeric or polymeric molecule that will generate a carboxylic... Agent: Law Offices Of Jack Matalon

20090318558 - Solvent system of hardly soluble drug with improved dissolution rate: The present invention relates to a solvent system with improved disintegration degree and dissolution ratio of a hardly soluble drug by highly concentrating the drug through partial ionization, and by establishing optimal conditions for enhancing bioavailability of the drug, such as the co-relation between the acid drug and the accompanied... Agent: Smith Patent Office

20090318560 - Formulations for cathepsin k inhibitors: The instant invention relates to pharmaceutical compositions comprising cathepsin K inhibitors as the active ingredient with excipients which include binders, diluents, lubricants, and disintegrants. Also disclosed are processes for making said pharmaceutical compositions for oral and intravenous delivery.... Agent: Merck And Co., Inc

20090318559 - Modafinil-based treatment for premature ejaculation: Methods and compositions comprising modafinil are described for treating premature ejaculation in a male individual.... Agent: Leon R Yankwich Yankwich & Associates

20090318561 - Colchicine products, method of manufacture, and methods of use: Disclosed herein is a method of using colchicine. In one embodiment, the method comprises administering to a patient colchicine and a substrate of cytochrome P450 1A2 and monitoring the patient during administration of colchicine and the substrate for an adverse event. Also disclosed are articles of manufacture comprising a container... Agent: Cantor Colburn, LLP

20090318563 - Nematicidal compositions and methods: Certain ethanolamine analogs and related compounds useful in the control of nematodes that infest plants or the situs of plants are described. Nematodes that parasitize animals can also be controlled using the methods and compounds of this invention... Agent: Fish & Richardson PC

20090318562 - Use of bupropion metabolites for the treatment of inflammatory disorders: r

20090318564 - Process for preparing and drying solid rasagiline base: Disclosed is crystalline R(+)-N-propargyl-l-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the preparation of solid rasagiline base.... Agent: Cooper & Dunham, LLP

20090318565 - Novel compositions for the enhancement of the anti-oxidant potential of hydrogenated curcuminoids or combinations thereof: Disclosed are novel compositions for the enhancement of the anti-oxidant potential of natural or metabolite hydrogenated (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione derivatives. It was discovered that the antioxidant potential of hydrogenated curcuminoids was highly enhanced when a closely structurally related 1,7-Bis(4-hydroxyphenyl)-3,5-heptanedione, exhibiting unexpectedly pro-oxidant properties, was removed from the compositions.... Agent: Sabinsa Corporation

20090318566 - Gossypol derivatives, production method thereof and uses of same: s

20090318567 - Lycopene for the treatment of metabolic dysfunction: This invention relates to the treatment of metabolic dysfunction and disorders associated with metabolic dysfunction using lycopene compounds. Methods of treatment and uses of lycopene compounds in such methods are provided.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090318568 - Adherent coating for tissue surface and/or trans-tissue surface substance delivery: An adherent coating composition is described having a reservoir of medication or other substance and capable of intimate contact with a target area of exposed tissue, rapid conveyance of the medication onto or into the target area. Mixtures of polyvinylpyrrolidone and glycerin have been found to dissolve a large number... Agent: Cochran Freund & Young LLC

20090318569 - Method for producing microspheres loaded with drugs and microspheres loaded with drugs produced thereby: The present invention relates to a method for producing polymeric microspheres loaded with drugs and polymeric microspheres loaded with drugs produced thereby, specifically a method for producing polymeric microspheres loaded with drugs, the method comprising the steps of a) adding a dispersion phase containing a high molecular compound, a drug,... Agent: Buchanan, Ingersoll & Rooney PC

20090318570 - Skin protection compositions, in particular cream to protect against cold: e

  
12/17/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090312232 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312233 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312234 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312235 - Method for producing insulin in the form of an oral preparation: t

20090312236 - Pegylated insulin lispro compounds: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of... Agent: Eli Lilly & Company

20090312237 - Regulating fat and carbohydrate oxidation in muscle tissue comprising controlling garnitine content in muscle: Methods, compositions and substances for regulating fat and carbohydrate oxidation in the muscle tissue of human and/or animal bodies, which involve controlling the carnitine content of the muscle tissue. Regulating carbohydrate and fat oxidation, and particularly increasing the level of fat oxidation in accordance with the present invention, by providing... Agent: Brooks Kushman P.C.

20090312239 - Preparation, for use, in particular, for tissue augmentation and healing: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible... Agent: Stites & Harbison PLLC

20090312238 - Protection against oxidative damage in cells: The present invention relates to the use of MT as a reducing system for the Msr enzymes and other oxioreductase enzymes which form similar intermediates. Specifically, the invention provides for a reduction in the level of oxidative damage in cells through an increase in levels of MT by administration of... Agent: Darby & Darby P.C.

20090312240 - Synthesis of sialic acid in plants: A method of synthesizing sialic acid in plants, and plants capable of synthesizing sialic acid is provided. Furthermore, a method of producing sialylated a protein in a plant is also provided. The method to synthesize sialic acid comprises providing a plant comprising a nucleotide sequence encoding N-acetyl neuraminic acid (Neu5Ac)... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090312242 - Flibanserin for the treatment of urinary incontinence and related diseases: The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090312241 - Macrocyclic compounds as antiviral agents: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, m, R1, R2, R3, R4, R5, Ra, M, Z and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C... Agent: Merck And Co., Inc

20090312261 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312252 - Antimicrobial activity in variants of lacritin: The present invention provides recombinant proteins with antimicrobial activity and methods for treating animals including humans by administering the novel recombinant proteins. In particular, the invention provides methods for treating and/or preventing microbial diseases and infections using lacritin and homologs, fragments, modifications, and derivatives thereof.... Agent: University Of Virginia Patent Foundation

20090312248 - Antimicrobial protein: The present invention provides improved antimicrobial compositions comprising peptide fragments of tammar wallaby milk proteins and analogs and derivatives thereof exemplified by the amino acid sequences of SEQ ID Nos: 1-40 and uses therefor in the treatment of a range of infections by bacteria and fungi. The antimicrobial compositions are... Agent: Knobbe Martens Olson & Bear LLP

20090312244 - Compounds and methods for immunotherapy and diagnosis of tuberculosis: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M.... Agent: Townsend And Townsend And Crew, LLP

20090312260 - Drug therapy for celiac sprue: Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090312250 - Epidermal growth factor increasing insulin secretion and lowering blood glucose: The present inventors show that a brief exposure to EGF stimulates insulin secretion glucose-independently via a Ca2+ influx- and PLD2-dependent mechanism. Furthermore, the present invention shows that EGF is a novel secretagogue that lowers plasma glucose levels in normal and diabetic mice, suggesting the potential for EGF treatment in diabetes.... Agent: Sheridan Ross PC

20090312259 - Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract,... Agent: Jones Day

20090312254 - Long-acting polypeptides and methods of producing same: A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention... Agent: Pearl Cohen Zedek Latzer, LLP

20090312253 - Methods of effecting wnt signaling through dkk structural analysis: Compositions and methods related to Wnt signaling regulation by Dickkopf (Dkk) polypeptides and Wnt-related diseases are disclosed. For example, compounds that bind a Dkk or LRP polypeptide are disclosed. Compounds that disrupt binding of a Dkk polypeptide to an LRP polypeptide are also disclosed. Methods for using the described compounds... Agent: Enzo Biochem, Inc.

20090312251 - Methods of regulating differentiation in mammals: Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms with loss of expression of the differentiation regulator, and methods of preparing the transgenic organisms, are provided.... Agent: LexyoumeIPGroup, LLC

20090312247 - Natriuretic peptide related fragment in cardiovascular disease: This disclosure provides an intracellular fragment of natriuretic peptide receptor A (NPRA), referred to herein as soluble natriuretic peptide receptor-related fragment (sNRF). It is shown herein that sNRF causes NP resistance. Based on these observations, methods of treating a cardiovascular disorder by inhibiting the activity of sNRF are disclosed. Assays... Agent: Klarquist Sparkman, LLP

20090312245 - Sra binding protein: An isolated polypeptide comprising: (i) SEQ ID No: 2; (ii) amino acids 27 to 109 of SEQ ID No: 2 (iii) amino acids 22 to 109 of SEQ ID No: 2 (iv) amino acids 21-91 of SEQ ID No: 2 (v) amino acids 21-26 and/or 60-67 of SEQ ID No:... Agent: Edwards Angell Palmer & Dodge LLP

20090312255 - Stimulation of trpv1+ sensory neurons to control beta-cell stress and islet inflammation in diabetes: The present invention provides a method of altering the function of TRPV1+ sensory afferent neurons in the pancreas as a way of treating, managing, alleviating, etc., the symptoms and/or underlying causes of diabetes or abnormal glucose metabolism by increasing the release of neuropeptides, such as substance P (sP) or other... Agent: Vedder Price, PC

20090312249 - Tlr4 decoy receptor protein: The present application discloses a nucleic acid molecule encoding a fusion polypeptide capable of binding myeloid differentiation protein-2 (MD-2) polypeptide, which includes: a nucleotide sequence encoding an MD-2 polypeptide-binding portion of human toll-like receptor 4 (TLR4), a leucine-rich repeats (LRR) module, and a multimerizing component.... Agent: Jhk Law

20090312243 - Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds: Inhibitors of angiogenesis are disclosed as being useful therapeutics for treating various aspects of inflammatory bowel disease, in particular Crohn's Disease. A method for decreasing the magnitude of intestinal inflammation or inflammatory infiltrate in bowel tissue, a method for lowering systemic or gut-associated levels of a proinflammatory cytokine in a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090312246 - Uses of glucoregulatory proteins: The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090312256 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Knobbe Martens Olson & Bear LLP

20090312257 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Knobbe Martens Olson & Bear LLP

20090312258 - Uses of human zven proteins and polynucleotides: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.... Agent: Knobbe Martens Olson & Bear LLP

20090312263 - Gene differentially expressed in breast and bladder cancer and encoded polypeptides: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to methods of treating or preventing a disorder in a subject. The invention further relates to uses of C35 polypeptides in immunogenic compositions or vaccines, to induce antibody... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090312262 - Peptide compound with biological activity, its preparation and its applications: The invention relates to a peptide compound with biological activity, which in particular possesses antimicrobial properties, its preparation and its applications.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090312265 - Novel antimicrobial peptides and use thereof: The invention relates to a molecule comprising at least the amino acid sequence K X K X1 X2 X K G X wherein X is any amino acid residue X1, and X2 is K or R and wherein said molecule have a length of from about 10 to about 100... Agent: Merchant & Gould PC

20090312264 - Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule: Provided is a squamous cell carcinoma antigen derived peptide which is capable of binding to an HLA-A24 molecule and recognized by the cellular immune system, and a pharmaceutical composition comprising said peptide for the treatment or prevention of squamous cell carcinoma.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090312267 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312268 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312269 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Daffer Mcdaniel, LLP

20090312266 - Peptide derived from vascular endothelial growth factor receptor-1 binding integrin alpha5beta1 having proangiogenic activity: Description of a sequence peptide isolated in the domain II type-immunoglobulin (Type-Ig) of the Vascular Endothelial Growth Factor receptor 1 (VEGF-1) binding integrin α5β1, usable for the preparation of pharmacological agents having proangiogenic activity.... Agent: Young & Thompson

20090312271 - Method for elevating prolactin in mammals: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20090312270 - Peptides having an ace inhibiting effect: Use of the tripeptide MAP optionally in combination with tripeptide ITP and salts thereof for the preparation of a functional food angiotensin-converting enzyme inhibitor. Also provided is the use of the tripeptide MAP and optionally the tripeptide ITP or salts thereof as an angiotensin-converting enzyme inhibitor in functional foods.... Agent: Unilever Patent Group

20090312272 - Transglutaminase inhibitors and methods of use thereof: Transglutaminase inhibitors and methods of use thereof are provided.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090312273 - Compositions compromising dimethyl sulfoxide (dmso): The invention relates generally to compositions comprising dimethylsulfoxide (DMSO) and associated compounds in combination with one or more of the following: fructose 1,6-diphosphate, L-arginine, L-lysine, L-aspartate, and urea. Methods for treating traumatic brain injury, ischemic stroke, atherosclerosis, spinal cord trauma, and neurodegenerative illnesses are also provided.... Agent: Knobbe Martens Olson & Bear LLP

20090312274 - Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases: Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor... Agent: Wilson, Sonsini, Goodrich & Rosati

20090312275 - Agent for improving insulin resistance: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains 3-O-β-D-glucopyranosyl-4-methylergost-7-en-3-ol, or an organic solvent extract, a hot water extract... Agent: Knobbe Martens Olson & Bear LLP

20090312276 - Compositions and methods for treating cancer: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.... Agent: Townsend And Townsend And Crew, LLP

20090312277 - Compositions and methods for reversing or preventing resistance of a cancer cell to a cytotoxic agent: The present invention provides a composition and method for increasing sensitivity of a cancer cell and to reverse or prevent resistance to a cytotoxic agent. The composition includes an inhibiting agent and, optionally, a cytotoxic agent. The inhibiting agent is present in a sub-lethal dose with respect to the cancer... Agent: Brinks Hofer Gilson & Lione

20090312278 - Treatment of cancers of the blood using selected glycomimetic compounds: Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual... Agent: Seed Intellectual Property Law Group PLLC

20090312279 - Antimicrobial compositions: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids,... Agent: Whiteford, Taylor & Preston, LLP Attn: Gregory M Stone

20090312395 - Assay: RAN and RAN Binding Protein 1 have been determined to be markers of invasive and metastatic potential of a tumour cell. There is described methods and kits for the detection of the level of RAN and RAN Binding Protein 1 and the use thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090312393 - Cancer therapy using bcl-xl-specific sina: The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more... Agent: Alston & Bird LLP

20090312396 - Methods for cancer treatment using tak1 inhibitors: The invention includes, in part, a method of inhibiting lymphoid tumour cell proliferation by contacting the lymphoid with a TAK1 inhibitor.... Agent: Astrazeneca R&d Boston

20090312394 - Protection against and treatment of age related macular degeneration: Methods and reagents in relation to the diagnosis, protection and treatment of Age Related Macular Degeneration (AMD). In particular, the methods and reagents in relation to RNA; determined to provide a strong protection to a subject against development of AMD.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090312397 - Rnai modulation of apob and uses thereof: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.... Agent: Alnylam/fenwick

20090312403 - Compositions and methods for wt1 specific immunotherapy: Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that... Agent: Seed Intellectual Property Law Group PLLC

20090312398 - Compositions and their uses directed to il-4r alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to... Agent: Swanson & Bratschun, L.L.C.

20090312402 - Encapsulated nanoparticles for drug delivery: Compositions and methods are provided for preparing nanosized biologically nucleic acids, including agents formulated for target specific drug delivery. In some embodiments, the nanoparticles comprise a polymer coating, which can provide for controlled delivery, targeting, controlled release, and the like. In other embodiments, the nanoparticles comprise a target specific tag... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090312399 - Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells: The present invention relates to guanosine-rich oligonucleotides having the capacity to induce cell death, having characteristics of programmed cell death, in non-quiescent cells of higher eukaryotic organisms. The invention also relates to therapeutic methods involving the administration of these nucleic acid molecules to subjects suffering from, or being predisposed to,... Agent: Philip S. Johnson Johnson & Johnson

20090312401 - Isolated dna fragment of the sparc human promoter and its use for driving the expression of an heterologous gene in tumor cells: An isolated DNA sequence corresponding to a region of the SPARC gene human promoter from base pair −513 to base pair +3 5 capable of driving the expression of a heterologous gene of interest, that can be associated to any other promoter sequence, such as radiation responsive sequence, hypoxia responsive... Agent: Fish & Richardson PC

20090312400 - Methods for therapy of neurodegenerative disease of the brain: A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified... Agent: Stacy L. Taylor Dla Piper LLP (us)

20090312280 - Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide: The present invention relates to novel combination therapies of (2R,Z)-2-amino-2-cyclohexyl-N-(5-(1-methyl-1H-pyrazol-4-yl)-1-oxo-2,6-dihydro -1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide (compound 1), a pharmaceutically acceptable salt thereof, or a mixture thereof, in combination with an anti-cancer agent or radiation therapy.... Agent: Pfizer Inc

20090312281 - Process for the preparation of a pulverulent composition and product as obtained: Method of preparing a non-hygroscopic pulverulent composition, includes a step for the spray drying, without an atomization support, of an aqueous solution containing at least one initially hygroscopic product, having a glass transition temperature ranging from 10° C. to 110° C., and a cryogenic fluid, especially a food-grade cryogenic fluid,... Agent: Young & Thompson

20090312283 - Branched hyaluronic acid and method of manufacture: A branched hyaluronic acid, wherein the linear backbone comprises hyaluronic acid in which one or more N-Acetyl-Glucosamine has been deacetylated to Glucosamine, with branching sidechain(s) covalently linked to the primary amine(s) of said deacetylated Glucosamine thus forming a secondary amine(s); a precursor for producing said branched hyaluronic acid; and a... Agent: Novozymes North America, Inc.

20090312282 - Novel low molecular weight hyaluronic acid and/or salt thereof, and cosmetic preparation, pharmaceutical composition, and food composition each using same: A low-molecular-weight hyaluronic acid and/or its salt has an average molecular weight of 5000 to 20,000, and has a molecular weight distribution in which the proportion of components having a molecular weight of 10,000 or less is 40 wt % or more and the proportion of components having a molecular... Agent: Wolf Greenfield & Sacks, P.C.

20090312284 - Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors: The present invention is concerned with combinations of a proteasome inhibitor and a histone deacetylase inhibitor with combined activity on class-I and class-IIb histone deacetylases, for inhibiting the growth of tumor cells, useful in the treatment of cancer.... Agent: Philip S. Johnson Johnson & Johnson

20090312285 - Biological specimen collection and transport system and methods of use: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing... Agent: Haynes And Boone, LLPIPSection

20090312286 - Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors: s

20090312287 - Multi-carotenoids compositions and methods: A stable nutritional supplement composition for oral administration comprising, in one form, about 71% by weight, of a tomato extract containing therein at least 2% to 10% by weight of lycopene, 0.25% to 2% by weight of phytoene, and 0.2% to 2% by weight of phytofluene, and about 29% by... Agent: David T. Bracken Law Offices

20090312288 - Kinase inhibitors: s

20090312289 - Ibandronate polymorph: The present invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with the following formula... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090312290 - Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia: e

20090312291 - Agent for preventing infection: An agent for preventing an infection with an influenza virus or a food or drink for preventing infection with an influenza virus is provided. It is the agent for preventing an infection with an influenza virus and a food or drink for preventing an infection with an influenza virus, which... Agent: Morgan Lewis & Bockius LLP

20090312292 - Peracetic acid composition: The invention relates to anti-microbial compositions useful against a wide range of microorganisms undesirable on a wide variety of materials, including food, food contact and non-food contact surfaces, and surfaces in industrial, recreational, health care, and other institutional environments. More particularly, the anti-microbial compositions comprise peracetic acid in combination with... Agent: Patent Administrator Fmc Corporation

20090312293 - process for the isolation of pharmacologically active principles of vegetable and animal origin: A process for the recovery and purification of natural hydrophilic water-soluble products in conjugated form from vegetable aqueous extracts or physiological fluids, by adsorption of the extracts or fluids on a lipophilic resin, followed by desorption and recovery of the eluate, which process is characterized in that the resin is... Agent: Young & Thompson

20090312296 - Active ingredient combination of a retinoid and a hormone combination with contraceptive action as medicament for treatment of skin diseases: The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a... Agent: Norris, Mclaughlin & Marcus, Pa

20090312294 - Method and agent for reducing weight, accelerating lipid catabolism, and/or restricting calories: A method and an agent for reducing weight, accelerating lipid catabolism, and/or restricting calories includes a preparation having chrysin and cholic acid for producing a medicament.... Agent: Lerner Greenberg Stemer LLP

20090312295 - Second line treatment of metastatic hormone refractory prostate cancer using satraplatin: The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the 2nd line treatment of metastatic hormone refractory prostate cancer.... Agent: Leon R. Yankwich

20090312299 - Isolated isomers of norelgestromin and methods of making and using the same: The invention is directed to a process of preparing substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3E- and -3Z-oxime isomers, as well as a process for the synthesis of the mixture of isomers and the pure isomers. The invention also relates to substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene20-yn-3-one-3E-oxime and substantially pure d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-3Z-oxime isomer. Further aspects of the invention... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090312298 - Methods and compositions related to gaba receptor subunits: Disclosed are compositions and methods related to GABAA receptors.... Agent: Ballard Spahr LLP

20090312297 - Methods for treating hypercholesterolemia and atherosclerosis: The invention provides compounds and pharmaceutical compositions that can be used to treat or prevent atherosclerosis, stroke, and other ischemic vascular diseases, dyslipidemia and hypercholestcrolemia and prevent complications of these conditions. Agents in accordance with the invention include; tauroursodeoxycholic acid (TUDCA), and analogs and derivatives thereof; 4-phenyl butyric acid (PBA),... Agent: Edwards Angell Palmer & Dodge LLP

20090312300 - Novel macrocyclic peptides: Disclosed are cyclosporine derivatives in which the 3-Sarcosine carbon and 5-Valine nitrogen are each substituted by a non-hydrogen substituent, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.... Agent: Jones Day

20090312301 - Transition metal complexes for inhibiting resistance in the treatment of cancer and metastasis: The present invention relates to organometallic compounds useful in the treatment of metastasis. The organometallic compounds comprise a ligand that is covalently bound to a bioactive compound, which is an inhibitor of a resistance pathway or a derivative thereof. Preferably, the organometallic compounds are half-sandwich (“piano-stool”) compounds. The compounds of... Agent: Clifford W Browning Krieg De Vault

20090312302 - Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders: The invention relates to compositions containing cholesterol absorption inhibitors alone or in combination with other therapeutic agents for treating non-alcoholic fatty liver disease-associated disorders by administering a therapeutically effective amount of the compositions to a subject in need thereof.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090312303 - Antidiabetic bicyclic compounds: Bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, to which is attached a 5-membered heterocyclic ring, including pharmaceutically acceptable salts and prodrugs thereof, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type... Agent: Merck And Co., Inc

20090312305 - Bicyclic compounds having activity at the cxcr4 receptor: c

20090312304 - Organic compounds: 3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of... Agent: Novartis Corporate Intellectual Property

20090312306 - Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands: 4

20090312307 - Heterocyclo inhibitors of potassium channel function: Novel heterocyclo compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur), methods of using such compounds in the prevention and treatment of arrhythmia and... Agent: Louis J. Wille Bristol-myers Squibb Company

20090312308 - Compounds and compositions as hedgehog signaling pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Genomics Institute Of The Novartis Research Foundation

20090312310 - Imidazothiazole derivatives: e

20090312309 - Novel medicaments: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system,... Agent: High Point Pharmaceuticals, Inc.

20090312311 - Combination of organic compounds: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases... Agent: Novartis Corporate Intellectual Property

20090312313 - Compound having tgfbeta inhibitory activity and pharmaceutical composition comprising the same: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090312314 - Heteroaromatic monoamides as orexinin receptor antagonists: e

20090312312 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and... Agent: Amgen Inc.

20090312315 - Pai-1 inhibitor: wherein: R1 represents a C6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0 or 1; when m is 0, G represents —N—C(═O)—CO2H or the like; when m is 1, G represents an oxygen atom or the like; R2... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090312316 - Novel compounds: The present invention relates to derivatives of borrelidin that are useful in medicine, e.g. in the treatment of cancer or B-cell malignancies, or other diseases in which angiogenesis contributes to the pathology including ophthalmic disorders such as diabetic retinopathy as well as age related macular degeneration (AMD), corneal neovascularisation and... Agent: Dann, Dorfman, Herrell & Skillman

20090312317 - Coumarin compounds and their use for treating cancer: e

20090312318 - Therapeutic compounds and methods: The present invention provides compounds of Formula (I): wherein A, X, Q, R2-R6, m, and W have the values described herein, as well as compositions comprising such compounds. The compounds are protease inhibitors and are useful for inhibiting the development of drug resistance in animals.... Agent: Gilead Sciences Inc

20090312319 - Certain chemical entities, compositions and methods: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090312320 - Methods of treatment comprising the administration of haloaryl substituted aminopurines or compositions thereof: wherein R1, R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related... Agent: Jones Day

20090312321 - Compositions and methods for fgf receptor kinases inhibitors: Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as Abl, ALK, AMPK, Aurora, Axl, Bcr-Abl, BIK, Bmx, BRK, BTK,... Agent: Genomics Institute Of The Novartis Research Foundation

20090312322 - Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3: The present invention relates to a new use of oxindole derivatives of formula I, as a free base or a pharmaceutically acceptable salt thereof, [Chemical formula should be inserted here. Please see paper copy.] wherein R1, R2, R3, m and n are as defined as in claim 1, as well... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20090312324 - Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml: Chronic myelogenous leukemia (CML), and in particular imatinib resistant CML is treated using compositions and methods in which a Rad51-inhibitor and a kinase inhibitor are administered. Most preferably, the Rad51 inhibitor comprises an indolyl isoquinoline structure and the kinase inhibitor is a BCR-ABL inhibitor.... Agent: Fish & Associates, PC Robert D. Fish

20090312323 - Compounds for the treatment of spinal muscular atrophy and other uses: Compounds of Formula (I) or (II) useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or... Agent: Leydig, Voit & Mayer, Ltd.

20090312325 - Quinoline derivatives as phosphodiesterase inhibitors: m

20090312326 - Substituted imidazoles: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20090312327 - Pyrrolidine derivatives as nk2 receptor antagonists: i

20090312329 - Cyclic hydroxylamine as psychoactive compounds: A compound of formula (I): in which X represents O or CH2; R3 and R4 each independently represent hydrogen or C1-6 alkyl; p represent 0 or 1; and R represents a five- or six-membered saturated or unsaturated ring selected from: formula (II), (III) and (IV); or R represents a five-... Agent: Nixon & Vanderhye, PC

20090312328 - Sulfonamide compound or salt thereof: Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090312330 - Isoxazoline-substituted benzamide compound and pesticide: wherein A1, A2 and A3 independently of one another are carbon atom or nitrogen atom, G is benzene ring, etc., X is halogen atom, C1-C6haloalkyl, etc., Y is halogen atm, C1-C6alkyl, etc., R1 is C1-C12alkyl arbitrarily substituted with R16, C3-C12alkenyl, arbitrarily substituted with R16 is oxygen atom or sulfur atom,... Agent: Oliff & Berridge, PLC

20090312331 - Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein: Novel Form N-1 crystals of the Form N-1 and Form N-4 crystals of the hydrochloride salt and Form N-1 crystals of the methanesulfonic acid salt of the above free base, pharmaceutical compositions containing such novel forms and a method of treating p38 kinase associated conditions, including rheumatoid arthritis are also... Agent: Louis J. Wille Bristol-myers Squibb Company

20090312332 - Compounds for the treatment of auricular fibrillation: Adenosine A2A receptor antagonists are useful for the preparation of medicaments against atrial fibrillation in mammals, including humans. It has been found that the adenosine A2A receptor is present in human atrial cardiomyocytes and participates in the pathological mechanisms underlying atrial fibrillation. An advantage of using A2A antagonists over other... Agent: Moore & Van Allen PLLC

20090312333 - 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses: The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090312334 - Immunomodulating heterocyclic compounds: wherein R1 and R3 independently represent H; F; Cl; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR6R7, —NR7C(═O)R6, —NR7C(═O)OR6, —NHC(═O)NR7R6 or —NHC(═S)NR7R6 wherein R6 represents H, or... Agent: Banner & Witcoff, Ltd.

20090312337 - Compositions containing alpha-2-adrenergic agonist components: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.... Agent: Allergan, Inc.

20090312336 - Dihydropteridine compounds as anti proliferative agents: Compounds of formula (I), or optionally the pharmacologically acceptable acid addition salts thereof, and their use in the inhibition of PLK activity are described.... Agent: Astrazeneca R&d Boston

20090312335 - Hiv integrase inhibitors: Substituted hydroxytetrahydropyrrolopyrazinone and substituted hydroxytetrahydro-pyrazolopyrazinone compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein R1, R2, R3, R4; R5, X, ring A, and Q are as defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in... Agent: Merck And Co., Inc

20090312338 - Novel tricyclic compounds: b

20090312339 - Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group: The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.... Agent: Philip S. Johnson Johnson & Johnson

20090312340 - Use of ranolazine for the treatment of cardiovascular diseases: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20090312341 - Cyclic amine bace-1 inhibitors having a heterocyclic substituent: s

20090312343 - Quinazoline derivatives as tyrosine kinase inhibitors: wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be... Agent: Morgan Lewis & Bockius LLP

20090312342 - Quinazolines useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20090312344 - Arylpiperazine derivatives as adrenergic receptor antagonists: The present invention relates to α1, and/or α1d adrenergic receptor antagonists, which can function as α1a and/or α1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of... Agent: Ranbaxy Inc.

20090312345 - Pharmacological chaperones for treating obesity: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R... Agent: Hoffmann & Baron, LLP

20090312346 - Method for increasing the bioavailability of benzhydryl piperazine containing compounds: A method of increasing the bioavailability of a compound of formula 1 by orally administering to a patient a compound of formula 1, or a pharmaceutically acceptable salt thereof, with food:... Agent: Arent Fox LLP

20090312347 - Novel oxadiazole derivatives and their medical use: This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent: Birch Stewart Kolasch & Birch

20090312348 - Use of sodium blockers for an early therapy of obstructive lung diseases: The present invention relates to a blocker of sodium channels in cell membranes, particularly in membranes of epithelial cells of organs belonging to the respiratory tract to be used as the pharmaceutically active ingredient in a medicament for treating an obstructive lung disease in a patient.... Agent: Knobbe Martens Olson & Bear LLP

20090312349 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or... Agent: Wilmerhale/deciphera Pharmaceuticals

20090312350 - Compositions comprising balaglitazone and further antidiabetic compounds: Methods for treating conditions benefiting from a decrease in insulin resistance, a reduction of plasma glucose levels, a reduction of plasma fatty acid levels, a reduction of plasma triglyceride levels or reduction of VLDL levels comprising the administration of a composition consisting essentially of balaglitazone in combination with one or... Agent: Dr. Reddy''s Laboratories, Inc.

20090312351 - Processes for the preparation of alfuzosin: The invention relates to processes for the preparation of alfuzosin or pharmaceutically acceptable salts thereof in high purity. More particularly, it relates to the preparation of pure crystalline alfuzosin base. The invention also relates to pharmaceutical compositions that include the pure alfuzosin or a pharmaceutically acceptable salt thereof.... Agent: Bio Intellectual Property Services (bio Ips) LLC

20090312352 - Compositions and methods for treatment of disease caused by yersinia spp infection: The invention generally relates to compositions and methods for treatment of disease caused by Yersinia spp. infection. More specifically, the invention relates to protein tyrosine phosphatase inhibitors and derivatives and analogs thereof, pharmaceutical compositions containing the protein tyrosine phosphatase inhibitors and analogs, methods of making the protein tyrosine phosphatase inhibitors... Agent: Woodcock Washburn LLP

20090312353 - Methods and compositions for treating liquid tumors: The application relates to a method of using compositions having anti-alpha-4 integrin and/or anti-alpha-9 integrin activity to inhibit liquid tumor growth, malignancies thereof and/or development of metastases thereof that involve expression of an alpha-4 integrin and/or alpha-9 integrin. Pharmaceutical compositions and combination therapies (for example, with chemotherapies) for the inhibition... Agent: Crowell & Moring LLP Intellectual Property Group

20090312354 - Dha esters and use thereof in treatment and prevention of cardiovascular disease: The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV)... Agent: Birch Stewart Kolasch & Birch

20090312355 - Non-flushing niacin analogues, and methods of use thereof: One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090312356 - Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom: The invention discloses compounds of formula I endowed with agonistic activity at the alpha7 nicotinic acetylcholine receptors (α7 nAChRs), a process for the preparation thereof, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric disorders as well as inflammatory diseases.... Agent: Steinfl & Bruno

20090312357 - Rifaximin: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.... Agent: Conley Rose, P.C.

20090312358 - Method for management of diarrhea: The present invention is directed to methods of treatment and/or management of diarrhea, such as chronic diarrhea using sequential administration of opioid agonists to suppress gut mobility and opioid antagonists to reverse the effect to controllably allow bowel movements. The agonists and antagonists are administered with a time interval in... Agent: Ronald I. Eisenstein

20090312359 - Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids: A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.... Agent: Wolf Greenfield & Sacks, P.C.

20090312360 - Antineoplastic combinations containing hki-272 and vinorelbine: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also... Agent: Wyeth Patent Law Group

20090312361 - Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular... Agent: Fulbright & Jaworski L.L.P.

20090312362 - Inhibitors of the unfolded protein response and methods for their use: Compounds that are inhibitors of the unfolded protein response and endonuclease IRE1 are provided, together with compositions comprising such compounds, and methods for their use in the treatment of various disorders, such as cancer, autoimmune disorders, and diabetes. Also provided are packaged pharmaceuticals comprising these compositions. The compositions may be... Agent: Ropes & Gray LLP

20090312363 - Bifunctional histone deacetylase inhibitors: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone... Agent: Choate, Hall & Stewart/harvard University

20090312364 - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20090312365 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090312366 - Novel p2x7r antagonists and their use: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090312367 - Combination of modafinil and an antagonist or inverse agonist of the h3 receptor: The invention relates to a combination of modafinil and at least one histamine H3 receptor antagonist or inverse agonist, which can be used in particular for the treatment of narcolepsy-cataplexy and more generally for disorders of sleep, wakefulness and vigilance.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090312368 - Pyridine analogues iv: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20090312369 - Renin inhibitors: The present invention is directed to aspartic protease inhibitors represented by the following structural formula (I), or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the aspartic protease inhibitors of Structural Formula (I). Methods of antagonizing one or more aspartic proteases in a... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090312370 - Macrocyclic compounds useful as bace inhibitors: e

20090312371 - Substituted arylpyrazoles: This invention relates to a combination product comprising a range of 1-aryl-4-cyclopropylpyrazoles in which there is at least one fluorine attached to the cyclopropyl ring, and one o more further therapeutic agents, particularly anti-parasitic agents.... Agent: Pharmacia & Upjohn

20090312372 - Chemical compounds: i

20090312373 - Methods for the treatment of cancer using piperlongumine and piperlongumine analogs: The invention provides methods for the treatment of cancer in a subject using piperlongumine and/or piperlongumine analogs.... Agent: Wolf Greenfield & Sacks, P.C.

20090312374 - Derivatives of 4,6-disubstituted 1,2,4-triazolo- 1,3,4-thiadiazole, a process and uses thereof: The present invention is in relation to the derivatives of 4,6-disubstituted 1,2,4-triazolo-1,3,4-thiadiazole and a process to synthesize the said derivatives. Also, the present invention was able to establish the activity of the instant derivatives against anti-cancerous activity specific to cervical and oral cancer.... Agent: Darby & Darby P.C.

20090312375 - Heterocyclic compounds, compositions comprising them and methods of their use: Heterocyclic compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of inflammatory and autoimmune diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20090312376 - 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases: or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, and to a method for the treatment an acute or chronic inflammatory disease by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha, IFN-gamma, IL-8 and IL-10, which comprises administering to a patient who needs such treatment a... Agent: Intellectual Property / Technology Law

20090312377 - Derivatives of benzo[d]isothiazoles as histones deacetylase inhibitors: The invention relates to derivatives of benzo[d]isothiazoles as histone deacetylase inhibitors, selected from among compounds of general formula (Ia) and (Ib) or one of the salts thereof, particularly one of the pharmaceutically acceptable salts thereof, or one of the corresponding solvates thereof. These compounds are histone deacetylase enzyme inhibitors and... Agent: Cantor Colburn, LLP

20090312379 - Dimeric small molecule potentiators of apoptosis: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and... Agent: Richard Aron Osman

20090312378 - Ectoparasiticide composition and a method for exterminating ectoparasites: s

20090312380 - Novel compositions and methods: This invention relates to active pharmaceutical ingredients (APIs) with specific water surface areas, to pharmaceutical compositions comprising said APIs, to processes for preparing such compositions, and to methods for determining the water surface areas of substances such as APIs and other particles.... Agent: Venable LLP

20090312381 - Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors: The present application relates to novel, substituted 4-arylimidazol-2-ones and 5-aryl-1,2,4-triazolones, processes for the production thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases and the use thereof for the production of medicaments for the treatment and/or prevention of diseases, in particular for the treatment... Agent: Edwards Angell Palmer & Dodge LLP

20090312382 - Novel imidazolidine derivatives: e

20090312384 - Benzimidazole as cooling compounds: in which R1, R2 are independently in either the meta- or para-position and independently comprise at least one of hydrogen, halide, C1-C3 alkyl (linear or branched), halide, C1-C3 alkoxy, nitro, nitrile, amide or ester; R3 comprises at least one of C1-C5 alkyl or C1-C5 alkenyl groups (linear or branched), R4... Agent: Curatolo Sidoti Co., Lpa

20090312383 - Fused heterocyclic compounds: wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; R2 is an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or —NR3— (wherein R3 is a hydrogen, an optionally... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090312385 - Cannabinoid receptor modulators for treating non-immediate type allergic diseases: The present invention relates to the use of cannabinoid receptor modulators, particularly selective CB2 receptor agonists, for treating non-immediate type allergic diseases in mammals. The invention further relates to a pharmaceutical composition for non-immediate type allergic diseases.... Agent: Glenmark Pharmaceuticals S.a. C/o Darby & Darby P.C.

20090312386 - Novel crystals of substituted phenylalkanoic acid and method of producing the same: e

20090312387 - Composition for controlling parasites on animals: The invention relates to novel compositions for controlling parasites on animals, comprising an N-phenylpyrazole in a formulation comprising aliphatic cyclic carbonates.... Agent: Bayer Healthcare LLC

20090312388 - Benzo [f] isoindoles as ep4 receptor agonists: The present invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090312389 - Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them: Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders,... Agent: The Firm Of Hueschen And Sage

20090312390 - Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma: The use of inhibitors of GSK-3 useful for treating glaucoma is disclosed.... Agent: Alcon

20090312391 - Unifying mechanism and methods to prevent cancer and neurodegenerative diseases: The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of... Agent: Schwegman, Lundberg & Woessner, P.A.

20090312392 - Amino ceramide-like compounds and therapeutic methods of use: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases... Agent: Foley & Lardner LLP

20090312404 - Cleavable carnitine compound: The invention includes novel compounds, including but not limited to formula A and formula B, and an improved delivery method. These compounds and methods are useful in preventing or treating diseases or conditions associated with or caused by the presence of free radicals, and are useful for increasing cellular metabolism... Agent: William J Bundren The Law Office Of William J Bundren

20090312405 - Methods to predict and prevent resistance to taxoid compounds: Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also... Agent: Wolf Greenfield & Sacks, P.C.

20090312406 - Coumarin compounds and their use for treating viral infection: b

20090312408 - Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors: Disclosed is the use of isoflavan and isoflav-3-ene compounds for the treatment of pathological conditions associated with or dependent on enhanced or abnormal angiogenesis in a mammal.... Agent: Birch Stewart Kolasch & Birch

20090312409 - Lipopexia inhibitor and food or beverage: A lipopexia inhibitor which inhibits fat accumulation, comprising an effective amount of any methylated catechin having the following chemical formula (1) obtained by extraction of green tea or Pouchung tea, in which each of R1, R2, R3 and R4 independently is a hydrogen atom or methyl; and each of X1... Agent: Knobbe Martens Olson & Bear LLP

20090312407 - Synthetic flavonoids and pharmaceutical compositions and therapeutic methods of treatment of cancer and other pathologies: l

20090312410 - Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease, specifically MI and including early-onset MI, and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules,... Agent: Celera Corporation

20090312411 - Preventing or reducing risk of miscarriages: The present disclosure provides methods of reducing pregnancy loss or miscarriage in patients by administering compounds that inhibit tissue factor (TF) expression and/or activity on neutrophils and/or monocytes, such as for example, statins, and methods of diagnosing patients having an increased risk of miscarrying.... Agent: Dechert LLP

20090312412 - 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers: The present invention is directed to novel 3,4-diamino-3-cyclobutene-1,2-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.... Agent: Philip S. Johnson Johnson & Johnson

20090312413 - Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof: A composition comprising tanshinone compounds selected from the group consisting of miltirone, 1,2-didehydromiltirone, tanshinone IIA, tanshinone I and dihydrotanshinone I isolated from Salviae miltiorrhizae Bunge showing potent inhibiting effect on the aggregation and toxicity of beta-amyloid and recovering activity of memory learning disorder confirmed by Y maze study and Passive... Agent: Kirk Hahn

20090312414 - Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists: A method is disclosed utilizing a cannabinoid receptor type 2-receptor-selective agonist for treating or preventing lower urinary tract dysfunction, including overactive bladder, lower urinary tract symptoms and detrusor overactivity.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090312415 - Remedy/preventive for vascular disorders and hypertension and method of screening the same: It is intended to clarify a transportation system participating in the uric acid uptake in vascular smooth muscle cells (VSMCs) and provide a novel remedy, a preventive or a treating agent for vascular disorders, hypertension and renal disorders with the use of a drug participating in this transportation system. It... Agent: Edwards Angell Palmer & Dodge LLP

20090312416 - Treatment of sleep-wake disorders: This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group... Agent: Gibbons P.C.

20090312417 - Platinum(ii) complexes, preparation and use: The invention relates to a method for the preparation of platinum (II) complexes, in particular dicarboxylatoplatinum (II) complexes containing a neutral bidentate ligand, such as oxaliplatin. The method includes the step of reacting a bis-dicarboxylatoplatinate (II) species with a suitable neutral bidentate ligand to form a neutral dicarboxylatoplatinum (II) complex... Agent: Morrison & Foerster LLP

20090312418 - Alkanediol composition, process for producing the same, and cosmetic: An alkanediol composition contains 0.005 parts by mass or less of ester compound per 100 parts by mass of alkanediol compound having four or more carbon atoms. An alkanediol composition contains 0.2 parts by mass or less of dioxane compound per 100 parts by mass of alkanediol compound having four... Agent: Sughrue Mion, PLLC

20090312419 - Creatine -ßalaninate: a novel salt for increasing athletic performance: Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20090312420 - Production of peracids using an enzyme having perhydrolysis activity: A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090312421 - Gel useful for the delivery of cosmetic active ingredients: It is described a gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles.... Agent: Lucas & Mercanti, LLP

20090312422 - Method of modulating cellular activity and agents useful for same: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.... Agent: Bozicevic, Field & Francis LLP

20090312423 - Therapeutic treatment for lung conditions: Methods and compositions for treating lung conditions such as bronchopulmonary dysplasia or hypoxia-induced pulmonary hypertension in a subject, including administering to the subject an effective amount of a nitric oxide precursor such as citrulline.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090312424 - Aromatic prodrugs of propofol, compositions and uses thereof: Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090312425 - Process for producing 1,4-dihydroxy-2-naphthoic acid: A composition containing 1,4-dihydroxy-2-naphthoic acid at a high concentration is obtained by intracellularly and extracellularly producing 1,4-dihydroxy-2-naphthoic acid using a bacterium belonging to the genus Propionibacterium and collecting it. This composition is efficacious in improving intestinal flora, alleviating abdominal ailments in association with the intake of milk, and preventing metabolic... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090312426 - Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid: c

20090312427 - Medicament for use in connection with cartilage impairment: Use of a substance for treating medical joint conditions, e.g. arthrosis, rheumatoid arthritis and cartilage impairment. The use includes the use of alpha-ketoglutaric acid, glutamine or glutamic acid, as well as salts, amides, di- or tripeptides of the mentioned substances.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090312428 - Biocide compositions comprising quaternary ammonium and urea and methods for their use: Composition and method for treating and/or preventing biological contamination using a biocide composition comprising at least one quaternary ammonium compound and urea. The method includes drying urea, and thereafter combining at least one quaternary ammonium compound and urea and may produce a potent biocide composition that is stable and able... Agent: Sutherland Asbill & Brennan LLP

20090312429 - Administration of nepafenac or derivatives thereof for treating dermatological/keratinization disorders: Nepafenac or derivatives thereof are useful for the treatment of dermatological conditions related to a keratinization disorder that may have an inflammatory immunoallergic component, for example rosacea, acne, psoriasis or atopic dermatitis.... Agent: Buchanan, Ingersoll & Rooney PC

20090312430 - Colchicine solid-state forms; methods of making; and methods of use thereof: Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof.... Agent: Cantor Colburn, LLP

20090312431 - Methods and compositions for removing a foreign body from a host: A composition and method for eliminating foreign bodies from a host. The composition include active ingredients of menthol, camphor, and capsaicin, as well as additional components including aloe vera extract, carbomer, decyl polyglucose, deionized water, grapefruit seed extract, green tea extract, orange peel extract, queen of the prairie extract, rose... Agent: Kirton And Mcconkie

20090312432 - Fluorosurfactants: The present invention relates to fatty acid alkanolamides or polyolamides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—,... Agent: Millen, White, Zelano & Branigan, P.C.

20090312433 - Treatment of vr1-antagonist-induced increase in body temperature with an antipyretic agent: The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.... Agent: Amgen Inc.

20090312434 - Use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug: The present invention relates to the use of 3,5-seco-4-nor-cholestane derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug, notably a cardioprotective or hepatoprotective drug.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090312435 - Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic... Agent: Global Patent Group - Apx

20090312436 - Rasagiline for parkinson's disease modification: A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the... Agent: Cooper & Dunham, LLP

20090312437 - Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions: Compositions derived from Rheum palmatum are provided. Also provided are methods of using said extracts to induce apoptosis in specific cells, especially in a human. Provided as well are uses of the extracts of Rheum palmatum for the preparation of a medicament for the selective induction of apoptosis... Agent: Wilson, Sonsini, Goodrich & Rosati

20090312438 - Compositions and methods for attenuating the formation of a2e in the retinal pigment epithelium: A method of decreasing the content of 2-(2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E,3E,5E,7E-octatetraenyl)-1-(2-hydroxyethyl)-4-(4-methyl-6-(2,6,6-trimethyl-1cyclohexen-1-yl)-1E,3E,5E-hexatrienyl-pyridinium (A2E) and its isomers in a subject by administering a therapeutically effective amount of a macular carotenoid formulation.... Agent: Davis, Brown, Koehn, Shors & Roberts, P.C. The Davis Brown Tower

20090312439 - Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions: The use of Schülpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions, the pharmaceutical compositions per se, as well as an adsorbate consisting of the Schülpen and at least one further substance selected from pharmaceutical active constituents and excipients, and the produce of such adsorbates, are described.... Agent: Smith, Gambrell & Russell

20090312440 - Agent for improving tissue penetration: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090312441 - Organic compounds: A solid pharmaceutical composition comprising a poorly water soluble drug, a polymer which is solid at room temperature, and a disintegrant in an amount of less than 10% by weight, wherein the amounts by weight are based on the total weight of the composition.... Agent: Novartis Corporate Intellectual Property

  
12/10/2009 > patent applications in patent subcategories. patent applications/inventions, industry category

20090305946 - Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090305944 - Methods for providing palliative care with avr 118: The invention relates to methods for providing palliative care. Specifically, methods for treating patients having an end-stage disease, such as cancer, comprising administering an effective amount of AVR118 are disclosed. Pharmaceutical compositions and kits comprising AVR118, an additional medicament, and pharmaceutically acceptable carriers are also disclosed. The disclosed methods are... Agent: Downs Rachlin Martin PLLC

20090305945 - Novel nutraceutical compositions: The present invention describes a composition which comprises a protein hydrolysate or a protein hydrolysate and one amino acid hydrolysate for the long term treatment or prevention of type 2 diabetes or pre-diabetes or metabolic syndrome or obesity.... Agent: Nixon & Vanderhye, PC

20090305947 - Livestock management for improved reproductive efficiency: The present invention relates to methods for controlling the reproductive cycles and weaning in livestock, particularly to the use of casein-derived peptides for estrus induction and reduction of anestrus intervals, enabling early weaning without negatively affecting the livestock welfare. The present invention further relates to estrus synchronization in a livestock... Agent: Fennemore Craig

20090305952 - Anionic polyamide functionalized with a tryptophan unit: L being selected from the group constituted of a single bond, a —CH2— group or a —CH2CH2— group, -Trp being an L and/or D tryptophan residue produced from the coupling between the amine of the tryptophan or of a tryptophan derivative, selected from the group constituted of tryptophanol, tryptophanamide and... Agent: Oliff & Berridge, PLC

20090305948 - Branched polyamino acids functionalized with hydrophobic groups, and applications thereof particularly therapeutic applications: The invention concerns novel materials based on biodegradable branched polyaminoacids particularly useful for transporting active principle(s). The invention also concerns novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on polyaminoacids. The invention aims at providing a novel polymeric material, capable of being used for transporting active principle(s) and enabling all... Agent: Patton Boggs LLP

20090305951 - Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090305953 - Dalbavancin compositions for treatment of bacterial infections: The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Compositions comprise a mixture of dalbavancin multimer and... Agent: Pfizer Inc. Patent Department

20090305949 - Glycosylated specificity exchanger: The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein.... Agent: Knobbe Martens Olson & Bear LLP

20090305950 - Multimer of extracellular domain of cell surface functional molecule: As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded.... Agent: Sughrue-265550

20090305955 - Cyclopeptide with anti-cancer activity derived from collagen type iv: The present invention relates to a cyclopeptide characterized in that it comprises the YSNS amino acid sequence, and more particularly a cyclopentapeptide which forms a β-bend structure at the YSNS amino acids. In one specific embodiment, the cyclopeptide of the invention is capable of binding to the αVβ3-integrin. The application... Agent: Birch Stewart Kolasch & Birch

20090305954 - Histidine-containing diastereomeric peptides and uses thereof: Diastereomeric peptides with a net positive charge greater than +1, and cyclic derivatives thereof, are provided, having at least 13 amino acid residues, comprising histidine and one or more hydrophobic amino acid residues, optionally esterified or amidated at the C-terminus and/or acylated at the N-terminus. The peptides may contain other... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090305957 - Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for... Agent: Schwegman, Lundberg & Woessner, P.A.

20090305958 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof,... Agent: Dla Piper LLP (us)

20090305956 - Treatment of ras-expressing tumors: The present invention provides compositions and methods for the treatment of /?αs-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).... Agent: Choate, Hall & Stewart LLP

20090305960 - Melanocortin receptor-specific peptides for treatment of obesity / 669: e

20090305959 - Use of peptidic vasopressin receptor agonists: The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of, inter alia, conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilised are represented by the general... Agent: Merchant & Gould PC

20090305991 - 33 human secreted proteins: The present invention relates to 33 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090305990 - Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy: The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and method of use.... Agent: Angiodynamics, Inc.

20090305968 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling.... Agent: Morgan Lewis & Bockius LLP

20090305989 - Composition and method for potentiating drugs: A method of potentiating the activity of a drug which affects the central nervous system (CNS) comprising systemically administrating to a subject said drug together with an effective amount of a compound which stimulates peripheral chemoreceptors of vagal afferents and, optionally, with an effective amount of a stimulator of peripheral... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090305979 - Compositions comprising hpv polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer: The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing... Agent: Holme Roberts & Owen LLP

20090305983 - Curable bone cement: The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement.... Agent: Townsend And Townsend And Crew, LLP

20090305976 - Cytokine mediating composition: The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity.... Agent: Edwards Angell Palmer & Dodge LLP

20090305984 - Engineered cxcl 12 alpha locked dimer polypeptide: The present invention provides a novel CXCL12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.... Agent: Quarles & Brady LLP

20090305986 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20090305967 - Glycopegylated factor vii and factor viia: The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090305962 - Il-6 binding proteins: Polypeptides comprising monomer domains that bind to IL-6, or portions thereof, are provided.... Agent: Amgen Inc.

20090305985 - Immunomodulatory agents for treatment of inflammatory diseases: The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and/or S100A9 for reducing inflammation.... Agent: Morrison & Foerster LLP

20090305963 - Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis: The invention features methods and compositions for treating and preventing cancer metastasis, angiogenic disorders, and fibrotic disorders using lipocalin 2 compounds.... Agent: Clark & Elbing LLP

20090305987 - Method for inducing beta cell neogenesis from epithelial cells: The invention provides a method of inducing β-cell neogenesis from epithelial cells. The method includes the step of exposing epithelial cells that have a disrupted G1-S cell cycle transition to a hedgehog protein in an amount effective to stimulate β-cell neogenesis from the epithelial cells. Cells resulting from the method... Agent: Quarles & Brady LLP

20090305977 - Method for treating peripheral arterial disease with zinc finger proteins: Disclosed is a method for the administration of zinc finger proteins (ZFPs) or nucleic acids that encode such ZFPs for treating peripheral arterial disease, particularly by the repeated administration at regular intervals if such ZFPs or nucleic acids that encode such ZFPs.... Agent: Townsend And Townsend And Crew, LLP

20090305980 - Methods and compositions related to tr4: Disclosed are compositions and methods related to TR4 and cancer.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090305978 - Methods for increasing the size of animals using needleless delivery constructs: The present invention relates, in part, to methods for increasing the size of a subject by administering a delivery construct comprising growth hormone to a subject. In one aspect, the method for increasing the size of a subject by at least about 12% comprises contacting an apical surface of a... Agent: Jones Day

20090305988 - Modified peptide of human acidic fibroblast growth factor: An modified peptide of human acidic fibroblast growth factor (aFGF), comprising a native human aFGF shortened by a deletion of a deletion of 20 amino acids from N-terminal of the native human aFGF, and an addition of alanine (Ala) before the shortened native aFGF is provided.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090305982 - Muteins of tear lipocalin and methods for obtaining the same: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed... Agent: Foley And Lardner LLP Suite 500

20090305971 - Nogo-b receptor: Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090305972 - Novel cancer-associated antigen: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20090305961 - Novel chimeric plasminogen activators and their pharmaceutical use: The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well... Agent: Biotechnology Law Group 12707 High Bluff Drive

20090305973 - Novel peptide and use thereof: The present invention relates to a novel peptide and use thereof, more particularly to an isolated peptide comprising 21-41 contiguous amino acids selected from the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of... Agent: Seed Intellectual Property Law Group PLLC

20090305964 - Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug: The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090305981 - Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers: The present invention relates to compositions and methods of use thereof for cancer therapy sensitization. Such compositions comprise functional fragments of the nucleotide and/or polypeptide sequences of a Secreted Protein Acidic and Rich in Cysteine (SPARC). The compositions can be used in combination with existing chemotherapeutic agents for treatment of... Agent: Leydig Voit & Mayer, Ltd

20090305969 - Skin repair accelerating therapeutic agent containing desacyl ghrelin and derivatives thereof as active ingredient: The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing desacyl ghrelin or a pharmaceutically acceptable salt thereof as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090305965 - Stabilized parathyroid hormone composition comprising parathyroid hormone, buffer and stabilizing agent: Disclosed relates to a stabilized parathyroid hormone (PTH) comprising a buffer and a stabilizing agent and, more particularly, to a stabilized PTH composition in which succinic acid, malic acid, histidine or ammonium bicarbonate is used as the buffer and sorbitol or mannitol is used as the stabilizing agent. The PTH... Agent: Sughrue Mion, PLLC

20090305974 - Therapeutic indications of colony stimulating factors: The present invention relates to the use of at least one colony stimulating factor (CSF) for the production of medicinal products in the treatment or prophylaxis of coma or neurotoxicity.... Agent: Foley And Lardner LLP Suite 500

20090305970 - Toxin-like polypeptides, polynucleotides encoding same and uses thereof: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide which comprises an amino acid sequence at least 90% identical to a sequence as set forth in SEQ ID NO: 1, wherein the polypeptide comprises an ion channel modulatory activity. Polypeptides and uses thereof are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090305992 - Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes: Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the... Agent: Birch Stewart Kolasch & Birch

20090305966 - Use of histones for therapeutic purposes: The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.... Agent: Kubotera & Associates, LLC

20090305975 - Use of trap protein per se as an active ingredient for the manufacture of a medicament for the treatment of staphylococcus aureus infection: Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20090305993 - Methods and composition for the treatment of gastrointestinal disorders: Pharmaceutical compositions comprising certain peptides that are capable of activating the guanylate-cyclase C (GC-C) receptor are described as are the peptides and method for using the peptides and pharmaceutical compositions for treating gastrointestinal disorders and other disorder.... Agent: Honigman Miller Schwartz & Cohn LLP

20090305994 - Compounds modulating vegf receptor and uses thereof: The present invention is related to the use of compounds which bind to the Vascular Endothelial Growth Factor Receptors and modulate the angiogenic response. The compounds, which mimic the VEGF amino acid region 17-25 involved in receptor recognition thereby inhibiting or stimulating the angiogenic process, can be used in the... Agent: Young & Thompson

20090305995 - Agonists and antagonists of the somatostatin receptor: The invention relates to substituted F3-Phe-trp-F 3-Lys-beta-tri-peptides and derivatives thereof, a process for their preparation, pharmaceutical preparations which contain these compounds which are agonists/antagonists of somatostatin receptors, as active agents for the treatment of disorders which can be influenced by a modulation of somatostatin receptor activity, in particular somatostatin receptor... Agent: Novartis Corporate Intellectual Property

20090305998 - Hsp90 inhibitors: e

20090305997 - Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity: The present invention relates to a novel galactose derivatives of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090305996 - Use of non-digestable sacharides for giving an infant the best start after birth: A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system of the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth.... Agent: Foley And Lardner LLP Suite 500

20090306000 - Tanaproget derivatives, metabolites, and uses thereof: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.... Agent: Howson & Howson LLP / Wyeth

20090305999 - Utilization of hypertension/hypercardia-preventing effect of d-allose: The object is to provide a novel application of D-allose (e.g., use for prevention of hypertension or hypercardia). Thus, disclosed is a composition for preventing the increase in blood pressure which comprises D-allose as an active ingredient; or a composition containing D-allose and/or a derivative thereof, preferably in an amount... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090306002 - Iron metabolism-improving agent: An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090306001 - Novel amphiphilic derivatives of alpha-c-phenyl-n-tert-butylnitrone: Compounds derived from α-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases.... Agent: Alston & Bird LLP

20090306003 - Pesticide delivery system: An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphophilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a second compound. Compositions based on the microblend and methods of using the compositions to control pests... Agent: Patent Administrator Fmc Corporation

20090306004 - Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation: A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain... Agent: Pearl Cohen Zedek Latzer, LLP

20090306005 - Compounds and methods for modulating expression of pcsk9: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Drinker Biddle & Reath (dc)

20090306181 - Compositions and methods for evaluating and treating heart failure: The invention relates to compositions, formulations, kits, and methods useful for the treatment and evaluation of heart disease in an individual.... Agent: Wolf Greenfield & Sacks, P.C.

20090306183 - Compositions and methods for the treatment of diseases associated with aberrant cilia assembly and regulation: Compositions and methods are provided for identifying agents which have efficacy for the treatment of disorders related to aberrant cilial structure and function, including polycystic kidney disease.... Agent: Dann, Dorfman, Herrell & Skillman

20090306180 - Compounds and methods for modulating expression apob: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20090306179 - Compounds and methods for modulating expression of gcgr: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Mcdermott Will & Emery

20090306178 - Conjugated double strand compositions for use in gene modulation: The present invention provides conjugated double stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and/or sugar modified nucleosides. More particularly, the present compositions comprise a linked conjugate group on one strand and a non hybridizing region of 2′-modified nucleosides on the other... Agent: Woodcock Washburn LLP

20090306177 - Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification: Double-stranded short interfering ribonucleic acid (siRNA) are modified to reduce or eliminate their immunostimulatory effect without significantly affecting their gene silencing effect. Modified siRNA include one or more 2′ sugar modifications and, optionally, internucleotide linkages on the sense strand. Compositions containing the modified siRNA and methods of making and using... Agent: Wolf Greenfield & Sacks, P.C.

20090306185 - Nanogenomics for medicine: sirna engineering: Described herein are materials and methods for the delivery of siRNA and the production of nanoparticles useful for the delivery of siRNA. Methods of treating a disease or disorder using the nanoparticles described herein also are disclosed.... Agent: Foley And Lardner LLP Suite 500

20090306186 - Novel tissue protective erythropoietin receptor (nepor) and methods of use: There is disclosed a molecular composition(s) of a novel tissue protective erythropoietin (EPO) binding receptor protein complex, termed NEPOR. Presence of NEPOR components on a tumour allows EPO to impinge on the survival of associated cells thereby enhancing tumour progression and negatively effecting patient survival. Presence of NEPOR represents a... Agent: Foley & Lardner LLP

20090306184 - Rna interference mediated inhibition of hepatitis c virus (hcv) expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to... Agent: Sirna Therapeutics, Inc.

20090306182 - Rna interference mediated inhibition of map kinase gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating mitogen activated protein kinase (MAP kinase) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MAP... Agent: Sirna Therapeutics, Inc.

20090306176 - Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors: This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or... Agent: Jacobson Holman PLLC

20090306192 - Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases, and for modulation of cell survival and/or death: The present invention provides BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for modulation of cell survival and/or death, in particular in leukemias, other neoplasias and apoptosis-involving diseases. More particularly the invention refers to the use of specific antisense-based constructs and peptide-specific polyclonal and monoclonal... Agent: Abelman, Frayne & Schwab

20090306195 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to fusion proteins containing at least two Mycobacterium species antigens. In particular, it relates to nucleic acids encoding fusion proteins that include two or more individual M. tuberculosis antigens, which increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in... Agent: Townsend And Townsend And Crew, LLP

20090306188 - Importation of mitochondrial protein by an enhanced allotopic approach: The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3′UTR sequences. The CDS sequence which codes for the protein to be delivered... Agent: Young & Thompson

20090306189 - Methods for controlling pests using rnai: The present invention relates to methods for controlling pest infestation using double stranded RNA molecules. The invention provides methods for producing transgenic cells expressing the double stranded RNA molecules, as well as compositions and commodity products containing or treated with such molecules.... Agent: Foley And Lardner LLP Suite 500

20090306187 - Modulators of itch ubiquitinase activity: The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability... Agent: Marshall, Gerstein & Borun LLP

20090306190 - Neuroprotectants: Methods of protecting cells against cytotoxic insults are provided. The methods involve administering a composition including a CpG oligonucleotide to a subject. The methods are applicable to the protection of neural and non-neural cells. For example, methods of protecting a neural cell against excitotoxic brain injury are provided. Methods for... Agent: Klarquist Sparkman, LLP

20090306194 - Novel compositions for the in vivo delivery of rnai agents: This application describes emulsion formulations containing neutral phospholipids for delivering RNAi, anti-miRNA, or aptamer agents in vivo. The application also relates to methods of making the formulations, and uses of the formulations as delivery agents.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306193 - Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer: A novel gene (designated 121P1F1) and its encoded protein, and variants thereof, are described wherein 121P1F1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P1F1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P1F1 gene... Agent: Agensys C/o Morrison & Foerster LLP

20090306191 - Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification: Also disclosed herein is a medicinal composition for treating a subject having or suspected of having a disease or condition associated with aberrant hypomethylation of one or more genes in the subject, the composition including methylated polynucleotides directed to hypomethylated genes in the subject, so as to result in a... Agent: Occhiuti Rohlicek & Tsao, LLP

20090306006 - Use of nicotinic acid adenine dinucleotide phosphate or derivative thereof as agent for treating type-2 diabetes: Nicotinic acid adenine dinucleotide phosphate and a pharmaceutically acceptable derivative thereof are useful for the treatment of type-2 diabetes.... Agent: Dickstein Shapiro LLP

20090306007 - Nucleosides with antiviral and anticancer activity: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.... Agent: Viksnins Harris & Padys Pllp

20090306008 - 3'-ethynylcytidine derivative: (wherein X represents a (substituted) alkylcarbonyl group, a (substituted) alkoxycarbonyl group, or a hydrogen atom; one of Y and Z represents a hydrogen atom or a group represented by (R1)(R2)(R3)Si— and the other represents a group represented by (R4)(R5)(R6)Si—; and R1, R2, R3, R4, R5, and R6 each represent a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090306009 - Modulation of the p2y2 receptor pathway: The present invention relates to the field of regulating the activity of the purinergic receptors for the modulation of the vascular tone, particularly for the purpose of treatment of haemodynamic conditions by overriding of vasoconstriction activity, such as increases in sympathic vasoconstriction. Modulators, such as UTP analogues as described herein... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20090306010 - P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating disorders: The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal... Agent: Howery LLP

20090306011 - Use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, and compositions containing it: The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.... Agent: Woodcock Washburn LLP

20090306012 - Therapeutic protocols: The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate... Agent: Morrison & Foerster LLP

20090306013 - Drugs and food products for hypophosphoric normo-,hyper-and hypoproteic diets, and hypophosphoric beverages: The present invention relates to an alimentary component comprising a physiologically acceptable phosphorus binding agent, in particular polyallylamine hydrochloride, polyallylamine carbonate, lanthanum carbonate, aluminium hydroxide, magnesium acetate, magnesium carbonate, calcium carbonate, calcium acetate, calcium citrate, calcium alginate, styrene divinyl-benzene ionic exchange resin, stabilized polynuclear iron hydroxide, calcium acetate plus magnesium... Agent: Abelman, Frayne & Schwab

20090306014 - C-10 carbamates of taxanes: Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy.... Agent: Woodcock Washburn LLP

20090306016 - Fatty acid amide hydrolase inhibitors: Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands... Agent: Alix Yale & Ristas LLP

20090306015 - Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds: Novel compositions of silicon-containing sulfhydryl compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative sulfhydryl compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics.... Agent: K&l Gates LLP

20090306017 - Methods and compositions for modulation of innate immunity: The present invention is directed towards a method of modulation of the innate immune of an organism system with the phosphorylated polyprenols of the present invention. The present invention is also directed towards a method of activation and/or modulation of the Toll-like Receptors with the phosphorylated polyprenols of the present... Agent: Kevin Farrell Pierce Atwood

20090306018 - Skin conditioner: Moisture retention ability of skin is improved and/or skin is protected or treated for another purpose by applying thereto a composition containing at least one of the following compounds: ethanolamine, 2-methoxyethylamine, O-phosphorylethanolamine, 2-ethylaminoethanol, diethanolamine, 2-dimethylaminoethanol, choline, 2-amino-2-hydroxymethyl-1,3-propanediol, noradrenalin, phenethylamine, ethylenediamine, taurine, phosphatidylethanolamine, N-(2-hydroxyethyl)acetoamide, 2-(methylamino)ethanol, 2-anilinoethanol, 2-(benzylamino)ethanol, 3-amino-1-propanol, 2-amino-1-butanol, putrescine, DL-pyroglutamic... Agent: Jordan And Hamburg LLP

20090306019 - Compositions for treatment of eosinophilia and related disorders: The present invention discloses compositions comprising phosphatidic acid and uses thereof for the treatment of subjects suffering from eosinophilia or related disorders such as asthma and/or the prevention of these disorders in subjects having environmental or genetic predisposition thereto.... Agent: The Nath Law Group

20090306020 - Combination therapy comprising diaryl ureas for treating diseases: The present invention relates to pharmaceutical compositions and combinations for treating cancer, comprising a diaryl urea compound and an PI3K/AKT signaling pathway inhibitor. Useful combinations include e.g. BAY-43-9006 as a diaryl urea compound.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090306021 - Antimicrobial therapy for bacterial infections: The disclosure provides compounds and methods to treat bacterial pathogenesis, and demonstrates that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.... Agent: Joseph R. Baker, Apc Gavrilovich, Dodd & Lindsey LLP

20090306022 - 7-substituted tetracycline compounds: The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090306023 - Stable organic peroxide compositions: Benzoyl peroxide compositions containing antioxidants and/or malonic acid. Treatment of acne vulgaris with a combination of actives, namely benzoyl peroxide and salicylic acid, include applying such benzoyl peroxide compositions to an area of the body afflicted with acne followed by application of a topical, at least partially neutralized salicylic acid... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090306024 - Combination preparations of o-acetylsalicylic acid salts: The present invention relates to a fixed combination comprising a salt of o-acetylsalicylic acid with a basic amino acid as component A and an HMG-CoA reductase inhibitor as component B, a medicament comprising this combination and a process for its production.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090306025 - Method and composition for skin inflammation and discoloration: The invention provides a method and compound for treating darkness and/or swelling/inflammation of the skin of humans. An antihistamine compound and a non-steroidal anti-inflammatory drug (NSAID) compound in combination have been found to effectively treat under eye darkness, swelling and puffiness in particular, when applied topically to the affected skin.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090306028 - Compositions and methods for treating inflammatory disorders: The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and an anti-inflammatory agent.... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20090306027 - Genetic risk assessment in heart failure: impact of the genetic variation of g-protein beta 3 subunit polymorphism: The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least... Agent: Wilmerhale/nitromed

20090306026 - Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction: The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analogue thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)).... Agent: Traskbritt, P.C.

20090306029 - Process for the preparation of sterile powdered pharmaceutical compounds: The invention relates to a process for the preparation of pharmaceutical powders, the process comprising: a) solubilization of the pharmaceutical compound in water or in an organic solvent at a concentration close to saturation; b) evaporating the solvent at constant temperature while subjecting the solution to ultrasound. In another embodiment,... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20090306030 - Methods of inhibiting osteoclast activity: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an... Agent: Woodcock Washburn LLP

20090306031 - 5alpha-androstane-3,6,17-trione (kneller's trione) and methods of use therefor: Disclosed are compounds such as 5α-androstane-3,6,17-trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.... Agent: Morse, Barnes-brown & Pendleton, P.C. Attn:IPManager

20090306032 - Use of solid lipid nanoparticles comprising cholesteryl propionate and/or cholesteryl butyrate: The present invention refers to the use of solid lipid nanoparticles (SLN) obtained from warm microemulsions, containing cholesteryl propionate and/or cholesteryl butyrate, for preparation of a medicament for the prevention and treatment of vascular or inflammatory pathologies.... Agent: Abelman, Frayne & Schwab

20090306033 - Novel cyclic peptides: e

20090306034 - Use of picoplatin to treat colorectal cancer: The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090306035 - Compounds and methods for modulating the silencing of a polynucleotide of interest: Methods and compositions comprising chemical compounds that modulate the silencing of a polynucleotide of interest in a cell are provided. Such chemical compounds when used in combination with an appropriate silencing element can be used to modulate (increase or decrease) the level of the polynucleotide targeted by the silencing element.... Agent: Alston & Bird LLP

20090306036 - Methods of screening agents, conjugates or conjugate moieties for transport by a pept2 transporter: The invention provides methods of screening agents, conjugates or conjugate moieties, linked or linkable to agents, for capacity to be transported as substrates through the PEPT2 transporter. The invention also provides methods of treatment involving delivery of agents that either alone, or as a result of linkage to a conjugate... Agent: Townsend And Townsend And Crew, LLP

20090306037 - Combination of a dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity: The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.... Agent: Merck And Co., Inc

20090306040 - Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia: The invention relates to the use of a functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof for the treatment of negative symptoms of schizophrenia. It also relates to adjunctive and simultaneous combination therapies for the treatment of negative symptoms of schizophrenia in which the functional muscarinic M1/M4... Agent: Nixon & Vanderhye, PC

20090306041 - Inhibitors of bruton's tyrosine kinase: wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090306042 - Novel compounds 010: e

20090306043 - Pyrrolidine ether derivatives as nk3 receptor antagonists: wherein R1, R2, R3, R′, Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090306038 - 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity: 2-Aminopyrimidine derivatives of formula (I) that are useful as modulators of the H4 receptor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306039 - Compounds and compositions as itpkb inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).... Agent: Genomics Institute Of The Novartis Research Foundation

20090306044 - Quinazoline derivatives for the treatment of cancer diseases: The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306045 - Inhibition of glycogen synthase kinase and methods of treating autoimmune or immune inflammatory disease: The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which... Agent: Coleman Sudol Sapone, P.C.

20090306046 - Method of treatment of hormone depletion induced vasomotor symptoms: The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090306047 - Heterocyclic aspartyl protease inhibitors: e

20090306048 - Pharmaceutical use of substituted piperidine carboxamides: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment... Agent: High Point Pharmaceuticals, Inc.

20090306051 - Methods and compositions for the treatment of epilepsy, seizure disorders, and other cns disorders: The present invention relates to methods and compositions for treating CNS-related disorders.... Agent: Adamas Pharmaceuticals, Inc.

20090306050 - Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA: 5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20090306049 - Treatment of barrett's esophagus: The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to the treatment of epithelial changes in the esophagus. Even more specific, the invention relates to the treatment of Barrett's esophagus. The invention provides a method for at least in part decreasing Barrett's esophagus present... Agent: Traskbritt, P.C.

20090306052 - Indenyl derivatives and use thereof for the treatment of neurological disorders: The present invention relates to novel indenyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090306053 - Highly selective rho-kinase inhibitor: (wherein R1 represents an amino acid residue; R2 represents a hydrogen atom or an alkyl group; R3 represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogen atom, a nitrile group, or a hydroxyl group; and R4 represents a hydrogen atom, a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306054 - Integrase inhibitors: Tricyclic compounds of formulae I-III, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.... Agent: Gilead Sciences Inc

20090306055 - Phenylazole compounds, production process and antioxidants: Z represents (a chroman-2-yl group, a chroman-4-yl group, a 2,3-dihydrobenzofuran-2-yl group, a 2,3-dihydrobenzofuran-3-yl group, etc.) which is substituted with NHR10 or OR11)] or pharmaceutically acceptable salts thereof, and to antioxidants, therapeutic agents for kidney diseases or cerebrovascular disorder, and retinal oxidative damage inhibitors, which include the compounds as the active... Agent: Oliff & Berridge, PLC

20090306056 - Pyrrolo-pyridine kinase modulators: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090306057 - [1,2,4]thiadiazine 1,1-dioxide compounds: The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.... Agent: Connolly Bove Lodge & Hutz LLP

20090306058 - Sulphone derivatives for treatment of cancer: Compounds of Formula (I) are disclosed for treatment of cancer.... Agent: Merck And Co., Inc

20090306059 - Cyclic amine derivative having substituted alkyl group: m

20090306061 - Fungicidal combinations comprising a glyoxalic acid methyl ester-o-methyloxime derivatives:

20090306060 - Method for improving seed lot quality: The present invention relates to a method for improving seed lot quality, seed shelf life, and seed lot retention, comprising applying to a seed within the seed lot an effective amount of a strobilurin fungicide alone, or in combination with at least one additional fungicide. In a preferred embodiment, the... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090306062 - 2,5-disubstituted piperidines: The application relates to 2,5-disubstituted piperidines, their preparation and use as medicines, especially as renin inhibitors, of the general formula (I) in which R, R1 and X are each as defined in detail in the description, and pharmaceutical preparations comprising these compounds.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090306063 - Oxadiazoanthracene compounds for the treatment of diabetes: wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful... Agent: Transtech Pharma, Inc.

20090306067 - 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer: The present invention encompasses compounds of general formula (1) wherein Q and R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306065 - Aerosol formulation for inhalation containing an anticholinergic agent: The invention relates to specific aqueous aerosol formulations that are devoid of propellant, containing one or more anticholinergic agents of formula (1), in which X represents an anion, and containing at least one pharmacologically compatible organic acid and optionally additional pharmacologically compatible adjuvants and/or complexing agents. The cation of formula... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306069 - Azolidinone-vinyl fused-benzene derivatives: e

20090306068 - Novel enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof:

20090306066 - Peptide deformylase inhibitors:

20090306064 - Substituted piperidines as renin inhibitors: Compounds of the general formula (I) in which the meanings of the substituents R1, R2, R3, R4, X, Z and n as stated in claim 1 have renin-inhibiting properties and can be used as medicines.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090306070 - Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular,... Agent: Darby & Darby P.C.

20090306071 - Inhibitors of janus kinases: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a... Agent: Merck And Co., Inc

20090306072 - Use of tyrosine kinase inhibitors for the treatment of inflammatory processes: e

20090306073 - Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers: Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed.... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20090306074 - Thiazolidinedione derivatives as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090306075 - Chemical compounds: v

20090306076 - Morpholine carboxamide prokineticin receptor antagonists: The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which prokineticin receptors are involved. The invention is also directed to... Agent: Merck And Co., Inc

20090306077 - Novel n- (2-aminophenyl) benzamide derivative having urea structure: The present invention relates to a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of a pharmacological effect of the derivative. A compound represented by the general formula (1) or a salt thereof has an... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090306079 - 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands: e

20090306078 - Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component: Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of... Agent: Lucas & Mercanti, LLP

20090306080 - Veterinary formulation: The present invention relates to a liquid veterinary formulation comprising a stable solution of cyromazine, or a pharmaceutically acceptable salt thereof, in a solvent system which may comprise water and one or more polyethylene glycols. A liquid concentrate is also described in which the cyromazine, or a pharmaceutically acceptable salt... Agent: Judy Jarecki-black, Ph.d. Merial Ltd.

20090306081 - Solid dosage formulations of hydralazine compounds and nitric oxide donor compounds: The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the... Agent: Wilmerhale/nitromed

20090306084 - Heteroaryl 11-beta hydroxysteroid dehydrogenase type i inhibitors: e

20090306082 - Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, a diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases... Agent: Darby & Darby P.C.

20090306083 - Use of trifluoromethyl substituted benzamides in teh treatment of neurological disorders: The invention relates to methods of using the compounds of the invention, including trifluoromethyl substituted benzamide compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph... Agent: Novartis Institutes For Biomedical Research, Inc.

20090306086 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on Fms and/or Kit protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of Fms and/or Kit protein kinases.... Agent: Foley & Lardner LLP

20090306087 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of... Agent: Foley & Lardner LLP

20090306085 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20090306088 - Substituted heteroaryl pyridopyrimidone derivatives: Wherein m, n, o, Y, Z, R1, R2, R3, R4, R5 R6 and R7 are as described herein. Also disclosed are the salts of compounds of formula (I). The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090306089 - Compounds: e

20090306090 - Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors:

20090306091 - Antimalarial therapy using a combination of synthetic artemisinin derivative and bisquinoline derivative: The technical field of the present invention relates to antimalarial therapy using a synthetic artemisinin derivative and bisquinoline derivative.... Agent: Ranbaxy Inc.

20090306092 - Method for treating cognitive deficits: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090306093 - Method for treating patient having benign prostate hyperplasia: A method for treating a patient having lower urinary tract symptoms is provided. The method comprises a step of administering to the patient a therapeutically effective amount of one selected from a group consisting of a treating compound of 7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine, a salt of the treating compound, a solvate of... Agent: Volpe And Koenig, P.C.

20090306094 - Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides: The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090306095 - Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the... Agent: Louis J. Wille Bristol-myers Squibb Company

20090306096 - Novel isoxazoles and methods of use thereof: The invention relates to isoxazole derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20090306097 - Use of allopurinol for the treatment of palmar plantar erythrodysesthesia: Allopurinol or a pharmaceutically acceptable salt thereof can be used for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt may be administered topically to the affected areas, palms and soles, preferably in the form of a cream.... Agent: Cooper & Dunham, LLP

20090306098 - Combination of roscovitine and a hdca inhibitor to treat proliferative diseases: A first aspect of the invention relates to a combination comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA). A second aspect of the invention relates to a pharmaceutical... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090306099 - Method of screening for drug hypersensitivity reaction: Methods of assessing the risk of clinical signs of hypersensitivity reaction to nucleoside antiviral compounds, including abacavir, are described. The methods include genotyping subjects for polymorphisms in the TNFα gene, the class 1 HLA genes, or a combination of both the TNFα and HLA genes.... Agent: Glaxosmithkline Corporate Intellectual Property

20090306100 - Methods of treating schizophrenia: This invention relates to methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia.... Agent: Lexicon Pharmaceuticals, Inc.

20090306102 - 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases: This invention relates to novel pyridinyl-quinazoline derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20090306103 - Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders: Pyridonecarboxamide derivatives, pharmaceutical compositions which contain the same and methods for treating hyper-proliferative disorders and angiogenesis disorders using the same.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090306104 - Use of lck inhibitors for treatment of immunologic diseases: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306105 - Bicyclic heterocycles, medicaments containing these compounds, their use and process for preparing them: The present invention relates to bicyclic heterocycles of the general formula (I), their tautomers, their stereoisomers, their mixtures and their salts, in particular physiologically tolerable salts with inorganic or organic acids, which have valuable pharmacological properties, in particular an inhibiting action on the signal transduction transmitted by tyrosinekinases, their use... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306106 - Forms of crystalline lapatinib and processes for preparation thereof: The present invention provides new crystalline forms of lapatinib base, Form X and Form Y, and amorphous lapatinib base, pharmaceutical compositions comprising the new crystalline forms of lapatinib base, and/or the amorphous lapatinib base, and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20090306101 - Combination treatment of cancer comprising egfr/her2 inhibitors: The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups Ra to Rd have the meanings given in... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090306107 - Organic compounds: The present invention relates to compounds that are useful to inhibit, regulate and/or modulate tyrosine and serine/threonine kinase and kinase-like proteins, such as RAF kinase, a serine/threonine kinase that functions in the MAP kinase signaling pathway. The application is also concerned with compositions which contain these compounds, and methods of... Agent: Carstens & Cahoon, LLP

20090306109 - Fungicide active substance combinations: e

20090306110 - N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor: The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.... Agent: Eli Lilly & Company

20090306108 - Substituted pyrimidinones: and pharmaceutically acceptable salts thereof, wherein R1, R2, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the... Agent: Pfizer Inc. Patent Department

20090306112 - Antiviral protease inhibitors: The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.... Agent: Gilead Sciences Inc

20090306111 - Pharmaceutical comprising ppar agonist: There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPARα or δ agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090306113 - Pharmaceutical formulation: The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090306114 - Polymorphic and other crystalline forms of cis-ftc: Solid phases of (−)-cis-FTC, which are designated herein as amorphous (−)-FTC and Forms II and III (−)-cis-FTC) are provided that can be distinguished from Form I (−)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated... Agent: King & Spalding

20090306115 - Phenyl ethyne compounds: In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen atoms. The ring additionally includes four carbon atoms. The heterocyclic ring has at least one substituent... Agent: Merck And Co., Inc

20090306116 - Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity: A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.... Agent: Astrazeneca R&d Boston

20090306117 - Rosuvastatin zinc salt: The present invention is related to rosuvastatin zinc salt of the Formula (I), process for preparation thereof and medicinal products containing said salt. Rosuvastatin zinc salt according to the present invention is prepared by reacting rosuvastatin with a zinc alcoholate, zinc enolate or an inorganic or organic zinc salt and... Agent: K.f. Ross P.C.

20090306118 - Trisubstituted thiophenes as progesterone receptor modulators: The present invention is directed to novel trisubstituted thiophene derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical usage of these compounds are related to hormonal contraception, the treatment and/or prevention... Agent: Philip S. Johnson Johnson & Johnson

20090306119 - Non-codeine opioid analgesic process and formulations: The invention is directed to the relief of pain using opioid analgesics other than codeine, preferably in combination with a non-steroidal anti-inflammatory agent. Treatment is by self-administration. Compositions for the treatments are provided. Compositions of opioid analgesics other than codeine adapted to avoid the problems of potential abuse are also... Agent: Peter G Carroll Medlen & Carroll

20090306120 - Terpolymers containing lactide and glycolide: The present invention provides an amorphous terpolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same.... Agent: Squire, Sanders & Dempsey LLP

20090306121 - Aza-beta-carbolines and methods of using same: e

20090306122 - Substituted tetrahydropyrroloquinoline derivatives as kinase modulators, especially of tyrosine and raf kinases: Compound of the formula (I), in which X, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20090306124 - 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors: The present invention relates to a compound of formula (I) wherein R1 is H, C1-C6-alkyl, phenyl-C1-C4-alkyl or phenyl, R2 is a phenyl group which is substituted with 2 or 3 C1-C6-alkoxy groups and R3 is indolyl or azaindolyl which may carry one or two substituents independently selected from C1-C6-alkyl, C1-C6-alkoxy,... Agent: Viksnins Harris & Padys Pllp

20090306123 - Bicyclononene derivaties: The invention relates to novel bicyclononene derivatives of Formula (I); and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use... Agent: Hoxie & Associates LLC

20090306127 - Certain chemical entities, compositions and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306126 - Indole derivatives: or pharmaceutically-acceptable salts thereof, wherein each of Ring A, m, R1, R2, n, R3 and G1 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K... Agent: Morgan Lewis & Bockius LLP

20090306125 - Mitochondria-targeted antioxidant prodrugs and methods of use: The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug... Agent: Licata & Tyrrell P.C.

20090306128 - Pharmaceutical compositions containing a fluoroquinolone antibiotic drug: Pharmaceutical compositions containing a fluoroquinolone antibiotic drug are disclosed. The compositions exhibit improved homogeneity, improved bioavailability, lower turbidity or a combination thereof. The composition can be use as otic or nasal compositions, but are particularly useful as ophthalmic compositions.... Agent: Alcon

20090306129 - Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV).... Agent: Ranbaxy Inc.

20090306130 - Novel tetrahydro-isoquinolines: The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure,... Agent: Dann, Dorfman, Herrell & Skillman

20090306131 - Cell lines with latent immunodeficiency virus and methods of use thereof: The present invention provides isolated cells that comprise, integrated into the genome of the cell, a transcription-competent immunodeficiency virus or a transcription-competent immunodeficiency virus-based retroviral vector. Under basal in vitro culture conditions, the immunodeficiency virus is latent, and the expression of the latent immunodeficiency virus can be reactivated. The invention... Agent: Bozicevic, Field & Francis LLP

20090306132 - Use of derivatives of naphthalenesulphonic or quinolinesulphonic acid in the treatment of vasoproliferative ocular diseases: The invention relates to the use of derivatives of sulphonic acid (I) or one of the pharmaceutically-acceptable prodrugs or salts thereof in the preparation of a medicament for the treatment of vasoproliferative ocular diseases, said sulphonic acid having formula (I).... Agent: Sheridan Ross PC

20090306133 - New acetyl coenzyme a carboxylase (acc) inhibitors and uses in treatments of obesity and diabetes mellitus - 087: or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for their therapeutic use, particularly... Agent: Pepper Hamilton LLP

20090306134 - Muscarinic receptor antagonists: Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said... Agent: Theravance, Inc.

20090306135 - Stable amorphous fexofenadine hydrochloride: The present invention relates to stable amorphous form of fexofenadine hydrochloride, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of allergic reactions.... Agent: Ranbaxy Inc.

20090306136 - Benzenesulfonamide compounds and the use thereof: The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z, p and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090306137 - Treatment for depressive disorders: A method of treating depression comprising administering a melatonin agonist.... Agent: Hoffman Warnick LLC

20090306140 - 3 or 4-substituted piperidine compounds: m

20090306139 - Heteroaryl-substituted piperidines: The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases.... Agent: Nixon Peabody LLP

20090306138 - Pyrrolidine derivatives acting as ccr3-receptor antagonists: e

20090306141 - Novel compounds: The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20090306142 - Methods to control qoi-resistant fungal pathogens: Processes and compositions have been discovered that are suitable for controlling a pathogen induced disease in a plant that is at risk of being diseased from a pathogen resistant to a Qo inhibitor. Such processes and compositions comprise contacting said plant(s) with a composition comprising an effective amount of a... Agent: Dow Agrosciences LLC

20090306143 - Derivatives of n-(heteroaryl)-1-heteroaryl-1h-indole-2-carboxamides, preparation thereof and therapeutic use thereof: o

20090306144 - Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents:

20090306145 - Pyridylisoxazole derivatives:

20090306147 - Biological efficacy of agrochemical compositions on application in the growth substrate suitable formulations and use thereof: In soil applications, the action of crop protection compositions comprising active compounds from the classes of the neonicotinoids, the pyrethroids, the butenolides, the ketoenols, the phenylpyrazoles or the fungicides can be improved by adjuvants. The present invention describes corresponding methods and suitable compositions.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090306146 - Nicotinyls, pyrethroids, and ketoenols as a gel formation or foam formulation for perennial cultures: Method of controlling insects with a gel or foam formulation containing at least one insecticidal active substance, characterized in that the agrochemical formulation is applied externally to the trunk of the plant to be protected.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090306148 - Use of thiazolidinediones for the partial inhibition of androgen binding to aromatase: A method for the treatment or prophylaxis of a disorder, wherein the disorder is affected by estrogen, comprising partially inhibiting aromatase activity or interfering with the binding of androgen to aromatase by administering a therapeutically effective amount of a thiazolidinedione to the patient. The use of rosiglitazone or pioglitazone to... Agent: Ostrager Chong Flaherty & Broitman PC

20090306150 - Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine: m

20090306149 - Use of biarylcarboxamies in the treatment of hedgehog pathway-related disorders: The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway. In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Novartis Institutes For Biomedical Research, Inc.

20090306151 - Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker: A pharmaceutical preparation comprising an angiotensin II receptor antagonist, a calcium channel blocker and at least one substance selected from a hydrophilic polymer, an acidic substance and a fluidizing agent. The pharmaceutical preparation demonstrates improved dissolution properties.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090306152 - Cooling cosmetic or dermatological preparations comprising (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethyl)-cyclohexane carboxamide and/or (1r,2s,5r)-n-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide in combination with menthox: A cooling topical cosmetic or dermatological preparation which comprises (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane carboxamide and/or (1R,2S,5R)-N-(4-cyanomethyl-phenyl)-2-isopropyl-5-methylcyclohexane carboxamide, in combination with menthoxypropanediol.... Agent: Greenblum & Bernstein, P.L.C

20090306153 - Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases: In one embodiment of the present disclosure, an inactivator of protein arginine deiminase 4 is disclosed. The inactivator includes: (I) and x includes F; Cl, and H, y includes OH and NH2, R includes H, an alkyl group, an alkenyl group, an alknyl group, and n is greater than 0.... Agent: Dority & Manning, P.A.

20090306154 - Synergistic anti-microbial mixtures of tropolone (derivatives) and selected compounds:

20090306155 - Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and the compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds... Agent: Vertex Pharmaceuticals Inc.

20090306156 - Phosphodiesterase 4 inhibitors: e

20090306157 - Antiseptic alginate preparation: An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also... Agent: Panitch Schwarze Belisario & Nadel LLP

20090306158 - Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286:

20090306159 - Inhibition of intermediate-conductance calcium activated potassium channels in the treatment and/or prevention of atherosclerosis: Methods for treating or preventing atherosclerosis in human or non-human animal subjects by inhibiting or blocking intermediate-conductance calcium activated potassium channels associated with vascular smooth muscle and/or other cells which play a role in the pathogenesis of atherosclerosis (e.g., KCa3.1, KCNN4, IKCa1, IK1, SK4 channels).... Agent: Stout, Uxa, Buyan & Mullins LLP

20090306160 - Methods for improving drug disposition: The invention provides a method for improving the bioavailability, preferably, oral bioavailability and/or drug disposition, e.g. brain penetration, of an iron chelator, which method comprises co-administering to a mammal, especially a human, in need of such treatment, a combination of an iron chelator and an efflux protein inhibitor.... Agent: Novartis Corporate Intellectual Property

20090306161 - Methods of treating alpha adrenergic mediated conditions: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.... Agent: Allergan, Inc.

20090306162 - Fungicidal control of moulds: A composition for treating fungus infection of turfgrass, such as snow mould infection, comprises a mixture of fungicidally effective amounts of formulae 1 and 2: And in particular mixtures of oprodione and trifloxystrobin. A method for treating snow moulds comprises applying the mixture before the onset of continuous snow cover,... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090306163 - Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling: The described invention relates to the formulation and delivery of topical compositions comprising a cosmetically effective amount of at least one imidazolidinedione analog reduce the appearance of wrinkles.... Agent: Greenberg Traurig, LLP

20090306164 - Methods for treating papilloma virus infection: The present invention relates to polyamide compositions and therapies for treating cells infected with papilloma virus (PV).... Agent: Spencer Fane Britt & Browne LLP

20090306165 - Dipeptide compounds containing d-histidine: D-Camosine lipophilic derivatives are disclosed, characterized by higher bioavailability than L-camosine and intended for the pulmonary distribution where they can exert detoxifying activity on the cytotoxic carbonyl compounds induced by cigarette smoke.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090306166 - Method of controlling phytopathogenic diseases on turfgrass: C

20090306167 - Pharmaceutical compositions for intranasal administration comprising a melatonin receptor agonist, uses thereof: The present invention relates to intranasally deliverable compositions comprising melatonin receptor agonists and to methods of using such compositions in the treatment of various diseases and disorders.... Agent: Goodwin Procter LLP Patent Administrator

20090306168 - Sirt inhibitors that bind to nad: e

20090306169 - Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases and d-amino acid oxidase inhibitors: The present invention provides the use of fused pyrrole carboxylic acids of formula (I) for the manufacture of a medicament to inhibit D-amino acid oxidase, particularly for the treatment of neurodegenerative and psychiatric disorders or diseases; certain compounds of formula I being novel, pharmaceutical compositions containing them, their use in... Agent: Merck And Co., Inc

20090306170 - Synthesis of tegaserod or a salt thereof: The present invention relates to a novel process for the synthesis of 1-((5-methoxy-1H-indol-3-yl)methyleneamino)-3-pentyl-guanidine, commonly known as tegaserod, which is used as a gastroprokinetic, and salts thereof. The present invention also relates to tegaserod and salts thereof having an HPLC purity of about 95% or more. The present invention further relates... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090306171 - Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors: Indole and indole-related compounds according to the formula (I) or (II) optionally having additional heteroatoms, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related... Agent: Mcandrews Held & Malloy, Ltd

20090306172 - Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the... Agent: Howard Eisenberg, Esq.

20090306173 - Crystalline forms of atorvastatin magnesium: The present invention relates to crystalline forms of Atorvastatin magnesium and processes for their preparation. The crystalline forms of the present invention are designated as form X, form Y, form Z and form P of atorvastatin magnesium. The present invention further relates to pharmaceutical compositions comprising form X, form Y,... Agent: Ranbaxy Inc.

20090306174 - Novel five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090306175 - Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor: The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a... Agent: Dykema Gossett PLLC

20090306196 - Imine based liquid crystals for the controlled release of bioactive materials: The present invention relates to a delivery system based on a film of an imine forming liquid crystalline phase, mixed with at least with one biologically active substance, to which a constant or variable electric field can be applied. The delivery system can be used as a delivery system for... Agent: Winston & Strawn LLP Patent Department

20090306197 - Substituted chromanol derivatives and their use: The present invention relates to substituted chromanol derivatives, to processes for their preparation, to their use on their own or in combination for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention... Agent: Barbara A. Shimei Director, Patents & Licensing

20090306198 - Anti-oxidant synergy formulation nanoemulsions to treat caner: A uniform microfluidized nanoemulsion is disclosed containing a synergistic combination of two antioxidants and a cell membrane stabilizer phospholipid (i.e., an anti-oxidant synergy formulation; ASF). The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of typically... Agent: Carroll Peter G Medlen & Carroll

20090306199 - Method for inhibiting activation of macrophages, inhibiting formation of osteoclasts, inhibiting function of osteoclasts, and/or activating osteoblasts: A method for inhibiting the activation of macrophages, inhibiting the formation of osteoclasts, inhibiting the function of osteoclasts, and/or activating osteoblasts in a mammal is provided. The method comprises the administration of an effective amount of kinsenoside of formula (I) or a pharmaceutically acceptable salt or ester thereof to the... Agent: Patterson, Thuente, Skaar & Christensen, P.A.

20090306200 - Prophylactic or therapeutic agent for nocturnal conduct disorder associated with dementia: The present invention provides a prophylactic or therapeutic agent for nocturnal conduct disorders associated with dementia, comprising (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide.... Agent: Edwards Angell Palmer & Dodge LLP

20090306201 - Selective inhibitors for transferases: A pharmaceutical composition comprising a compound of formula I or II and a pharmaceutically acceptable carrier. Methods for treating a proliferative disorder mediated by a methyl transferase comprising administering an anti-proliferative effective amount of the compound of formula I or II are also presented.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090306202 - D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands: The present invention is directed to D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090306203 - Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group: The present invention relates to Compounds of general formula (I), wherein R is hydrogen and R1 is hydroxy or acyloxy, or R is acyl and R1 is hydroxy or acyloxy, X is sulphur, oxygen or NR10, wherein R10 is hydrogen or (C1-4)alkyl; Y is sulphur or oxygen; R2 is hydrogen... Agent: Knobbe Martens Olson & Bear LLP

20090306204 - Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association: The present invention relates to an association of active ingredients. More specifically: to an association of cyclobenzaprine and aceclofenac. Additionally, the present invention is also related to the use of aceclofenac and cyclobenzaprine, in association for the preparation of a medicine useful in the treatment of painful muscular diseases, as... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306205 - Methoxypolyethylene glycol thioester chelate and uses thereof: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl... Agent: Wilmerhale/dc

20090306206 - Solid form sodium lauryl sulfate (sls) pesticide composition: A pesticide composition and method of eliminating pests combines water and a solid form of sodium lauryl sulfate to form a pesticide composition effective to cause mortality in pests. The pesticide composition is applied to the indoor structure in an area which the pests inhabit. The sodium lauryl sulfate can... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property (74074)

20090306207 - Treatment of drug-resistant proliferative disorders: p

20090306209 - Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same: Oral amino acid formulations comprising polyethylene glycol are enteric coated. Most preferred amino acids are leucine, glutamine, and arginine. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range... Agent: Hogan & Hartson LLP

20090306208 - Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria: According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306210 - Solubilizates of preservatives and method for producing the same: Described is a solubilisate of a preservative containing an aliphatic and/or aromatic acid such as sorbic acid and/or benzoic acid that is free of stabilizing agents, as well as one or more emulsifiers with an HLB value between 9 and 18 with a concentration of about 50% and about 95%... Agent: Jacobson Holman PLLC

20090306211 - Peritoneal dialysis fluid: The present invention concerns a peritoneal dialysis fluid with enhanced ultrafiltration during the dialysis dwell period. According to the present invention this is achieved by a peritoneal dialysis fluid comprising sodium ions, osmotic agent and a buffer, characterised in that it comprises citrate at a level of 4 to 10... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090306212 - Compositions and methods for treating diabetes and neuropsychological dysfunction: The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090306213 - Process for synthesis of glycomimicking cationic amphiphiles: The present invention provides processes for the synthesis of novel Shikimic acid head-group containing non-toxic cationic amphiphiles capable of facilitating transport of biological macromolecules into cells.... Agent: Fulbright & Jaworski L.L.P.

20090306214 - Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders: The invention relates to polyalkylene glycol compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090306215 - Deuterium-enriched arformoterol: The present application describes deuterium-enriched arformoterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090306216 - Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain: A compound for therapeutic use, of the formula (I), wherein R1 is aryl or heteroaryl optionally substituted with R5; R2 is H, alkyl or CH2OH or forms part of a ring with R4; R3 is H, alkyl or CH2OH or forms part of a ring with R4; R4 is H,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090306217 - Method and compositions: The present invention provides compositions for inhibiting the activity of an insect pest against a subject (or repelling an insect pest from an environment or preventing attraction to an environment) which compositions comprise geranylacetone as an active ingredient plus a carrier plus a further active ingredient selected from the list... Agent: Wolf Greenfield & Sacks, P.C.

20090306218 - Antimicrobial formulations: An antimicrobial formulation containing a synergistic combination of a quinone, such as an optionally substituted benzoquinone or hydroquinone, and a bismuth salt. The formulation may in particular be used against propionibacteria, more particularly to treat skin and skin structure conditions such as acne, or against microbial infections within the oral... Agent: Bell & Associates

20090306219 - Topical use of plant extract for skin detoxification: Specific plant extracts are applied topically to upregulate genes which code for proteins to prevent the build-up of and mitigate the activity of various harmful materials within the skin. These upregulated proteins include glutathione transferases, peroxiredoxins, oxidoreductases, glutaredoxins and glutathione syntheses. These proteins produce additional glutathione, glyoxalase I, maintain cellular... Agent: Ladas & Parry LLP

20090306220 - Stable organic peroxide compositions: Methods of treating acne include the use of formulations including a benzoyl peroxide solution and a poly-carboxylic acid.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20090306221 - Use for cannabinoid: The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and/or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative... Agent: Wolf Greenfield & Sacks, P.C.

20090306222 - Food supplements and uses thereof: The invention features compositions for administration of an oxidatively transformed carotenoid, fractionated oxidatively transformed carotenoid and components of oxidatively transformed carotenoid. The compositions are useful for supplementing the diet of an animal.... Agent: Clark & Elbing LLP

20090306223 - Surface-active material and its application: There is provided a surface-active material that comprises fibres which have been modified so as to impart surface-active properties onto said fibres and giving it a contact angle between 60° and 120°, wherein the fibres have an aspect ratio of more than 10 to 1,000. The surface-active material can be... Agent: Unilever Patent Group

20090306224 - Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions: The use of Schülpen based on pyrogenically produced silicon dioxide in pharmaceutical compositions is described.... Agent: Smith, Gambrell & Russell

20090306225 - Auris formulations for treating otic diseases and conditions: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and... Agent: Wilson, Sonsini, Goodrich & Rosati

20090306226 - Procedures for obtaining polymers derived from vinyl acetate and their uses: the drying of the semisolid humid polymer mass by means of heating of the said mass at a temperature between 80 and 140° C., under vacuum (0.02-13 kPa), and stirring the mass slowly until the polymer contains a humidity less than 1.5% by weight and remnant monomer less than 2... Agent: Arent Fox LLP

20090306227 - Tablet for removing tongue coating: A tablet for removing tongue coating, wherein the tablet contains highly soluble saccharide and lowly soluble saccharide, the highly soluble saccharide and the lowly soluble saccharide are water-soluble, of water-soluble saccharides contained as the primary component in the tablet, the highly soluble saccharide has the highest solubility in water at... Agent: Mark D. Saralino (general) Renner, Otto, Boisselle & Sklar, LLP

20090306228 - Active agent delivery systems and methods for protecting and administering active agents: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.... Agent: Darby & Darby P.C.

20090306229 - Perfum composition for expressing the fragrance of green tea flower: Disclosed is a perfume composition having a fragrance like that of green tea flowers. The perfume composition contains artificial synthetic substance trans-4,8-dimethyl-1,3,7-nonatriene or lilac alcohol, in addition to the main fragrant components of green tea flowers, analyzed by an SPME method or a solvent extraction method, and thus has a... Agent: Nixon & Vanderhye, PC

20090306230 - High throughput testing for presence of microorganisms in a biological sample: Provided are methods and apparatus for high throughput testing of biological samples that may or may not comprise microorganisms. The methods include the use of a diagnostic multiplexing panel (DMP) specifically designed for the simultaneous identification of a plurality of potential microorganisms that may be present in the biological sample... Agent: Dinsmore & Shohl LLP

  
12/03/2009 > 217 patent applications in 135 patent subcategories. patent applications/inventions, industry category

20090298743 - Hydrophobic compositions containing reconstitution enhancer: Disclosed are compositions comprising a hydrophobic active agent, a polymer and a reconstitution enhancing agent. Reconstitution of the lyophilized form of the compositions takes less time than in the absence of the enhancing agent.... Agent: Novartis Corporate Intellectual Property

20090298740 - Novel nucleotide sequences: The present invention relates to the field of cancer therapy. More specifically, the invention relates to use of certain nucleotide sequences for the treatment of cancer.... Agent: Carstens & Cahoon, LLP

20090298742 - Process for manufacturing lactose: A process for forming crystalline lactose suitable for use in a pharmaceutical formulation comprises subjecting a solution comprising a plurality of nanosized lactose particles to conditions sufficient to cause crystallization to occur on the nanosized lactose particles such that a plurality of lactose particles are formed therefrom having a median... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090298741 - Trophic factor combinations for nervous system treatment: The present invention relates to a composition including an effective amount of at least one of an antimicrobial peptide and a substance having an antimicrobial peptide effect and an effective amount of a neurotrophin. The composition can also include an effective amount of at least one of a growth factor... Agent: Whyte Hirschboeck Dudek S.c./warf Intellectual Property Department

20090298744 - Heterocyclic compounds as adenosine receptor antagonist: e

20090298745 - treatment of diabetes with glycogen phosphorylase inhibitors: The invention provides a method of treatment of diabetes, particularly type II diabetes, or a diabetes related condition, comprising night time dosing of an inhibitor of glycogen phosphorylase, optionally in combination another anti-diabetic therapy.... Agent: Osi Pharmaceuticals, Inc.

20090298746 - Pegylated hemoglobin and albumin and uses thereof: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated... Agent: Amster, Rothstein & Ebenstein LLP

20090298749 - Dalbavancin compositions for treatment of bacterial infections: The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, C0, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a... Agent: Pfizer Inc. Patent Department

20090298747 - Methods and compositions for treatment of nitric oxide-induced clinical conditions: The present invention provides compositions and methods for modulating cellular nitric oxide (NO) production and for treating a clinical condition associated therewith.... Agent: Don D. Cha

20090298748 - Methods of administering dalbavancin for treatment of bacterial infections: The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels... Agent: Pfizer Inc. Patent Department

20090298752 - Aplidine treatment of cancers: Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumors, and various dosing regimes are given. Tumor reduction has been observed in several tumor types including renal carcinoma, colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role... Agent: Fish & Richardson PC

20090298751 - Arylalkyl and heteroarylalkyl derivaties of cyclosporine a for the treatment and prevention of viral infection: This invention provides compounds of general formula (T): (I) wherein A, B, R1, R2, and X are as defined in this specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus and/or human immunodeficiency virus.... Agent: Jones Day

20090298750 - Daptomycin for the treatment of biofilm and catheter salvage: Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or... Agent: Intellectual Property Department Cubist Pharmaceuticals, Inc.

20090298753 - Methods for the therapeutic use of cyclosporine components: Methods of treating humans or animals having various conditions are disclosed which include administering a therapeutically effective amount of a cyclosporine component to the human or animal, thereby treating the condition. Among the conditions treated are systemic lupus eryhematosis, multiple sclerosis, maloplabia of the skin, oral frictional hyperkeratosis, oral manifestations... Agent: Allergan, Inc.

20090298774 - Bifunctional molecules for inhibiting hiv entry: Disclosed herein are bifunctional molecules which inhibit HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV, including non-B and multi-drug resistant strains.... Agent: K&l Gates LLP

20090298759 - C-reactive protein and its use to treat systemic lupus erythematosus and related conditions: The present invention relates to the use of C-reactive protein, its mutants, metabolites and polypeptides and related compounds thereof for the treatment of various disease states and conditions associated with systemic lupus erythematosus (SLE), including lupus of the skin (discoid), systemic lupus of the joints, lungs and kidneys, hematological conditions... Agent: Coleman Sudol Sapone, P.C.

20090298769 - Compounds and methods of modulating angiogenesis: A method of modulating angiogenesis in a tissue comprises administering to the tissue a therapeutically effective amount of an agent that modulates complex formation of αvβ3 integrin and VEGFR2.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20090298762 - Conjugates of biologically active proteins having a modified in vivo half-life: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the... Agent: Townsend And Townsend And Crew, LLP

20090298766 - Detection and treatment of cancers: The present invention relates to methods and compositions for the detection and treatment of melanoma and skin cancers. More particularly, the invention discloses that BCSC-1 expression is altered in melanoma and skin cancer cells, allowing the design of effective detection methods and kits for such conditions. The invention also shows... Agent: Ladas & Parry LLP

20090298767 - Formulation comprising whey protein and hydrolysates for improving muscle recovery: The present invention relates to a formulation comprising whey protein or a hydrolysate of whey protein, which formulation is capable of inhibiting the expression of TNFα in lipopolysaccharide-stimulated macrophages in vitro. Also provided are uses of the formulation for attenuating a reduction in muscle function which results from muscle damage... Agent: Myers Bigel Sibley & Sajovec

20090298756 - Functions and uses of gpr39 gene in mammalian central nervous system: The present invention provides mammalian GPR39 gene, its coded products, and the uses in regulating appetite and pain sensitivity. A pharmaceutical composition and a health product comprising GPR39 protein are also provided. The health product and the pharmaceutical composition for suppressing appetite or decreasing pain sensitivity comprise a safe and... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090298764 - Gene and pathway and their use in methods and compositions for predicting onset or progression of autoimmune and/or autoinflammatory diseases: Embodiments of the present invention concern methods, compositions and uses thereof, relating to at least one of vitiligo, or vitiligo-associated autoimmune/autoinflammatory disease (VAAAD). In particular embodiments, genetic variations in the NALP1 gene are of use to detect, diagnose, predict the risk of or treat at least one of vitiligo or... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090298754 - Hai-1 and hai-2 in cancer therapy: The invention relates to a novel therapeutic composition for treating cancer, and particularly prostrate and breast cancer, the composition comprises mixture of two hepatocyte growth factor activator inhibitors HAI-1 and HAI-2.... Agent: King & Schickli, PLLC

20090298770 - Mammalian relaxin receptors: High affinity relaxin receptors, polypeptide compositions related thereto, as well as nucleotide compositions encoding the same, are provided. These proteins, herein termed LGR7 and LGR8, are orphan leucine-repeat-containing, G protein-coupled receptors. These receptors have a wide and a unique tissue expression pattern. The receptors, particularly soluble fragments thereof, are useful... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090298765 - Metastin derivatives and use thereof: The invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, etc.). By modifying the constituent amino acids of metastin with specific modifying groups, metastin derivatives having more improved blood stability, etc. than native metastin and showing excellent cancer metastasis suppressing... Agent: Edwards Angell Palmer & Dodge LLP

20090298775 - Method of measuring neprilysin activity: The present invention provides a method of measuring the activity of neprilysin, etc. More specifically, the present invention provides a method of measuring the activity of neprilysin in nerve cells; a method of screening a protein, a peptide or a compound enhancing the activity or expression of neprilysin in nerve... Agent: Edwards Angell Palmer & Dodge LLP

20090298773 - Methods of producing functional miso: According to the present invention a miso with good flavor and a processed food containing the miso are provided, wherein the miso and the food are expected to have an repressing effect on an increase in blood pressure or hypotensive effect by continually taking the miso or food for routinely... Agent: Birch Stewart Kolasch & Birch

20090298761 - Methods of treating cartilage defects using a soluble morphogenic protein complex: The present invention provides methods of repairing and regenerating cartilage tissue using a soluble morphogenic protein complex comprising (a) a morphogenic protein; and (b) a morphogenic protein pro region isolated from a morphogenic protein, or a conservative substitution variant or a fragment of said pro region, wherein said pro region... Agent: Ropes & Gray LLP

20090298760 - Modified coagulation factor viia with extended half-life: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090298755 - Novel chimeric analgesic peptides: The present invention provides a novel chimeric peptide containing an opioid peptide moiety and a nociceptive peptide moiety for producing analgesia.... Agent: Choate, Hall & Stewart LLP

20090298757 - Oxyntomodulin analogues and their effects on feeding behaviour: Compounds of the invention are novel peptide analogues of oxyntomodulin (oxm) in which one or more amino acids of the oxm sequence have been changed. Changing amino acids 15-24 of oxm to either amino acids 968-977 of the α-latrotoxin peptide (and variations thereof) or amino acids 15-24 of exendin-4 (and... Agent: Lando & Anastasi, LLP S2059

20090298763 - Polynucleotides and polypeptide sequences involved in the process of bone remodeling: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders.... Agent: Choate, Hall & Stewart LLP

20090298776 - Spinal fusion methods and devices: Methods, devices and compositions for fusing adjacent vertebrae, and otherwise localizing bone growth, are provided. In one form of the invention, a method for fusing adjacent vertebrae includes preparing a disc space for receipt of an intervertebral disc implant in an interwertebral disc space between adjacent vertebrae, inserting the implant... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090298777 - Spinal fusion methods and devices: Methods, devices and compositions for fusing adjacent vertebrae, and otherwise localizing bone growth, are provided. In one form of the invention, a method for fusing adjacent vertebrae includes preparing a disc space for receipt of an intervertebral disc implant in an intervertebral disc space between adjacent vertebrae, inserting the implant... Agent: Medtronic Attn: Noreen Johnson -IPLegal Department

20090298768 - Stable liquid formulation of human growth hormone: Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil.... Agent: Cantor Colburn, LLP

20090298772 - Therapeutics to inhibit mll-menin interaction for treating leukemia: Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute mycloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners.... Agent: Barnes & Thornburg LLP

20090298758 - Thymosin beta 4 derivatives and use thereof: The present invention relates to thymosin β4 (Tβ4) derivatives, Gly-Tβ4 and Ala-Tβ4. The present invention further relates to a pharmaceutical composition comprising the said Tβ4 derivatives. The present invention also relates to the use of said Tβ4 derivatives in manufacture of a medicament for treatment of skin lesion, heart injury,... Agent: Seed Intellectual Property Law Group PLLC

20090298771 - Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome: This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090298780 - Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof: Lyophilized lung surfactant compositions having reduced viscosity upon reconstitution are described. These compositions are produced by a method including solvent dissolution and lyophilization.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090298778 - Peptides modulating the activity of macrophages, useable for the treatment of rheumatoid arthritis: The invention relates to citrulline peptides with anti-inflammatory properties. The invention also relates to an in vitro model for activation of macrophages, induced by immune complexes between specified IgG of rheumatoid arthritis and their citrulline targets.... Agent: Morgan Lewis & Bockius LLP

20090298779 - Peptides which modulate blood coagulation and methods of use thereof: Peptide fragments that modulate thrombosis and methods of use thereof are provided. Also provided are synthetic bioactive anti-coagulation peptides, compositions comprising such peptides and methods for the administration to patients in need thereof.... Agent: Dann, Dorfman, Herrell & Skillman

20090298781 - Compounds for the inhibition of apoptosis: The present invention relates to compounds of formula (I) as well as to drug conjugates based on compounds of formula (I) acting as apoptosis inhibitors, as well as to processes for their preparation, to pharmaceutical compositions containing them and their use in medicine.... Agent: Merchant & Gould PC

20090298782 - Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof: Disclosed are compounds containing single amino acids, peptides, or derivatives thereof which are selectively delivered to the mitochondria of a cell. Compounds of the invention exhibit antioxidant activity thereby reducing reactive oxygen species in cells. These compounds are useful for inhibiting oxidative stress-induced cell injury or death both in vivo... Agent: Licata & Tyrrell P.C.

20090298783 - Cosmetic compositions: Disclosed is a method for preventing and/or soothing dry or sensitive skin against external stresses, comprising contacting the skin with a composition including an agent that decreases the release of granulocyte-macrophage colony-stimulating factor (GMCSF) from keratinocytes in the skin, wherein under conditions of external stress, dry or sensitive skin is... Agent: Fox Rothschild LLP

20090298784 - Isolation and structure of turbostatins 1-4: Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures elucidated. The new compounds exhibit significant cancer cell growth inhibition activity against a variety of murine and human... Agent: Fennemore Craig

20090298785 - Method for treating ocular cancer: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53.... Agent: Licata & Tyrrell P.C.

20090298786 - Methods of treating viral infections with anthracycline antibiotics: A method of treating hepatitis C viral infection or viremia in a patient by administering to the patient an anti-hepatitis C virally effective amount of a compound of Formula 1 or Formula 2. A method for inhibiting the replication of hepatitis C virus by exposing the virus to a hepatitis... Agent: Matthias Scholl

20090298787 - Dsrna as insect control agent: The present invention relates to methods for controlling pest infestation using double standard RNA molecules. The invention provides methods for making transgenic plants that express the double stranded RNA molecules, as well as pesticidal agents and commodity products produced by the inventive plants.... Agent: Wolf Greenfield & Sacks, P.C.

20090298912 - Arginase ii: a target treatment of aging heart and heart failure: The instant invention provides methods and compositions for the treatment of cardiac dysfunction. Specifically, the invention provides methods and compositions for modulating Arginase II for the treatment of cardiac dysfunction.... Agent: Edwards Angell Palmer & Dodge LLP

20090298909 - Multiple rna polymerase iii promoter expression constructs: Expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule, are disclosed herein. Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which... Agent: David S. Resnick

20090298916 - Pharmaceutical compositions for treatment of microrna related diseases: The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered... Agent: Baker Botts L.L.P.

20090298910 - Regulation of epigenetic control of gene expression: Methods are provided for the identification of compounds that selectively modulate epigenetic changes in gene expression. Compounds, compositions, kits or assays devices, and methods are provided for modulating the expression, endogenous levels or the function of small non-coding RNAs cognate to or transcribed by heterochromatic regions subject to epigenetic regulation... Agent: Woodcock Washburn LLP

20090298914 - Rna interference mediated inhibition of severe acute respiratory syndrome (sars) virus gene expression using short interfering nucleic acid (sina): The present invention comprises compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as severe acute respiratory syndrome (SARS) virus genes, using short interfering nucleic acid (siNA) molecules. This invention also comprises compounds, compositions, and methods useful for modulating the expression... Agent: Sirna Therapeutics, Inc.

20090298911 - Sirna having antiviral activity against nonpolio enterovirus: The present invention relates to an siRNA (small interfering RNA) having antiviral activity against nonpolio enteroviruses, and a pharmaceutical composition comprising same as an active ingredient for preventing and treating diseases caused by nonpolio enterovirus infection.... Agent: Brooks Kushman P.C.

20090298913 - Small interfering oligonucleotides comprising arabinose modified nucleotides: Small interfering ribonucleic acid duplexes that inhibit gene expression containing at least one arabinose modified nucleotide are provided. Preferably, the duplexes contain ribonucleotides at least one arabinose modified nucleotide is 2′-deoxy-2′-fluoroarabinonucleotide (FANA) nucleotide.... Agent: David S. Resnick

20090298915 - Topical drug delivery: Poly-pseudo-lysine conjugates have been shown to be able to penetrate into human skin and are proposed for both therapeutic and cosmetic treatments by topical application, e.g. change of skin pigmentation.... Agent: Morrison & Foerster LLP

20090298922 - Aav transduction of muscle tissue: A method of expressing a gene product in the muscle tissue of an animal, which comprises administering a recombinant AAV vector to the muscle tissue of the animal, wherein the vector comprises a non-AAV gene of interest ligated into an AAV vector genome.... Agent: Myers Bigel Sibley & Sajovec

20090298918 - Alternative splicing isoform of lox-i protein encoding gene, and uses thereof: The invention relates to a new alternative splicing isoform of OLR1 gene encoding for the LOX-1 protein, uses and methods related to the treatment and to the prediction of the risk of cardiovascular diseases.... Agent: Young & Thompson

20090298920 - Chimeric transfer rna and use thereof for the production of rna by a cell: The present invention relates to the use of a nucleic acid encoding a chimeric transfer RNA (tRNA), which chimeric tRNA originates from the modification of a tRNA by insertion of an RNA into the stem-loop of the anticodon of the tRNA and/or by substitution of all or part of the... Agent: Young & Thompson

20090298921 - Methods and compositions for use in homologous recombination: Methods for homologously recombining an exogenous nucleic acid into a target cell genome of a target cell are provided. In the subject methods, a targeting vector that includes a linearizing endonuclease site, e.g., a recombinase recognition site, and a homologous recombination integrating element, is contacted with the target cell(s) such... Agent: Bozicevic, Field & Francis LLP

20090298917 - Non-viral vector system for the delivery of nucleic acid into the lung: This vector system is used as gene transfer system for the epithelial cells of the bronchial tubes and alveoli of the lung. The system is highly stable, protects the DNA in the pulmonary environment, has a low zeta-potential and a low aggregation tendency in a medium with a high ionic... Agent: Clark & Brody

20090298919 - Tumor homing molecules, conjugates derived therefrom, and methods of using same: The present invention provides tumor homing molecules, which selectively home to a tumor. The invention also provides methods of using a tumor homing molecule to target an agent such as a drug to a selected tumor or to identify the target molecule expressed by the tumor. The invention also provides... Agent: Mcdermott, Will & Emery

20090298788 - 2-polycyclic propynyl adenosine analogs having a2a agonist activity: e

20090298789 - Organ arrest, protection and preservation:

20090298791 - Combinations comprising epothilones and antimetabolites: wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R′ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier and/or, optionally, a standard anti-diarrheal,... Agent: Novartis Corporate Intellectual Property

20090298790 - Novel therapeutic use for treating of leukemia: The disclosure relates to methods of treating leukaemia, in particular myeloid leukaemia, comprising administering the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a hydrate, a pharmaceutically acceptable salt or a solvate thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090298792 - Anti-inflammatory polymer: The present invention provides the use of cellulose sulfate or chitosan for the manufacture of an anti-inflammatory pharmaceutical or cosmetic composition for the treatment of inflammation.... Agent: Fulbright & Jaworski L.L.P.

20090298793 - Acylgycerophospholipids for treating symptoms concomitant with cancer: The invention relates to the use of acylglycerophospholipids, in particular of hydrogenated acylglycerophospholipids and of phospholipids with a high omega-3 fatty acid content, for the production of a medicament for treating symptoms concomitant with cancer, in particular for treating tumour cachexia, cancer-related problems and pain, and for the prophylaxis of... Agent: Ballard Spahr LLP

20090298794 - Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists: The present invention provides compounds having the following Formula IA and IB, which are useful as MCHR1 antagonists, and includes prodrugs and pharmaceutically acceptable salts thereof:... Agent: Louis J. Wille Bristol-myers Squibb Company

20090298795 - Thiol-sensitive positive inotropes: The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.... Agent: Morrison & Foerster LLP

20090298796 - Reducing risk of type 2 diabetes (t2d): This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.... Agent: Fish & Richardson PC

20090298797 - Combination therapy for the treatment of influenza: Compositions and methods for treating one or more symptoms of influenza, preferably influenza due to infection with influenza A (H5N1) are provided. It has been discovered that administration of a combination of a neuraminidase inhibitor with two immunomodulators increases survivability in subjects 24, 48, or even 72 hours post infection... Agent: Pabst Patent Group LLP

20090298798 - Combinations of adapalene and benzoyl peroxide for treating acne lesions: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by... Agent: Buchanan, Ingersoll & Rooney PC

20090298800 - 1,25-dihydroxy, 20-cyclopropyl,26-27-deuteroalkyl vitamin d3 compounds and methods of use thereof: The invention provides vitamin D3 analogs of cholecalciferol, substituted at carbons-26 and 27 with deuterated alkyl groups, e.g., trideuteromethyl, wherein carbon-16 is a single or double bond, and carbon-23 is a single, double, or triple bond. The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the... Agent: Edwards Angell Palmer & Dodge LLP

20090298799 - Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin d3 compounds: The invention provides for methods of using 20-methyl Gemini vitamin D3 compounds to treat osteoporosis and secondary hyperparathyroidism.... Agent: Edwards Angell Palmer & Dodge LLP

20090298801 - Petroleum jelly-free unguent compositions comprising vitamin d compounds and optionally steroidal anti-inflammatory agents: Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.... Agent: Buchanan, Ingersoll & Rooney PC

20090298802 - Pharmaceutical compositions: Disclosed are inhalable medicaments and methods based on an anticholinergic in combination with a corticosteroid, and a long acting beta agonist, for simultaneous or sequential administration in the prevention or treatment of a respiratory, inflammatory or obstructive airway disease. In addition, disclosed are inhalable medicaments and methods based on combinations... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090298803 - Pharmaceutical composition comprising fluocinonide: The present invention provides a composition, comprising fluocinonide in a vehicle comprising one or two penetration enhancers, solvents and emulsifiers wherein penetration enhancers are present in ratio of less than 0.90 to the total of the penetration enhancers, solvents and emulsifiers.... Agent: Glenmark Pharmaceuticals Inc Usa

20090298804 - Novel compounds and methods for their production: The present invention relates to 15-desmethoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for... Agent: Dann, Dorfman, Herrell & Skillman

20090298805 - Topical pyrithione compositions and methods for treatment of nail fungus: Disclosed is a formulation and method for the treatment of fungal infections of the nail (onychomycosis) utilizing a topical composition comprising zinc pyrithione, a solubilizer for the zinc pyrithione, a film former, and a volatile solvent. The formulation is preferably in the form of a lacquer. The composition containing the... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090298808 - Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Fish & Richardson PC

20090298807 - Compounds: e

20090298806 - Factor xa inhibitors: The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat... Agent: Foley & Lardner LLP

20090298809 - 5-ht3 receptor modulators, methods of making, and use thereof: Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention.... Agent: Nixon Peabody LLP - Patent Group

20090298810 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (II-8).... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090298812 - Substituted sulfonamide compounds: i

20090298811 - Benzimidazolone derivatives: This invention relates to compounds and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmaceutically acceptable salts... Agent: Pfizer Inc. Patent Department

20090298813 - Use of neuroprotective compounds in obtaining medicaments intended for the treatment of neurodegenerating diseases: Use of neuroprotective compounds in obtaining medicaments intended for the curative treatment of neurodegenerative disease and/or the prevention of the appearance of disorders ensuing from those diseases.... Agent: The Firm Of Hueschen And Sage

20090298814 - Novel salts of conjugated psychotropic drugs and processes of preparing same: Novel chemical conjugates of a psychotropic drug residue and an amino-containing organic acid residue selected to reduce side effects induced by the psychotropic drug when administered per se, to enhance the therapeutic activity of the psychotropic drug and/or to exert anti-proliferative activity, in which the amino group is in the... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090298815 - Benzene sulfonamide thiazole and oxazole compounds: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090298816 - Pesticides containing a bicyclic bisamide structure: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090298820 - 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses: m

20090298817 - Anti-amnesic compounds and pharmaceutical compositions comprising them:

20090298819 - Compositions, synthesis, and methods of using piperazine based antipsychotic agents: The present invention provides novel piperazine derivatives which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder and depression.... Agent: Fenwick & West LLP

20090298818 - Pharmaceutical compounds: The invention also provides the use of a compound of the formula (VI) for the manufacture of a medicament for the prophylaxis or treatment of a fungal, protozoal, viral or parasitic disease state or condition (other than a disease state or condition due to Plasmodium falciparum) or for use in... Agent: Frommer Lawrence & Haug

20090298821 - Hydroxy and alkoxy substituted ih-imidazonaphthyridines and methods: 1H-Imidazo[4,5-c]naphthyridin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are... Agent: Pfizer Inc. Patent Department

20090298823 - Inhibitors of protein kinases: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a... Agent: Townsend And Townsend And Crew, LLP

20090298822 - Use of activators of soluble guanylate cyclase for treating reperfusion damage: The present invention relates to the use of compounds for manufacturing a pharmaceutical product/medicament for the prophylaxis and/or treatment of reperfusion damage.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090298824 - Organic compounds: e

20090298825 - Bicycloheteroaryl compounds as p2x7 modulators and uses thereof: Bicycloheteroaryl compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury,... Agent: Klauber & Jackson

20090298826 - Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents: The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represent a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group;... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090298827 - Novel 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents: The R1 represents a hydrogen atom or a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 and R4 may be the same or different and represents a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom or a lower alkyl group;... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090298828 - Alkoxyalkyl-substituted cyclic keto-enols: e

20090298829 - Melanocortin receptor agonists: The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.... Agent: Birch Stewart Kolasch & Birch

20090298830 - 4-aryl-2-amino-pyrimidnes or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use: This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Patent Dept Exelixis, Inc.

20090298831 - Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof: The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and... Agent: Michael Best & Friedrich LLP

20090298833 - Piperidinyl derivatives as modulators of chemokine receptor activity: The present application describes substituted piperidinyl modulators of MIP-1α or CCR-1 or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using said modulators are disclosed.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090298832 - Trisubstituted thiazole compounds, preparations methods, pharmaceutical compositions and medicals uses thereof: The present invention relates to 2,4,5-trisubstituted thiazole compounds of formula (I) or all possible isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof for the inhibition of plasma PLTP activity and/or plasma CETP activity, wherein the substituents are as defined in the specification; a process for the preparation of the... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20090298834 - 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminomethyl)cyclohexanamine derivatives as shown in formula (1).... Agent: Morrison & Foerster LLP

20090298835 - Novel scaffolds for alpha-helix mimicry: Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins.... Agent: Townsend And Townsend And Crew, LLP

20090298837 - Compounds, methods and pharmaceutical compositions for inhibiting parp: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.... Agent: Connolly Bove Lodge & Hutz LLP

20090298836 - Thiadiazole modulators of pkb: e

20090298839 - Adrb2 gene polymorphism associated with intraocular pressure response to topical beta-blockers: The invention provides a single nucleotide polymorphism (SNP) rs1042714 in the human ADRB2 gene (Gln27Glu) associated with a clinically meaningful reduction in intraocular pressure (IOP) in a human following treatment with a topical beta-blocker. Nucleic acids comprising the SNP are used to screen glaucoma-afflicted individuals to thereby provide an improved... Agent: Quarles & Brady LLP

20090298840 - Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament: Disclosed are hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, processes for preparing them and their use as pharmaceutical compositions.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090298838 - Method for determination of effective dose of methotrexate: Means to Solve the Problems: There is obtained a test method of an A1298C polymorphism in MTHFR gene in a patient suffering from rheumatoid arthritis, the method being used for the determination of the effective dose of methotrexate in each patient, whereby a method for treatment of rheumatoid arthritis in... Agent: Birch Stewart Kolasch & Birch

20090298841 - Quinoline derivatives and their use as 5-ht6 ligands: The present invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090298842 - Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor: Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for... Agent: Leon R. Yankwich, Esq.

20090298843 - Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor: Disclosed are methods of treating a hematological malignancy by administering to a human in need thereof effective amounts of FTS (Farnesylthiosalicylic Acid), or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally in combination with a Bcr-Abl tyrosine kinase inhibitor. Also disclosed are pharmaceutical compositions comprising FTS, or various... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090298844 - Abl kinase inhibition: The present invention relates to inhibition of AbI kinase.... Agent: Vertex Pharmaceuticals Inc.

20090298845 - Piperazinyl derivatives as modulators of chemokine receptor activity: or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, T, W, R1, R4, R5, R5a and R5b are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators... Agent: Louis J. Wille Bristol-myers Squibb Company

20090298846 - Indolo[3,2-c]quinoline compounds: Indolo[3,2-c]quinoline compounds of formula (I) shown below. Each variable in this formula is defined herein. These compounds can be used to inhibit both growth of cancer cells and activity of telomerase.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090298847 - Manufacturing method of solid dispersion containing itraconazole: The present invention relates to a method for preparing an itraconazole-containing solid dispersion. The itraconazole-containing solid dispersion according to the preparing method of the present invention has both improved solubility and rapid dissolution rate so that it has an excellent bioavailability. The itraconazole-containing solid dispersion of the present invention is... Agent: Edwards Angell Palmer & Dodge LLP

20090298848 - Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions: Pharmaceutical compositions comprising the 2S,4R ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates are useful to increase cardiolipin synthesis and for the treatment of Barth Syndrome, diabetic myopathy, cardiomyopathy associated with aging, mitochondrial disease, and other conditions and disorders where cardiolipin deficiency plays a causative or symptomatic role.... Agent: Cantor Colburn, LLP

20090298849 - Materials and methods relating to the induction of apoptosis in target cells: Compositions, methods, uses and assemblages for the preferential induction of cell division cycle arrest and/or apoptosis, in a first population of cells compared to a second population of cells employ either: (i) an opioid or opioid-like agent and an NF-κB activating agent, which agents are other than the opioid-like agent... Agent: Dann, Dorfman, Herrell & Skillman

20090298850 - Treatment for neurological and mental disorders: Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that... Agent: King & Spalding

20090298851 - Phenyl piperazine compounds, pharmaceutical composition comprising the same and use thereof: The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effective amount of the piperazine compound and a method of treating central nervous system (CNS) disorder such as psychosis... Agent: Michael Best & Friedrich LLP

20090298852 - Pellet-form slow-release preparation for vertigo: The invention describes a pharmaceutical composition of a slow-release preparation in the form of pellets for the treatment of vertigo of any genesis. Thus, a pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down and the preparation is in the form... Agent: Kriegsman & Kriegsman

20090298853 - Carbamoyl compounds as dgat1 inhibitors 190: e

20090298854 - Indole acetic acid derivatives and their use as pharmaceutical agents: This invention is directed to indole acetic acid derivatives and their use in pharmaceutical compositions for the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic disease. The invention is also directed to intermediates useful in preparation of indole acetic derivatives and to methods of preparation.... Agent: Myers Bigel Sibley & Sajovec

20090298855 - Protein tyrosine kinase inhibitors: i

20090298856 - 2,3 substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilliod-1receptor (vr1): The use of a compound of formula (I): for the manufacture of a medicament for the treatment of conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1, also known as TRPV1).... Agent: Merck And Co., Inc

20090298857 - Treatment of neurodegenerative diseases through inhibition of hsp90: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.... Agent: Larson & Anderson, LLC Re: Msk

20090298858 - Potent parp inhibitors: e

20090298859 - Method for treating plants: The present invention relates to the use of a fungicide selected from the group consisting of (i) a strobilurin or strobilurin-type fungicide or (ii) a triazole or an insecticide selected from the group consisting of (i) an avermectin, (ii) an organophosphate, (iii) a benzoylurea or (iv) a neonicotinoid in the... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090298860 - Antifungal wallboards and building materials and methods for the production thereof: The present invention relates to, inter alia, methods for the treatment of wallboards with fungicides and the treated wallboards. In particular, the invention relates to the treatment of wallboards with a fungicidally effective amount of difenoconazole. The invention also provides for the treatment of wallboards with synergistic combinations of difenoconazole... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090298861 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, p, X, Y, R3, R4, t and, R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions contain them and their use in therapy.... Agent: Fish & Richardson P.C.

20090298862 - Methods useful for the treatment of pain, arthritic conditions or inflammation associated with a chronic condition: Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation.... Agent: Durect Corporation Thomas P. Mccracken

20090298863 - Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus: This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention... Agent: Connolly Bove Lodge & Hutz LLP

20090298864 - Methods for treating mild cognitive impairment: The present invention relates to compounds, compositions, and methods useful for: (i) treating or preventing mild cognitive impairment, or (ii) delaying the progression from mild cognitive impairment to Alzheimer's disease in a subject in need thereof.... Agent: Wilmerhale/columbia University

20090298865 - Derivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof: e

20090298866 - Indole compounds: The present application relates to compounds of formula (I) or a pharmaceutically acceptable derivative thereof: formula (I) wherein X, R1, R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090298867 - Tricyclic delta-opioid modulators: The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20090298868 - Quinoline compounds as melanogenesis modifiers and uses thereof: e

20090298869 - Crystalline pharmaceutical and methods of preparation and use thereof: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090298870 - Podophyllotoxin derivatives: 4-O esters of podophyllotoxin and 4′-demethylepipodophyllotoxin are provided. The compounds are 4-O esters of an alkanoic acid or substituted alkanoic acid and podophyllotoxin and 4′-demethylepipodophyllotoxin. The compounds are useful for treating cancer.... Agent: Swiss Tanner, P.C. P.o. Box 1749

20090298871 - Sulfonyl-phenyl-2h-[1,2,4]oxadiazol-5-one derivatives , processes for their preparation and their use as pharmaceuticals: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090298872 - Compounds and compositions as modulators of steroidal receptors and calcium channel activities: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorder associated with the activation of steroid hormone nuclear receptors.... Agent: Genomics Institute Of The Novartis Research Foundation

20090298873 - Methods of reducing microbial resistance to drugs: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity... Agent: Mccarter & English, LLP Boston

20090298875 - A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma: The present invention provides pharmaceutical compositions comprising a β2-agonist, and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.... Agent: Fish & Richardson P.C.

20090298874 - Bacterial atp synthase binding domain: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts... Agent: Philip S. Johnson Johnson & Johnson

20090298876 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090298877 - Salts of creatine imino sugar amides: The present invention relates to stable salts of creatine imino sugar amides and an inorganic or organic acid endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral and parenteral administration. Methods of preparation and use... Agent: Iovate Health Science Research Inc.

20090298878 - Oxime compounds and the use thereof: The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CR3R4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090298879 - Impurities of donepezil: The present invention relates to impurities of donepezil, or a pharmaceutically acceptable salt thereof, which may be produced during synthesis and storage of donepezil, or a pharmaceutically-acceptable salt thereof, and to methods of identifying such impurities. The invention also relates to the use of these impurities in analytical techniques and... Agent: Merchant & Gould PC

20090298880 - Methods for the administration of iloperidone: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.... Agent: Hoffman Warnick LLC

20090298881 - Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions and the use thereof: Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of... Agent: Nixon & Vanderhye, PC

20090298882 - Thioxoisoindoline compounds and compositions comprising and methods of using the same: Provided are thioxo isoindoline compounds, and pharmaceutically acceptable salts, solvates, and stereoisomers, thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20090298883 - N-piperidinyl acetamide derivatives as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).... Agent: Morrison & Foerster LLP

20090298884 - Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same: A strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.... Agent: M. Carmen & Associates, PLLC

20090298885 - Methylene urea derivatives: The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a... Agent: Arent Fox LLP

20090298886 - 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors: The present invention relates to 2-indolinone derivatives which are capable of inhibiting protein kinases and histone deacetylases. The compounds of this invention are therefore useful in treating diseases associated with abnormal protein kinase activities or abnormal histone deacetylase activities. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical... Agent: Eckert Seamans Cherin & Mellott

20090298887 - Method for improving harvested seed quality: The present invention is directed to a method for improving the quality of seeds harvested from seed-producing plants. The method comprises treating the pre-planted seeds of the seed-producing plants with a seed treatment insecticide and treating the resulting plant with foliar applications of a foliar insecticide; or treating the pre-planted... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090298888 - Method of improving plant development and increasing the resistance of plants to soil-borne harmful fungi: The present invention relates to a method of improving plant growth and increasing the resistance of plants to soil-borne harmful fungi by directly admixing neonicotinoid-containing formulations into nutrient solutions conventionally employed in raising plants.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090298889 - Pharmaceutical compositions containing 2-pyridone derivatives as effective components: The present invention herein provides a 2-pyridone derivative which has a cell adhesion-inhibitory activity and which is useful for preventing and/or treating pathema or disease conditions including, for instance, inflammations which relate to leukocytic infiltration. The 2-pyridone derivative is a compound represented by the following general formula (1). In the... Agent: Studebaker & Brackett PC

20090298890 - New n-methyl benzamide derivatives: e

20090298891 - Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents: The present invention features methods of inhibiting ribonucleotide reductase and DNA synthesis after administration of a dose of ionizing radiation to cells. The present invention further features methods of treating patients suffering from cancer comprising contemporaneous or sequential administration of a radiosensitizing dose of a 2-carboxyaldehyde pyridine thiosemicarbazone compound and... Agent: Edwards Angell Palmer & Dodge LLP

20090298892 - Treatment methods employing histamine h3 receptor antagonists, including betahistine: Methods of treating depression, binge eating disorder, narcolepsy, excessive daytime sleepiness, substance use disorders, and Prader Willi syndrome, disorders characterized at least in part by hypocortisolemia and decreased activity of the hypothalamic-pituitary-adrenal (HPA) axis, and disorders related to disturbances in circadian rhythm, comprising the step of administering an effective amount... Agent: Dinsmore & Shohl LLP

20090298893 - Addition salts of tolperisone, processes for their preparation and use thereof: Addition salts of 2,4′-dimethyl-3-piperidinopropiophenone (tolperisone) are described, wherein the salt is formed with an acid R—COOH and wherein R is the organic group of a physiologically compatible organic acid. Described also are processes for the preparation of these addition salts, the use thereof for pharmaceutical preparations and pharmaceuticals containing these... Agent: Kriegsman & Kriegsman

20090298894 - Amino acid compounds: d

20090298896 - Activating agent for peroxisome proliferator activated receptor delta:

20090298895 - Use of thioproline in body weight reduction treatments: The invention relates to thioproline, pharmaceutically acceptable salts and/or prodrugs thereof that can be used as anorexia-inducing agents in both therapeutic and cosmetic treatments to reduce body weight.... Agent: Moore & Van Allen PLLC

20090298897 - Treatment of inflammatory disorders with triazole compounds: The present invention relates to the use of triazole compounds for reducing inflammation and treating inflammation-associated disorders.... Agent: Glaxo Smith Kline C/o The Nath Law Group

20090298898 - Pesticidally active ketone and oxime derivatives: and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds and agrochemically acceptable salts... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090298899 - Ep2 receptor agonists: The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.... Agent: Brinks Hofer Gilson & Lione/ann Arbor

20090298900 - Oxo-imidazolyl compounds: e

20090298901 - (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone oxime dihydrate and methods of its use: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)-ethanone oxime dihydrate, compositions comprising it, and methods of its use are disclosed.... Agent: Lexicon Pharmaceuticals, Inc.

20090298902 - Pesticide compositions for combating arthropod pests, snails and nematodes: The present invention relates to a pesticide composition in the form of a water absorbent granular material and to the use of such compositions for combating arthropod pests, in particular soil-living arthropod pests, and nematodes, with particular preference given to soil-living insect pests. The pesticide composition according to the invention... Agent: Brinks, Hofer, Gilson & Lione

20090298903 - Use of tetramic acid derivatives for insect control: An improved miniature portable child's training toilet comprises a first chamber with a toilet seat opening, a second chamber connected thereto, and a flap member at a connection point. A miniaturized tank portion with valve means and means of selectively causing the valve to open, allows fluid from the tank... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090298904 - Novel peptides from actinomadura namibiensis:

20090298905 - Nitrogenatd trans-stilbene analogs, method for the obtention and medical applications thereof: This invention is related to new nitrogenated trans-stilbene analog compounds, more specifically, imine, pyrrol and Indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in... Agent: Darby & Darby P.C.

20090298906 - Proteasome inhibitors: Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.... Agent: Knobbe Martens Olson & Bear LLP

20090298907 - Method for the preparation of 4-fluoro-alpha-[2-methyl-1-oxopropyl]-y-oxo-n-beta-diphenylbenzenebutanamide and products therefrom: A method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-N-β-diphenylbenzenebutanamide also known as 2-[2-(4-fluorophenyl)-2-oxo-1-phenylethyl]-4-methyl-3-oxo-pentanoic acid phenylamide of the formula I containing about 0.1% or less of α-[2-methyl-1-oxopropyl]-γ-oxo-N-p-diphenylbenzene butanamide, about 0.05% or less of difluoro-α-[2-methyl-1-oxopropyl]-y-oxo-N-β-diphenylbenzene butanamide and about 0.1% or less of 3-[2-(4-Fluorophenyl)-2-oxo-1-phenyl-ethoxy]-4-methyl-pent-2-enoic acid phenylamide.... Agent: Akerman Senterfitt

20090298908 - Dmae as sole agent for the treatment of mild cognitive impairment: The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment... Agent: Birch Stewart Kolasch & Birch

20090298923 - Salicylate conjugates useful for treating metabolic disorders: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090298924 - Hydroxamic acid derivatives as inhibitors of hdac enzymatic activity: wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7cycloalkyl, aryl, aryl(C1-C6 alkyl)-, heteroaryl, heteroaryl(C1-C6 alkyl)-, —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen... Agent: Banner & Witcoff, Ltd.

20090298925 - Substituted benzopyrans as selective estrogen receptor-beta agonists: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.... Agent: Eli Lilly & Company

20090298926 - Process for the purification 10-deacetybaccatine iii from 10-deacetyl-2-debenzoyl-2-pentenoylbaccatine iii: A process for the preparation of 10-deacetyl-7,10-bis-trichloroacetylbaccatine III with HPLC purity higher than 99% and free from 2-debenzoyl-2-pentenoylbaccatine III by purification of 10-deacetyl-7,10-bis-trichloroacetylbaccatineIII followed by alkaline hydrolysis of the protecting groups in position 7 and 10.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090298927 - Thermal extraction method and product: The present invention is related to a thermal extract of a plant material and methods of extraction thereof. The method of producing a thermal extract from a plant starting material by means of a thermal extraction of the starting material wherein the improvement consists in requiring smaller amounts of costly... Agent: Clark & Elbing LLP

20090298928 - Composition and method for scalp and hair treatment: Provided is a composition for scalp and hair treatment, comprising a menthol derivative and a prostaglandin compound having two hetero atoms at the 15 position. The composition of the present invention is effective not only for preventing dandruff and itchy scalp but also for preventing or treating hair loss, baldness,... Agent: Sughrue Mion, PLLC

20090298929 - Novel natural cyclodextrin complexes: The present invention is directed to the novel use of complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of α-CD, β-CD and γ-CD and a cannabinoid selected from the classical cannabinoid-group consisting of canabinol, tetrahydrocanabinol and canabidiol.... Agent: Sughrue Mion, PLLC

20090298930 - Methods for purifying trans-(-) delta9-tetrahydrocannabinol and trans-(+)-delta9-tetrahydrocannabinol: Methods for making trans-(−)-Δ9-tetrahydrocannabinol and trans-(+)-Δ9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(−)-Δ9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-Δ9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(−)-Δ9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(−)-Δ9-tetrahydrocannabinol based on the total amount of... Agent: Dechert LLP

20090298931 - Novel chromenone potassium channel blockers and uses thereof: The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis,... Agent: Scully Scott Murphy & Presser, PC

20090298932 - Composition and method for the treatment of neurological disorders: The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.... Agent: Heidi A. Boehlefeld Renner, Otto, Boisselle & Sklar, LLP

20090298933 - Oral composition containing egcg and lycopene: Composition containing the combination of (−)-epigallocatechin gallate (EGCG) and lycopene characterized in that the ratio of EGCG to lycopene is in the range of 100:1 to 1:1.... Agent: Nixon & Vanderhye, PC

20090298934 - Diamidine inhibitors of tdp1: The instant invention is directed towards compounds, including diamidines, that inhibit Tdp1 and are useful in the treatment and/or prevention of cancer and parasitic disease.... Agent: Edwards Angell Palmer & Dodge LLP

20090298935 - Production and use of a gaseous vapor disinfectant: Smoke or vapor generating system disperses an airborne biocidal oil, such as methyl soyate, to decontaminate and area or object. The airborne forms of methyl soyate are have broad spectrum efficacy against a wide variety of microscopic pathogens including viruses, bacteria and fungi.... Agent: Lathrop & Gage LLP

20090298936 - Method for energizing human beings: The present invention relates to a method for energizing a human being and to administering an energizing (personal care) composition to human beings wherein said composition contains one or more fragrance materials of group (a) of the present invention.... Agent: Connolly Bove Lodge & Hutz LLP

20090298937 - Method for inhibiting the growth of bacteria: The present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.... Agent: Waddey & Patterson, P.C.

20090298940 - All natural antifungal and antimicrobial composition and method thereof: In accordance with the present invention, there is provided a novel all natural antifungal composition and method. There is further provided a novel all natural antibiotic and antimicrobial composition and method. There is provided an antifungal and/or antimicrobial composition and method that may be used to treat conditions caused by... Agent: Law Office Of Tracy P. Jong

20090298941 - Anti-adipocyte fatty acid-binding protein (ap2), anti-flap and anti-cyslt1 receptor herbal compositions: Herbal compositions having anti-adipocyte fatty acid-binding protein (aP2), anti-5-lipoxygenase-activating protein (FLAP) and anti-Cysteinyl Leukotriene (CysLT)-1 receptor expression activity contain an extract of Boswellia serrata. More particularly, these herbal compositions comprise an effective amount of an enriched Boswellia extract containing from 10% to 99% by weight of 3-0-acetyl-11-keto-β-boswellic acid; and an... Agent: Kramer & Amado, P.C.

20090298939 - Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals: The disclosure provides a method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100®, comprising (i) precipitating the spray drying carrier from C-MED-100®; (ii) using the resulting C-MED-100® to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100® spotting mixture... Agent: Davidoff Malito & Hutcher, LLP

20090298938 - Use of semi synthetic analogues of boswellic acids for anticancer activity: The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic... Agent: Fulbright & Jaworski L.L.P.

20090298942 - Animal composition: The present invention relates to a composition which delivers an amount of leucine sufficient to enhance the learning ability of an animal. The present invention also relates to a food supplement for enhancing the learning ability of an animal and to methods for enhancing such learning ability.... Agent: Fulbright & Jaworski, LLP

20090298943 - Use of creatine analogues and creatine kinase modulators for the prevention and treatment of obesity and its related disorders: The present invention relates to the use of creatine compounds for treating or preventing a metabolic disorder related to body weight control such as obesity, and it's associated diseases in a patient experiencing said disorder. The creatine compounds which can be used in the present method include (1) analogues of... Agent: Mccarter & English, LLP Boston

20090298944 - Pharmaceutical composition: The present invention relates to a pharmaceutical composition of practically water insoluble or low water soluble compounds containing catechol moiety by enhancing the solubility of such compounds using one or more alkalising agent and optionally adding one or more pharmaceutically acceptable excipient. The present invention also relates to a process... Agent: Global Patent Group - Tpl

20090298945 - Aqueous extracts from monocotyledon plants and their use in cardioprotection: Method of treating hypertension with a trans-aconitic acid containing composition (e.g., a water extract derived from a monocotyledon plant).... Agent: Occhiuti Rohlicek & Tsao, LLP

20090298946 - Local anesthetic deactivation: A chemical solution for deactivating the effects of local anesthetic is disclosed. Local anesthetic is important in many medical procedures, such as dentistry, surgical procedures, and veterinary medicine. In many cases, after the procedure has been completed, the need for blocking the nerve conductance is no longer needed or wanted,... Agent: Roman Aguilera Iii

20090298947 - Polymorphic and amorphous forms of lacosamide and amorphous compositions: The present invention relates to polymorphic and amorphous forms of Lacosamide, processes of preparing the polymorphic and amorphous forms, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing the same.... Agent: Merchant & Gould PC

20090298948 - Colchicine compositions and methods: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.... Agent: Cantor Colburn, LLP

20090298949 - Aminoalkylphenols, methods of using and making the same: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized... Agent: Merck And Co., Inc

20090298950 - Cyclopentane/cyclopentene aldehyde or ketone derivatives and their use as odorants: e

20090298951 - Nontoxic biocidal composition and method thereof: This invention discloses biocidal compositions and methods and more particularly, a novel nontoxic biocide and biostat composition and method for elimination and inhibition of gram negative bacteria (microorganism), viral, and/or fungal growth, especially molds. In one formulation, the novel biocidal composition is formed from equal amounts of potassium sorbate, lecithin,... Agent: Law Office Of Tracy P. Jong

20090298952 - Platable soluble dyes: Edible colored powders are formed by combining silica with a soluble dye, such as a natural dye. The colored powders can be used to color edible substrates such as particles and compressed tablets. Methods of forming the edible colored powders may include a drying step to reduce the moisture content... Agent: Michael Best & Friedrich LLP

20090298953 - Drug delivery system and method of making the same: Disclosed is a method for making a composition which comprises of an array of unsaturated, aliphatic, biocompatible and biodegradable polyesters with photo curing capability which upon mixing with an active ingredient will provide an inject able liquid or putty-like material. The composition can be injected via a customary syringe and... Agent: Barry Choobin

20090298954 - Affinity carrier and method for producing thereof: s

20090298955 - Altered virus capsid protein and use thereof: An altered capsid protein of a primate-infective papovavirus in which a foreign peptide sandwiched by 1 to several glycine residues at each end is inserted into at least one of the DE-loop or the HI-loop of the capsid protein of the primate-infective papovavirus, and a virus-like particle formed from the... Agent: Cantor Colburn, LLP

20090298956 - Self-preserved emulsions: The use of multifunctional synthetic compounds to both stabilize and preserve therapeutic emulsions is described. The multifunctional synthetic compounds have unique molecular arrangement wherein a phosphate group is linked to one, two or three quaternary ammonium functionalities via a substituted propenyl group, and each quaternary ammonium functionality is further linked... Agent: Alcon

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.48992 seconds

PATENT INFO